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Ketotifen (K) is a first-generation antihistamine with antiinflammatory potency. 
It penetrates the blood-brain barrier (BBB) and causes a sedative side effect. 
Norketotifen (N) is an active metabolite of K. The S-atropisomer of N (SN), 
however, has antihistaminic and antiinflammatory properties but less sedating 
side effect than RN and K. This may be due to: (1) higher concentrations of K and 
RN than SN in the central nervous system (CNS) and/or (2) higher affinity of K 
and RN than SN for rat brain H1-receptors. The aim of this thesis was to 
investigate the mechanism of why SN lacks a sedative side effect.  
 
To determine concentrations of racemic K and N and atropisomers of K and N in 
buffer solutions and bio-matrices, nonchiral and chiral high-performance liquid 
chromatography (HPLC) assays were developed and validated. Log P and log D of 
K and N (both octanol/buffer and liposomes/buffer) were determined to aid in 
interpretation of in vitro cell studies. Rat brain endothelial (RBE4) and colorectal 
adenocarcinoma (Caco-2) cell monolayers were used as in vitro models of the 
BBB to study the stereoselective uptake and permeability of K and N 
atropisomers. To investigate the distribution of K and N atropisomers between 
brain tissue and plasma, the total and free brain-to-plasma (B/P) ratios of K and 
N atropisomers were measured 5 min post-administration of racemic K and N 
through the rat tail vein. The affinity of K and N atropisomers to brain H1 
receptors was investigated by determining the extent of inhibition of [3H] 
mepyramine binding to H1 receptors in rat brain cell membranes. 
 
The in vitro studies indicated active mechanisms for transporting K and N in both 
RBE4 and Caco-2 cell lines; however, none of these mechanisms were 
stereoselective. Interestingly, for both cell lines, more N was found binding non-
specifically to cell membranes than that of K, though in a non-stereoselective 
manner. Liposomes/buffer distribution studies aided in interpretation of these 
results.  
 ii
Similarly, the total and free B/P ratios of K and N atropisomers suggested a 
predominant influx mechanism involved in transporting of K and N through the 
rat BBB. However, this mechanism was not stereoselective for either K or N 
atropisomers. In addition, K and N non-specifically bound to rat plasma protein 
and brain tissues in different degree but the non-specific binding was not 
stereoselective either.  
In contrast, H1 receptor affinity results suggested a stereoselective binding of SN 
for the H1 receptors in rat brain, in that SN had a lowest affinity compared with 
RN, SK and RK. Significant differences in the affinity for the H1 receptors were 
found between SN and SK, SN and RK, moreover, between SN and RN. Although 
the difference was significant but not substantial compared to some published 
stereoselective affinity for the H1 receptors, a similar degree of difference was 
observed and published by other research groups. Thus the lowest affinity of SN 
for the H1 receptors could participate in the observed less sedative effect caused 
by SN. 
In conclusion, there was no stereoselective transport of SN through the BBB 
either in vitro or in vivo, and there was no stereoselective non-specific binding of 
SN to rat plasma proteins or brain tissues. The lower sedative effect of SN is due 
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Chapter 1  Introduction 
1.1 Histamine, histamine receptors 
Histamine, a peripheral mediator in allergic reactions and a central nervous 
system (CNS) neurotransmitter, plays important roles in physiological and 
pathophysiological functions in human health. It is synthesized in tissues from 
the amino acid histidine by L-histidine decarboxylation (Ling et al, 2004), 
particularly abundant in skin, lung and gastrointestinal (GI) tract. It is stored in 
granules or vesicles of several types of cells including mast cells (main source of 
histamine), basophils, lymphocytes, platelets, enterochromaffin cells and 
histaminergic neurons (Carson et al, 2010; Simons and Simons, 2011). Histamine 
exerts its physiological and pathophysiological functions through histamine 
receptors. 
There are four subtypes of histamine receptors, H1 to H4, which all belong to the 
G-protein-coupled receptor (GPCR) family. They all are heptahelical 
transmembrane molecule, which transduce extracellular signals via G protein 
and an intracellular second messenger system. However, H1 to H4 receptors are 
expressed on different tissues at different densities where they mediate different 
biological effects (Table 1.1).
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Table 1.1 Summary of the four subtypes of histamine receptor. 
 H1 receptor H2 receptor H3 receptor H4 receptor 
Eosinophils, dendritic cells, monocytes, cardiovascular system 
Nerve cells, airway and vascular smooth muscle, endothelial cells, 
epithelial cells, neutrophils, T and B cells, hepatocytes, chondrocytes, 
nerve cells and macrophages 
Lungs 
Expression 
___ Gastric parietal cells High expression in histaminergic 
neurons; expression in peripheral 
neurons, endothelial cells, very low 
density in glial cells  
High expression in bone marrow 
and peripheral hematopoietic 
cells, neutrophils, T cells, 
basophils, mast cells. Moderate 
expression in spleen, thymus, 





Amthamine, dimaprit, impromidine α-methylhistamine, imetit, immepip, 
and methimepip  













288), MK-0249, JNJ-17216498** and 
PF-03654746** 
JNJ7777120, UR 65380, UR 
63825, VUF-6002, doxepine*, 








Neuroendocrine Presynaptic autoreceptor or 
heteroreceptor, reducing histamine, 
dopamine, serotonin, noradrenaline, 
5-hydroxytryptamine, glutamate, 
GABA, neuropeptides and 
acetylcholine release. Postsynaptic 
effects, activated MAPK, Akt 







Periphery takes part in acute 
immune response 
Negatively regulate histamine 
release from basophils and mast 
cells; inhibit synthesis of antibody, 
T-cell proliferation, cell mediated 
cytolysis and cytokine production  
Negative feedback mechanism 
reduces central histaminergic 
inflammatory; controls neurogenic 
inflammation 
Mediate eosinophil, chemotaxis, 
cell-shape change, modulate cell 
migration, regulate allergy and 
inflammatory responses 
* H1 antagonists were reported to show high affinity for H4 receptors 
**
 Drugs in clinical trials 

 Antagonists here refers to inverse agonists because the antagonist prefers binding to an inactive stage of the receptor thereby shifting the equilibrium 
towards the inactive stage  
(Adkinson et al, 2013; Ferreira et al, 2012; Gustavo et al, 2016; Haas et al, 2008; Leurs et al, 2011, Ling et al, 2004; Mahdy and Webster, 2014; Simons and 
Simons, 2008, 2011; Wang et al, 2016) 
 
 3 
The peripheral effects of activating histamine receptors, mainly H1, H2 and H4 
receptors, include smooth muscle contraction, increased vascular permeability, 
vasodilation and stimulation of gastric acid secretion (Simons and Simons, 2011). 
Therefore, histamine takes part in allergic responses and inflammation in asthma, 
allergic rhinitis, and food allergy (Wang et al, 2016). 
The H1 receptor mediates allergic reactions including smooth muscle contraction, 
vasodilation and sensory nerve activation, while the H2 receptor increases gastric 
acid secretion in stomach and promotes vasodilation (Faustino-Rocha et al, 2017). 
The H4 receptor regulates cell migration, the differentiation of myeloblasts and 
promyelocytes, and induces chemotaxis. In addition, the H4 receptor plays an 
important role in chronic inflammatory skin diseases. Previously, it was thought 
that the chronic inflammation was due to the activation of H1 receptors and was, 
therefore treated with H1 receptor antagonists. However, this did not work well 
until the H4 receptor was found and identified (Faustino-Rocha et al, 2017; Hill et 
al, 1997; Haas et al, 2008; Leurs et al, 2011). The H3 receptor peripherally inhibits 
excess bronchoconstriction and regulates pruritus (Bongers et al, 2007; Leurs et 
al, 2005). More pertinently, it acts as an auto- and/or heteroreceptor in the CNS to 
regulate neurotransmission by histamine and other biogenic amines including 
dopamine, serotonin and noradrenaline (Leurs et al, 2011). 
In the CNS, histamine is involved in many important central functions including 
regulation of sleep and wakefulness, memory and cognition (Table 1.1) (Haas et 
al, 2008; Mahdy and Webster, 2014; Simons and Simons, 2008). These functions 
are normally unaffected unless histamine agonists and/or antagonists penetrate 
the brain. In theory, histamine antagonists are commonly used peripherally to 
treat allergic conditions. However, some histamine antagonists (e.g., the first-
generation H1 receptor antagonists) do enter the brain and consequently result 
in side effects.  
This thesis is focused on the H1 receptor antagonist (inverse agonist) ketotifen 
(K) (Figure 1.1a) and its molecularly-similar active metabolite norketotifen (N) 
(Figure 1.1c). Both K and N are chiral compounds of a particular class called 
atropisomers (Figures 1.1b and d). As configurational descriptor, the torsion 
angel τ1 (Figure 1.2) and the heterocyclic system together make K atropisomers 
stable under room temperature as well as physiological conditions (Testa et al, 
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2016). Due to the structure similarity, this configurational descriptor mechanism 
also applies to N atropisomers. 
Figure 1.1 Structure of ketotifen (a), norketotifen (c) and mirror images of 
ketotifen atropisomers (b) and norketotifen atropisomers (d). 
Figure 1.2 An example of the configurational descriptor of ketotifen. 
(Testa et al, 2016) (Reproduced with permission) 
 
K shows both antihistaminic and antiinflammatory potency but has a serious 
sedative side effect because it enters the CNS where it binds to the H1 receptor. 
Interestingly, the S-atropisomer of N (SN) is reported to have higher potency 
without the sedative side effect (Aberg A. K. G, Patent US9439895 B2). To explore 
the reason why SN has high potency without the sedative side effect, the following 
sections describe H1 antagonists, characteristics of K and N, chirality, and the 





1.2 H1 receptor antagonists 
Histamine is one of the most important mediators involved in type I 
hypersensitivity allergy. A large amount of histamine is released from mast cells 
and basophils in the early phase of allergy to activate histamine receptors. In the 
late phase of allergy, inflammatory cytokines are secreted and endothelial cells 
are activated. Consequently, inflammation and tissue injury occur (Stojkovic et 
al, 2015). In chronic allergic inflammation, histamine activates inflammatory 
cells including basophils and eosinophils, and releases proinflammatory 
mediators including leukotrienes and cytokines (Faustino-Rocha et al, 2017). 
Therefore, to control allergic reactions, antihistamines were designed to inhibit 
the function of histamine by blocking histamine receptors (e.g., K) or inhibiting 
the activity of the enzyme L-histidine decarboxylase (Faustino-Rocha et al, 
2017). Some antihistamines (including K) show antiinflammatory activity by 
inhibiting the accumulation and activation of inflammatory cells by suppression 
of nuclear transcription factor kappa B (NF-κB) (Faustino-Rocha et al, 2017; 
Simons and Simons, 2011). In this thesis, the word antihistamine will be used to 
refer to H1 antagonists. 
Antihistamines are widely used in allergic conditions including rhinitis, atopic 
dermatitis, contact dermatitis, urticarial, allergic conjunctivitis, hypersensitivity 
reactions to drugs and mild transfusion reactions (Carson et al, 2010; Simons 
and Simons, 2011). Antihistamines are mainly used to improve symptoms in the 
early phase of allergic reactions such as sneezing, nasal and conjunctival itching, 
conjunctival erythema, rhinorrhea and tearing (Simons and Simons, 2008). In 
addition, some antihistamines, such as K, inhibit histamine release from mast 
cells and decrease mast cell activity. K inhibits mast cell degranulation by 
stabilizing their membranes. Therefore, K has both antiallergic and 
antiinflammatory potency that improve symptoms in both early and late phases 
of allergic reactions (Grant et al, 1990; Weller and Maurer, 2009).  
There are two ways to classify antihistamines. The first is based on their 
chemical structures where they are divided in to seven groups: alkylamines 
(chlorpheniramine, acrivastine), piperazines (cyclizine, cetirizine), piperidines 
(ketotifen, fexofenadine), ethanolamines (diphenhydramine, doxylamine), 
ethylenediamines (pyrilamine, tripelennamine), phenothiazines (promethazine) 
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and others (doxepin, emedastine) (Simons and Simons, 2008). The second 
classification is based on their selectivity for H1 receptors and their ability to 
enter the CNS. In this case they are termed either first-generation antihistamines 
(e.g., K and diphenhydramine) or second-generation antihistamines (e.g., 
fexofenadine and cetirizine). First-generation antihistamines have (1) low 
selectivity for H1 receptors, due to the direct interaction with tryptophan, a 
highly conserved key residue in GPCR activation (Shimamura et al, 2011) and (2) 
a marked ability to enter the brain. In contrast, second-generation 
antihistamines show high selectivity for H1 receptors and do not or only enter 
the brain to a limited extent (0–30% of CNS H1 receptor occupancy) (Mahdy and 
Webster, 2014). This leads to the difference of side effects (Table 1.2).  
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Table 1.2 Side effects of first- and second-generation antihistamines.  
Mechanism First-generation antihistamine 
Second-generation 
antihistamine 
H1 receptor inverse agonist CNS depression (somnolence, impaired cognitive and psychomotor 
performance) and other CNS effects (seizures, dyskinesia, dystonia, 
hallucinations) 
Minimal or no CNS 
depression with 
standard clinical dose 
Blockade of muscarinic 
receptors 
Dilation of pupils, blurred vision, dry eyes, dry mouth, urinary 
retention, hesitancy, constipation, erectile dysfunction, and memory 
deficits 
None or minimal 
Blockade of serotonin 
receptors 
Appetite stimulation and weight gain (especially with cyproheptadine 
and K) 
None or minimal 
Blockade of α-adrenergic 
receptors 
Peripheral vasodilation, orthostatic hypotension and dizziness None or minimal 
Blockade of cardiac ion 
channels  
Sinus tachycardia (does dependent), reflex tachycardia, prolonged 
atrial refractive period, and supraventricular arrhythmias 
Minimal 
Mahdy and Webster, 2014, Simons and Simons, 2011 
 
Through CNS H1 receptors, histamine regulates vigilance (alertness and attention), cognition, learning, memory, and the circadian 
sleep-wake cycle (Haas et al, 2008; Leurs et al, 2011; Thakkar, 2011). Therefore, blocking H1 receptors in the CNS results in various 
side effects including sedation (Table 1.2).
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Although the H1 receptor is linked to sedation, it remains unclear whether other 
histamine receptors are involved in the sedative effect.  
Three subtypes of histamine receptors are expressed in the CNS, the H1, H2 and 
H3 receptors. The H1 and H2 receptors are both found in some regions of the 
brain where are involved in regulation of the sleep-wakefulness cycle (Palacios 
et al, 1981; Vizuete et al, 1997). The expression level of H1 receptors in these 
regions is high to moderate whereas the expression level of H2 receptors is 
moderate to low. Despite the expression of the H2 receptor in sleep-wakefulness 
regulation regions, evidence indicates that the H2 receptor does not take part in 
regulation of sleep-wakefulness (Luo and Leung, 2009; Monti et al, 1986, 1990; 
Onodera et al, 1994; Sastry and Phillis, 1976). However, it has been reported that 
H3 antagonists cause dose-dependent prolonged wakefulness suggesting that the 
H3 receptor is involved in the regulation of the sleep-wakefulness cycle (Thakkar, 
2011). Therefore, H1 and H3 receptors are key mediators of histaminergic action 
on wakefulness, although the H3 receptor works in the opposite direction to the 
H1 receptor (Thakkar, 2011). The human H3 receptor only shares 22% homology 
with the H1 receptor (Gustavo et al, 2016) so that it is unlikely that H1 and H3 
receptors share common agonists or antagonists. Furthermore, there is no 
evidence to indicate whether K or N is an H3 receptor agonist or antagonist. 
Therefore, the hypothesis of this thesis is that the sedative effects of K and N are 
due to binding to the H1 receptor in the brain. The literature also supports this 
(Gupta et al, 2007; Tashiro et al, 2002, 2008; Yanai et al, 2011; Yanai and 
Tashiro, 2007).  
To evaluate the extent of blockade of CNS H1 receptors, animal models are 
available for in vivo experiments. In all examined mammalian species, the 
locations of histaminergic neurons are mainly in the tuberomammillary nucleus 
(TMN) and/or surrounding regions; only minor differences exist between 
species (Thakkar, 2011). Therefore, to investigate the sedative effect and sleep-
wake cycles related to antihistamines, different animals are used including cat 
(Lin et al, 1994), rabbit (Monnier et al, 1970), rat (Ahmad et al, 2016; Monti et al, 
1986, 1990, 1993, 1994; Shigemoto et al, 2004a, 2004b; Tokunaga et al, 2007; 
Unno et al, 2012;), mouse (Wang et al, 2015) and dog (Wauquier et al, 1981). Of 
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all these animal models, rat and mouse are the most commonly used because of 
their easier accessibility and lower cost. 
Although the mouse is cheaper and available in specific gene knockout (KO) 
models (Wang et al, 2015), the rat is superior for its behavioural characteristics 
and size in studying sleep-wakefulness (Revel et al, 2009). Specifically, Wistar 
(Monti et al, 1994; Rojas-Zamorano et al, 2009; Shigemoto et al, 2004a; Tasaka et 
al, 1988; Tokunaga et al, 2007) and Sprague-Dawley (Kalivas, 1982; Ramesh et 
al, 2004) rats have been widely used in many studies, which focused on the sleep 
and wakefulness induced by histamine, its agonists and antagonists. In addition, 
the Wistar rat has been used to determine the H1 receptor occupancy in brain 
homogenate (Midzyanovskaya et al, 2016; Wu et al, 2013). Therefore, in this 
thesis, the male Wistar rat was chosen as the animal model to study the reason 
for the purported difference in the CNS sedative side effect of K and N both in 
vitro and in vivo. 
1.3 Ketotifen and norketotifen 
K (Figure 1.1 a and c) and its active metabolite N (by oxidative N-demethylation 
pathway)(Figure 1.1 b and d) (Aberg et al, 2015; Le Bigot et al, 1987) are both 
chiral compounds that have S- and R-atropisomers (Breyer-Pfaff and Nill, 2000). 
Both K and N are relatively lipophilic, basic drugs (Table 1.3). The calculated log 
P (clog P) of K is reported to be less than that of N even though K has one more 
methyl group which, theoretically, make its log P value greater by 0.5 (Fujita et 
al, 1964). The calculated log D (clog D) values of K and N seem to agree with the 
theory.  
The anomaly of clog P of K and N could be due to the following reasons: (a) the 
deviation of the clog P from the experimental log P as the calculated value does 
not always in a line with the experimental value, or (b) the deviation of the clog P 
values caused by different calculation methods as there are several methods for 






Table 1.3 Physicalchemical properties of ketotifen (K) and norketotifen (N) 
including molecular weight (MW), clog P, log D (pH 7) and pKa values at 25°C 
obtained from SciFinder Scholar (CAS). 
 MW (g/mol) clog P clog D (pH = 7) pKa 
K 309.43 2.19 ± 0.73 0.37 8.84 ± 0.20 
N 295.40 2.65 ± 0.51 -0.26 10.35 ± 0.20 
 
Oral K has been used in patients with allergic rhinitis, allergic conjunctivitis, 
atopic dermatitis, urticaria, asthma, mastocytosis, and food allergy in some 
countries including Canada, Europe, and Mexico. For adult and children more 
than three years old, the recommended oral does for ketotifen is 1 mg twice a 
day (Sokol et al, 2013). 
After oral delivery, K is readily absorbed from the GI tract and reaches peak 
plasma/serum concentration (Cmax) within two to four hours. However, the 
bioavailability of K is only about 50% because of first-pass metabolism in the 
liver (Grant et al, 1990; Le Bigot et al, 1987). K is 75% bound to plasma proteins 
(FDA drug approval package). The clearance of K from plasma is biphasic, with a 
3-hour distribution half-life (t1/2) and a 22-hour elimination t1/2 in adults (Grant 
et al, 1990). The two main metabolic pathways for K in human are hepatocytes, 
keto-reduction (reduced K) and N-glucuronidation (K-glucuronide). Traces of N 
and oxidized K were also found (Figure 1.3) (Le Bigot et al, 1987).  
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Figure 1.3 Ketotifen and its metabolites including norketotifen. 
The enzymes that contribute to the main metabolic routes of K are UDP- 
glucuronosyltransferase (UGT)2B10, UGT1A4 and aldo-keto reductase (AKR)1C1 
for N-glucuronidation and keto-reduction respectively (Kato et al, 2013; Weiner 
et al, 2006). Although oxidative N-demethylation is not a main route of K 
metabolism, it contributes to produce the active mebabolite N in human 
hepatocytes (Le Bigot et al, 1987). 
Only two reports have discussed the pharmacokinetic parameters of N, one being 
a patent and the other one a research study. The patent reported that after 
dosing N for 28 days (5.6 mg/kg/day) to five male Beagle dogs, N accumulated in 
skin to a much higher extent than in plasma (Table 1.4) suggesting a possible 
application of N in skin conditions (Aberg A. K. G, Patent US9439895 B2). 
Table 1.4 Pharmacokinetic parameters of N after 28 days dosing (5.6 
mg/kg/day) in five Beagle dogs.  
SN RN Racemic N 
 
Plasma Skin Plasma Skin Plasma Skin 
AUC*0-∞ 1627 25710 1658 20376 3286 54187 
t1/2 (h) 10.9 162.7 7.7 157.0 10.5 167.6 
*AUC: Area under the curve 






N-glucuroketotifen N-oxidized ketotifen 
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The research paper reported PK parameters of both K and N, in a malarial mouse 
model (Milner et al, 2012). However, there were calculation and unit errors in 
this paper making it unreliable.  
Pharmacodynamic parameters of K and N have also been investigated in mice 
(Aberg A. K. G, Patent EP 2911510 A1). The results suggest that K has a higher 
affinity for the H1 receptor than N whereas N is more potent as an 
antiinflammatory agent (Table 1.5). 
 
Table 1.5 Antihistamine and antiinflammatory properties of ketotifen (K) and 
norketotifen (N) in mice. 
 H1 EC50 (nM)* Inhibition (%)** EC50 (μM)# 
K 2.3 98 91 
N 11 82 9.2 
* In vitro experiment using binding assay. EC50 values are the concentration that inhibits 50% of 
specific binding of the ligand. 
** In vivo experiment calculating inhibition (%) of histaminergic effects after 10mg/kg dosage of 
K and N in rats. 
# Inhibition of inflammatory mediator histamine release from human leukocytes. 
Patent EP 2911510 A1 
 
This patent also reported the sedative effects of K and N (racemate and 
atropisomers) in mice (Table 1.6). The results indicate that N has a lower 
sedative effect than K and that the sedative effect of N is due to its R-atropisomer 
(Patent EP 2911510 A1). 
 
Table 1.6 Sedative effects of ketotifen (K), norketotifen (N) and the 
atropisomers of N (SN and RN) in mice.  
 Oral dose (mg/kg) Sedated mice 
25 5/10 











Patent EP 2911510 A1 
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Based on the mechanism of the sedative side effect of antihistamines, there are 
two potential explanations for the difference in the sedative effects of SN, RN and 
K:  
1. Stereoselective transport by which (a) SN enters the brain to a less extent 
and/or (b) SN bound to plasma protein/tissue to a greater extent than K and RN, 
such that there is less SN available for binding to CNS H1 receptors;  
2. Stereoselective binding to H1 receptors by which SN has a lower affinity for 
CNS H1 receptors in than K and RN, such that there is less SN bound to CNS H1 
receptors.  
To explore these hypotheses requires an understanding of why stereo-isomers 
behave differently in bio-systems?   
1.4 Chirality  
The word “chiral” is derived from the Greek word “cheir”, which means, “hand”. 
In 1884 Lord Kelvin introduced the terminology “chiral” and defined it in his 
Baltimore Lectures as: “I call any geometrical figure, or any group of points, chiral, 
and say it has chirality, if its image in a plane mirror, ideally realized, cannot be 
brought to coincide with itself”. Human hands are the best example of chirality: 
the left hand is the non-superposable mirror image of the right hand. As 
antihistamine K and N are both chiral compounds, this section mainly focuses on 
chirality of antihistamines. 
1.4.1 Concepts 
There are several important concepts to understand about chirality and they are 
described in standard textbooks (Solomons et al, 2012): 
Enantiomers: Chiral molecules differ in their three-dimensional configurations 
and exist in two forms, which are the mirror images of each other. These mirror 
images are called enantiomers. Certain enantiomers can be inverted from one to 
the other through a series of states. 
Atropisomers:  The name atropisomer comes from Greek, as “a” (not) and 
“tropos” (turn) (Bringmann et al, 2005), the ortho-substituents in tetra-
substituted biaryls are large enough to hinder the rotation around a C − C single 
bond. Therefore, interconvertion of atropisomers requires a high energy, which 
makes it possible for separation and purification for these molecules, though at 
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higher temperatures interconvertion may occur. As a result, atropisomers is the 
“grey area” between stereoisomers and conformations (Orchin et al, 2005).  
The notation used for atropisomers are R (axially rectus)/P (plus) and S (axially 
sinister)/M (minus) (Bringmann et al, 2005). The absolute axial configuration 
can be analysed using the Newman projection along the biaryl axis using the CIP 
system (Prelog and Helmchen, 1982). In this thesis, the notation R and S are used 
for K and N atropisomers. 
Racemate: an equimolar mixture of opposite enantiomers/atropisomers. 
1.4.2 Chirality in biological systems 
Chiral compounds have identical molecular formulas. In an achiral environment, 
the two forms of a chiral compound have the same physical and chemical 
properties, except for their ability to rotate polarized light. However, in a chiral 
environment, such as in a biological system, atropisomers sometimes display 
significant differences in their physicochemical and biochemical properties. 
Plasma proteins and transporters, which are chiral macromolecules, may form 
diastereomeric complexes with only one form of the pair of atropisomers 
(Campo et al, 2009; Lu, 2007). Therefore, it is possible that atropisomers show 
differences in absorption (Miura and Uno, 2010), protein binding, enzyme 
interactions, metabolism (Lu, 2007), receptor interactions and DNA binding, etc. 
(Smith, 2009).  
Different binding of atropisomers to chiral macromolecules, for example 
receptors and transporters, often results in one of the atropisomers being active 
(eutomer) whereas the other is inactive (distomer). Easson and Stedman (1933) 
proposed that the eutomer and distomer are differentiated by a three-point 
attachment model (Figure 1.4). Importantly, the distomer may not simply be 
ballast but also antagonise the process of the eutomer, or sometimes be toxic 




Figure 1.4 Chiral recognition between target and (a) eutomer and (b) 
distomer.   
1.4.3 Chirality in absorption, distribution, metabolism and elimination 
Stereochemistry applies to interactions between drug and enzymes, receptors 
and transporters. In addition, binding to plasma and tissue proteins is crucial to 
the overall pharmacological activity of a drug, because only the free or unbound 
drug crosses membranes and participates in receptor interactions. Chirality of 
binding may influence the pharmacological properties of a drug by affecting the 
free stereoisomer (eutomer or distomer) concentration (Gupta et al, 2006). As a 
result, there may be different absorption, distribution, metabolism and excretion 
behaviours between atropisomers (Table 1.7).
a b 
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Table 1.7 Examples of stereoselective behaviour in absorption, distribution, metabolism and elimination of chiral antihistamines. 





Plasma concentration of R-enantiomer 
is about 2-fold higher than S-
enantiomer 
Miura and Uno, 
2010; Tateishi et al, 
2008 
Stereoselective P-glycoprotein 
(P-gp) efflux in intestine 
Cetirizine 
Plasma concentration of levocetirizine 
is 2-fold higher than that of 
dextrocetirizine 
Baltes et al, 2001  
Absorption 
Terodiline 
Cmax and AUC of R-enantiomer are 
significantly higher than S-enantiomer 




Apparent volume of distribution (Vd) 
of levocetirizine is significantly smaller 
than that of the distomer 
Baltes et al, 2001; 
Gupta et al, 2006 
Higher plasma protein and tissue 
binding for eutomer 
Terodiline 
Stereoselective metabolism of R-
enantiomer 








Stereoselective metabolism of R-






Clearance of dextocetirizine is higher 
than that of levocetirizine 
Baltes et al, 2001; 




For pharmaceutical compounds and nutrients, stereoselective transporters 
express in membrane barriers, such as the intestinal barrier membrane and the 
blood-brain barrier (BBB), play an important role in the barrier permeability 
(Chang et al, 2015; He et al, 2010; Makrides et al, 2007; Miura and Uno, 2010; 
Shen et al, 2007). Understanding of receptors has been derived from research 
using in vitro methods, such as colorectal adenocarcinoma (Caco-2) cell 
monolayers as a model for the intestinal barrier and brain capillary endothelial 
cell monolayers as a model for the BBB. Antihistamines have been found to be 
substrates and/or inhibitors of stereoselective transporters including P-gp, 
multidrug-resistance protein (MRP), organic anion transporter (OAT), and 
others. This, therefore, results in different pharmacokinetic and 
pharmacodynamic properties between antihistamine enantiomers/atropisomers 
(Akamine, 2015; He et al, 2010; Miura and Uno, 2010; Shen et al, 2007). Several 
stereoselective transporters have been found at the BBB, thus it is possible that 
these transporters may contribute to the stereoselective transport of N into the 
CNS. Therefore, it is important to understand the barriers between the blood and 
the CNS, transporters expressed on the barrier and which of them may 
contribute to transport K and/or N into the CNS. These are discussed in the next 
section (Section 1.5). 
1.5 The BBB and its characteristics 
1.5.1 What is the BBB?  
The brain is protected by the skull and three barriers: the blood-arachnoid 
barrier (BAB), the blood-cerebrospinal fluid barrier (BCSFB) and the BBB 
(Davson and Segal, 1995).  
The BAB, lying under the dura mater, is a membrane formed by multilayers of 
epithelial cells completely enclosing the CNS. The inner epithelial cells are 
connected by tight junctions, which effectively isolate the CNS extracellular fluids 
from the rest of the body (Abbott et al, 2006). By projecting through the dura 
mater, the arachnoid villi projects into the sinus but allow only cerebrospinal 
fluid (CSF) to pass, and is the mechanism by which substances in the CSF move 
from brain to blood. In addition, the surface area of this passive anatomical 
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barrier is relatively small; so that the BAB is not an important route for the entry 
of solutes into the brain (Eyal et al, 2009; Kandel et al, 2000).  
The BCSFB is primarily located within the choroid plexus (CP) and projects into 
brain ventricles. Drug transfer between the blood and CSF is limited by the 
BSCFB at which CP epithelial cells are sealed by tight junctions (Redzic and Segal, 
2004). Although drugs are transferred from blood to brain across the BBB and to 
CSF through the BCSFB, individual neurons are located closer to brain capillaries 
(< 20 µm) than to brain ventricles or circumventricular organs (mm or cm) 
(Schlageter et al, 1999). Therefore, the primary interface for the transfer of drugs 
between the circulation and the CNS is the BBB (Eyal et al, 2009).  
As discussed, the BBB is a delivery route as well as a barrier for most 
pharmaceutical compounds to enter the brain (Abbott et al, 2010; De Boer and 
Gaillard, 2007; Kandel et al, 2000). In this thesis, no further interest was taken in 
the BCSFB and BAB for delivering antihistamines into the CNS and they are not 
discussed any further in the following sections. 
The BBB is the interface between the blood and the brain and it significantly 
restricts the transport of drugs from cerebral capillaries in the brain. The BBB is 
formed by the brain capillary endothelial cells and their connecting tight 
junctions (Figure 1.5) that segregate the circulating blood from interstitial fluid 
in the brain (Reese and Karnovsky, 1967, Pardridge, 2016, Wilhelm et al, 2016). 
There are approximately 600 km of cerebral capillaries with an estimated area of 
almost 20 m2/ 1300g within the human brain (Kalimo, 2005; Pardridge, 1993).  
Besides endothelial cells and tight junctions, capillary astrocyte foot processes 
and pericytes (Figure 1.5) also contribute to BBB functions (Jiang, et al, 2018, 
Pandey et al, 2016; Pardridge, 1993; Pardridge, 2016; Wilhelm et al, 2016).  
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Figure 1.5 A diagram of (a) a brain capillary (the BBB) and comparison of an 
electron micrograph of (b) a highly permeable fenestrated (arrows) general 
capillary (c) brain capillary (E: endothelial cells, P: pericyte) and (d) higher 
magnification part of brain capillary (A: astrocyte foot process, BL: basal 
lamina and tight junctions: arrow).  
(Wolburg et al, 2009; Abbott et al, 2006) (Reproduced with permission) 
 
Compared with the general capillary, the brain capillary is ‘wrapped’ by several 
other types of cells including astrocyte foot processes and pericytes (Figure 1.5). 
The astrocyte foot processes contribute to upregulation of tight junction proteins 
(both in vivo and in vitro), the development of polarized transport in the 
endothelial cell membranes and expression of enzymes (Abbott et al, 2006; 
DeBault and Cancilla, 1980; Jiang, et al, 2018; Tao-Cheng et al, 1987; Wolburg et 





tight junction formation and BBB differentiation. They also contribute to 
microvascular vasodynamic capacity and structural stability (Balabanov and 
Dore-Duffy, 1998; Jiang et al, 2018).  
In addition to astrocytes and pericytes, nerve terminals and microglia (Figure 
1.5) are also closely associated with the endothelium. These cells form a second 
line of defence and play supporting roles in barrier induction, maintenance and 
function (Abbott et al, 2006; Abbott et al, 2010; Nakagawa et al, 2009; Shimizu et 
al, 2008).  
1.5.2 The BBB function 
Although it is only 0.4 μm thick, the BBB is claimed to stop most small molecular 
weight drugs and 100% of large molecular weight drugs from passing into the 
brain (Pardridge, 2005). The BBB does this via several mechanisms; by acting as 
a physical barrier (tight junctions between cells decreasing passive diffusion via 
the paracellular pathway), a metabolic barrier (enzymes metabolize molecules 
as they cross), and a transport barrier (efflux transporters) (Abbott et al, 2006). 
These three mechanisms are discussed in more detail below. 
The tight junctions restrict transport by paracellular pathways through the BBB. 
To measure the “integrity” of the BBB, the transendothelial electrical resistance 
(TEER, which represents ionic permeability through tight junctions) is used 
(Claude, 1978). The TEER value of the BBB is approximately 1000 – 5000 Ω cm2 
whereas, in general capillaries, it is about 10 Ω cm2 (Lo et al, 2001). Because of 
these complex and restricted tight junctions, only gases and small lipophilic 
molecules can pass the BBB by passive diffusion (Pardridge, 1993).  
To form these endothelial tight junctions, occludin and claudin families are the 
most important integral membrane proteins with four transmembrane domains 
and two extracellular loops (Figure 1.7). The occludin and claudin molecules are 
established in lipid structures where their extracellular loops may interact with 
each other to form a paracellular barrier (Piontek et al, 2008). Other integral 
membrane proteins including members of the Ig superfamily, the endothelial 
cell-selective adhesion molecule (ESAM) and the coxsackie and adenovirus 
receptor (CAR) also contribute to the “seals” between cells (Gonzalez-Mariscal et 
al, 2007). In addition, adaptor proteins are part of tight junction components. 
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First-order adaptors directly associate with Zonula occludens (ZO)-1, ZO-2, and 
ZO-3, whereas second-order adaptors indirectly associate with cingulin, cingulin-




























Figure 1.6 Molecular compositions of endothelial tight junctions. 
 Abbott et al, 2006, reproduced with permission 
 
While the tight junctions form a physical barrier, the BBB is not only a static 
physical barrier but also a dynamic interface with physiological functions. The 
high volume of mitochondrial expression (Wolburg et al, 2009) and a variety of 
enzymes on the cellular plasma membranes (aminopeptidases, 
carboxypeptidases, endopeptidases, cholinesterases, monoamine oxidase and 
others) are characteristics of brain capillary endothelial cells (Agundez et al, 
2014). Mitochondria and ecto-enzymes deactivate and/or inactive drugs that 
penetrate the cells of the BBB (Pardridge, 2002). It has been reported that 
CYP1B1 is the predominant CYP isoform (over 80%) in human brain 
microvessels (Dauchy et al, 2008). In addition, CYP2U1 and phase II enzymes 
encoded by GSPT1, GSTM2, 3, 5 and GSTO1 genes, are expressed at the BBB 
(Shawahna et al, 2011). Among which, glucuronosyltransferase, particularly 
UGT1A4 contributes to the main metabolic route of K (N-glucuronidation) 
(Kerdpin et al, 2009; Li et al, 2007). Interestingly, from another aspect, this 
metabolic barrier is also be used to produce active drugs from pro-drugs 
(Anderson, 1996).  
The last barrier is constituted by efflux transporters, which function as pumps to 
expel substrates from cells back to the blood. There are three main efflux 
transporters of the adenosine triphosphate (ATP) binding cassette (ABC) 
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superfamily have been found at the BBB. They are P-gp, MRPs and breast cancer 
resistance protein (BCRP). Details of these transporters along with other 
transporters expressed at the BBB are discussed in below (Section 1.6). 
1.5.3 General rules for passage through the BBB 
Although BBB permeability is limited for most compounds, there are still some 
that pass freely through the BBB. Polar lipid soluble small molecules with a 
molecular weight < 500 Da and surface area < 50 – 100 Å cross the BBB (Fischer 
et al, 1998). In addition, the number of hydrogen bond donor/acceptor groups of 
a compound must be < 10. Furthermore, the compound should not be a substrate 
of BBB enzyme systems or BBB efflux transporters and should not bind 
excessively to plasma proteins (Pardridge, 2002). 
Most of the rules apply to K and N, such as molecular weights are less than 500 
Da, surface area (K: 48.6 Å) is less than 50 Å, and sum of hydrogen bond donor 
and acceptor groups (K: 2 and N: 3) are less than 10. Although 75% K binds to 
plasma proteins, it is possible that both K and N are transported by passive 
diffusion if they are not a substrate of BBB enzyme systems or BBB efflux 
transporters. 
1.6 Transporters at the BBB 
As discussed in Section 1.5, though restricted permeability caused by the BBB 
applies to both pharmaceutical compounds and nutrients, the brain must take up 
nutrients and dispose of metabolic wastes.  
There are many transporters that serve important roles in drug delivery into/out 
of the CNS expressed at the BBB. These include the influx pumps organic anion 
transporting polypeptide (OATP)1A2, OATP2B1 and efflux pumps P-gp, BCRP, 
MRP4 and MRP5 (Figure 1.7). Compared with influx transporters, more interest 
has been focused on the efflux transporters. 
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Figure 1.7 Apical (luminal) transport proteins of brain capillary endothelial 
cells contributing to the function of the blood–brain barrier including the 
uptake transporters OATP1A2 and OATP2B1, and the efflux pumps P-gp, 
BCRP, MRP4 and MRP5.  
Giacomini et al, 2010, reproduced with permission 
 
1.6.1 Efflux transporters 
P-gp: 
P-gp belongs to the multiple drug resistance (MDR) family (ABC family, ABCB). It 
is an active transporter that uses ATP to efflux its substrates independent of 
concentration gradient, electrochemical transmembrane potential or proton 
gradient (Konig et al, 2013; Schinkel, 1999). Human P-gp is a large, glycosylated 
membrane protein, which consists of approximately 1280 amino acids with a 
molecular weight of about 170 kD. It locates on the luminal membranes of 
cerebral capillary endothelial cells (Linnet and Ejsing, 2008; Schinkel, 1999). In 
addition to the BBB, P-gp expressed at organs and tissues such as liver and 
kidney, where it restricts the penetration of xenobiotics into cells in the small 
intestine, placenta (Konig et al, 2013), testes (Hughes et al, 1998) and the blood 
vessels that supply human gliomas and metastatic brain tumours (Gerstner and 
Fine, 2007). 
P-gp recognizes and transports a very wide spectrum of substrates, which 
molecular weight from approximately 250 Da to more than 1850 Da (Linnet and 
Ejsing, 2008). It transports cationic and/or zwitterionic compounds (Tamai and 
Tsuji, 2000) including a wide variety of chemotherapeutic agents of natural 
origin (anthracyclines, vinca alkaloids, epipodophyllotoxins, and taxanes), 
peptides (immunosuppressive agents cyclosporine A), cardiac glycosides 
(digoxin), antipsychotics and antidepressants (risperidone, nortriptyline, and 
citalopram), HIV protease inhibitors, antibiotics (macrolides), β-blockers 









Brain capillary endothelial cells
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Ejsing, 2008) and antihistamine (fexofenadine) (Miura and Uno, 2010). 
Therefore, P-gp is important for delivery of pharmaceuticals and critical for 
transporter-mediated drug-drug interactions (DDIs) (Konig et al, 2013) and 
moreover, may potentially participate in transport of K and N.  
Inhibitors of P-gp are classified based on their specificity and affinity into three 
generations. First-generation inhibitors are pharmacologically active drugs that 
include calcium channel blockers (verapamil), immunosuppressants 
(cyclosporin A), antihypertensives (reserpine, quinidine and yohimbine) and 
anti-oestrogens (tamoxifen and toremifena). High doses are required to achieve 
inhibition, which may result in toxicity. Second-generation inhibitors are agents 
that lack pharmacological activity but usually possess a higher P-gp affinity 
including non-immunosuppressive analogues of cyclosporin A, PSC 833, the D-
isomer of verapamil (dexverapamil) and others such as biricodar (VX-710), 
GF120918 and MS-209. Because of the non-specific inhibition by this class of 
inhibitors, complicated DDIs may occur. Third-generation P-gp inhibitors are 
under development as highly specific inhibitors with low toxicity. Modulators 
such as LY335979, OC144093 and XR9576 have been shown to be highly potent 
as well as highly selective inhibitors of P-gp with potency about 10-fold greater 
than first- and second-generation inhibitors (Eyal et al, 2009; Varma et al, 2003). 
MRP:  
The human MRP family (ABC Family ABCC) consists of thirteen MRP proteins 
including one ion channel, two cell surface receptors, a truncated protein that 
does not mediate transport, and MRP 1 − 9. MRP 1 − 9 are ATP-dependent 
transporters, some of which require the presence of co-factors for their activity 
(Deeley et al, 2006). MRPs share approximately 15% amino acid sequence 
homology with P-gp (Loe et al, 1996). Consequently, there are partial overlaps of 
selectivity for other ABCC transporters, P-gp, ABCG2 and organic anion 
transporters (Eyal et al, 2009; Leggas et al, 2004).  
MRP1, 2, 4, 5, 8 and 9 have been found in the brain (Dallas et al, 2006). However, 
only MRP1, 2, 4 and 5 have been detected at the BBB (Eyal et al, 2009; Kusuhara 
and Sugiyama, 2005; Potschka et al, 2003) and only MRP1, 4 and 5 are confirmed 
to be located on the luminal membrane of the human BBB (Dallas et al, 2006). 
More recent research on brain MRP protein quantification using liquid 
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chromatography-mass spectrometry (LC−MS) suggests that only MRP4 is 
expressed in quantifiable levels at the human and rodent BBB (Agarwal et al, 
2012; Kalvass et al, 2013; Shawahna et al, 2011). Therefore, in respect of 
transporters in the BBB, MRP4 is the most important in the MRP family. 
Substrates of MRP4 include a variety of mono-phosphorylated compounds, cyclic 
nucleotides (cyclic adenosine monophosphate and cyclic guanosine 
monophosphate), nucleotide analogs (9-(2-phosphonylmethoxyethyl)adenine) 
and azidothymidine monophosphate and purine analogs (6-mercaptopurine and 
6-thioguanine) (Chen et al, 2001; Dallas et al, 2006; Lai and Tan, 2002; Reid et al, 
2003; Schuetz et al, 1999; Wielinga et al, 2003).  
Although MRP4 plays an important role in BBB function, it is predominantly an 
organic anion transporter, also transporting neutral organic compounds. 
Therefore, it is unlikely to participate in transport of K and not discussed further. 
BCRP: 
BCRP (ABC family, ABCG) is one of the luminal/apical localized ABC transporters 
present in human brain microvessels (Cooray et al, 2002; Dauchy et al, 2008; 
Zhang et al, 2003). This so-called half-size ABC transporter (consists of only 655 
amino acids, half the size of P-gp and MRP2) has been found at almost twice the 
concentration of P-gp in brain microvessels (Shawahna et al, 2011).  
Substrates of BCRP include antivirals (acyclovir), statins (Matsushima et al, 
2005) and antibiotics (ciprofloxacin and ofloxacin), as well as diclofenac, 
sulfasalazine, cimetidine, endogenous substances and metabolites (vitamin K3), 
and uric acid. The substrate specificity of BCRP partially overlaps with that of P-
gp. Compounds efflux by both P-gp and BCRP including zidovudine, lamivudine, 
prazosin, pantoprazole, and the chemotherapeutic agents methotrexate, 
doxorubicin, daunorubicin, mitoxantrone, topotecan, irinotecan, imatinib 
(Gleevec) and gefitinib (Iressa) (Eyal et al, 2009). 
Inhibitors of BCRP include GF 120918 (also inhibits P-gp), fumitremorgi C (FTC) 
and FTC analogues such as Ko132, Ko134, and CI1033 (Wolfgang and Heidrun, 
2005), cyclosporine, tacrolimus, omeprazole and pantoprazole and saquinavir 
(Konig et al, 2013). BCRP protects the brain against toxicants, xenobiotic, and 
their metabolites.  
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1.6.2 Other transporters (influx transporters) 
In addition to the three main efflux transporters, other drug transporters have 
been found at the BBB. Transporters of the solute carrier (SLC) superfamily 
include facilitated transporters and ion-coupled transporters and exchangers 
that do not require ATP. Over 360 human SLC transporters have been identified 
(Hediger et al, 2004). The SCL family plays an important role especially in 
organic anions transport (Kusuhara and Sugiyama, 2005). The organic anion 
transporting polypeptides and organic anion/cation/zwitterion transporter 
families have an important role in drug transport into the brain (Eyal et al, 
2009). They are divided into the following subfamilies: OAT, OATP, organic 
cation transporter (OCT), organic cation/zwitterion transporter (OCTN), 
concentrative nucleoside transporter (CNT), the equilibrative nucleoside 
transporter (ENT), multidrug and toxin extrusion transporter (MATE), and 
others (Bauer et al, 2005). Transporters that are not expressed in brain or at the 
BBB are not covered in this section. 
OATPs: 
There are eleven members in the human OATP family (SLC21/SLCO). Based on 
amino acid sequence similarities, they are divided into six subfamilies OATP1 – 6 
(Hagenbuch and Meier, 2004). The OATPs are sodium-independent, multi-
specific anion exchangers. They mediate bidirectional transport that depends on 
local substrate gradients. In this family, three transporters (OATP1A2, OATP2B1 
and OATP1C1) have been identified on human brain endothelial cells (Giacomini 
et al, 2010; Lai, 2013).  
Substrates of OATPs are anionic amphipathic molecules with molecular weights 
> 450 Daltons and a high degree of albumin binding. These consist of a broad 
range of drugs including antibiotics, chemotherapeutic agents, antihistaminic 
drugs, diuretics (fexofenadine, digoxin, and methotrexate) and several 
endogenously synthesized metabolites such as bile acids, thyroid hormones, or 
hormone conjugates (Konig et al, 2013; Lai, 2013).  
OAT: 
OATs do not require energy for transporting substrates. They are anion 
exchangers, which take up an organic anion into a cell and release another 
organic anion from the cell, or vice versa (Koepsell and Endou, 2004).  
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OATs consist of OAT1 – 4 (Konig et al, 2013). The summary of this transporter family is listed below (Table 1.8). 
 
Table 1.8 Summary of organic anion transporter. 
OAT 
family 
Expression location Substrate* examples Inhibitor* examples Reference 
OAT1 
(SLC22A6) 
It is highly expressed in basolateral 
membrane of proximal tubule cells 
in kidney. It is also expressed in the 
brain (cerebellum, choroid plexus, 
hippocampus and hypothalamus) 
and the placenta.  
  
Statins are OAT1 
inhibitors. 
 
Lopez-Nieto et al, 
1997; 
Cihlar and Ho, 2000;  
Sweet et al, 2002; 
Khamdang et al, 2004; 
Giacomini et al, 2010 
OAT2 
(SLC22A7) 
It is highly expressed in human 
liver. It is also expressed on 
basolateral membrane of proximal 
tubule cells in kidney.  
Substrates include angiotensin-converting 
enzyme (ACE) inhibitors (captopril), 
diuretics (bumetanide and furosemide), 
antibiotics  
(ceftibuten) and antivirals (ganciclovir).  
Statins are OAT2 
inhibitors. 
 
Sekine et al, 1997; 
Enomoto et al, 2002a; 
Khamdang et al, 2004  
OAT3 
(SLC22A8) 
It is expressed in basolateral 
membrane of proximal tubule cells 
in kidney. 
Substrates include ACE inhibitors (quinapril) 
angiotensin II receptor blockers (olmesartan) 
several diuretics, and antibiotics  
(rosuvastatin and pravastatin) and 
nonsteroidal antiinflammatory drugs 











Kusuhara et al, 1999;  
Hasegawa et al, 2002;  
Khamdang et al, 2004; 
Windass et al, 2007; 
Yuan et al, 2009; 
Yamada et al, 2007;  
Giacomini et al, 2010 
OAT4 
(SLC22A11) 
It is expressed in the luminal 
membrane of proximal tubule cells 
in kidney.  
Substrates include diuretics (bumetanide), 
torasemide and 
antineoplastic agent (methotrexate).  
 Babu et al, 2002;  
Hasannejad et al, 
2004;  
Hagos et al, 2007;  
Takeda et al, 2002 
* Detailed spectra of substrates and inhibitors are summarised in a book (Lai, 2013) 
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OCT and OCTN: 
Organic cation transporters (OCTs) are sensitive to potential. They are facilitated uniporters 
that are independent of Na+ (Koepsell et al, 2007). OCTs include OCT1 – 3 and 6, and mediate 
the absorption, distribution and excretion of cationic drugs (Ciarimboli et al, 2016). A 




Table 1.9 Summary of organic cation transporters. 
 Expression location Substrate* examples Inhibitor* examples Reference 
OCT1 
(SLC22A1) 
It is strongly expressed in the 
sinusoidal membrane of 
hepatocytes and has a weaker 
expression in small intestine, 
lung, heart, kidney, skeletal 
muscle, brain, placenta, eye, 
adrenal gland, immune cells, 
and skin. 
Endogenous compounds 
monoamine and neurotransmitters 
(serotonin, dopamine, and 
agmatine), etc. Drugs such as 
metformine, lamivudine, acyclovir, 
oxaliplatin, picoplatin and 
sorafenib. Toxins such as aflatoxin 
B1 or ethidiumbromide etc. 
Common inhibitors for both OCT1 and 
OCT2 include proton pump inhibitors 
(PPI, such as omaprazol and 
lansoprazole) 
tetrapropylammonium, 
tetrapentylammonium and desipramine, 
etc. EC50 for procainamide is 68-fold 
lower for OCT1 compared with OCT2 
Arndt et al, 2001; 
Koepsell, 2013; 
Ciarimboli et al, 2016; 




It is strongly expressed in the 
basolateral membrane of kidney 
proximal tubules and has a 
weaker expression in lung, 
placenta, brain (hippocampus, 
choroid plexus), small intestine, 
thymus, and inner ear 
The substrate specificity of OCT2 is 
broadly overlapping with OCT1, 
with some exceptions such as 
histamine, epinephrine and 
norepinephrine, etc. 
Common inhibitors for both OCT1 and 
OCT2 include PPI (omaprazol and 
lansoprazole etc.), 
tetrapropylammonium, 
tetrapentylammonium and desipramine, 
etc. EC50 for corticosterone is 38-fold 
lower for OCT2 compared to rOCT1 
Arndt et al, 2001; 
Busch et al, 1998; 
Koepsell, 2013; 
Ciarimboli et al, 2016; 
Lai, 2013; Nies et al, 
2011; Urtti, 2011 
OCT3 
(SLC22A3) 
It is expressed in brain (cortex, 
hippocampus, and substantia 
nigra), heart, skeletal muscle, 
liver, lung, kidney, small 
intestine, skin, mammary gland, 
and placenta 
Endogenous compounds such as 
neurotransmitters, epinephrine, 
norepinephrine, histamine and 
agmatine. Drugs such as 
metformin, oxaliplatin, lamivudine, 
lidocaine, quinidine, etilefrine, etc.  
Inhibitors include PPI (omaprazol and 
lansoprazole etc.) 
Koepsell et al, 2007, 
Koepsell, 2013;  





It is expressed in testis and 
epididymis, expressed at lower 
level in embryonic liver, 
hematopoietic cells, and several 
cancer cells 
It has a high affinity for carnitine.  Koepsell, 2013; 
Enomoto et al, 2002b 
* Detailed spectra of substrates and inhibitors are summarised in a book (Lai, 2013). 
 
It is reported that OCT1 and 2 may be involved in transport of cationic drugs through the BBB (Koepsell, 2013; Volk, 2014). However, 
literature suggests OCT is unlikely to be the transporter that participates in transport of K (Ishiguro et al, 2004). 
OCTN depend on membrane potential and/or concentration gradient for cation translocation (Lai, 2013). This transporter family incudes 
OCTN 1 – 3 (Volk, 2014). A summary of this transporter family is listed in the table below (Table 1.10).  
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Table 1.10 Summary of organic cation and zwitterion transporters (OCTNs). 
 Expression location Substrate* examples Inhibitor* examples Reference 
OCTN1 
(SLC22A4) 
It is expressed in kidney, intestine, 
spleen, heart, skeletal muscle, brain, 
mammary gland, thymus, airways, and 
male reproductive tract. 
Physiologically, OCTN1 is an ergothioneine 
transporter. 
Substrates include quinidine, verapamil, gabapentin, 










It is expressed in kidney, skeletal 
muscle, placenta, heart, prostate, and 
thyroid. It is also expressed at lower 
level in small intestine, liver, lung, or 
brain.  
Physiologically, OCTN2 is a carnitine transporter.  
Substrates include carnitine, TEA, choline, verapamil, 









OCTN3 Not detected in human 
* Detailed spectra of substrates and inhibitors are summarised in a book (Lai, 2013). 
 
Monocarboxylic acid transport systems (MCT): 
MCT1 (SCL16A1) present on both luminal and abluminal sides of brain capillary endothelial cells and it may be responsible for the 
transport of some organic anions from brain to endothelial cells and then to blood (Tamai and Tsuji, 2000). Substrates of MCT1 include 
lactate, pyuvate and the ketone bodies acetoacetate and β-hydroxybutyate (Galic et al, 2003). 
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1.7 Stereoselective transporters and receptors at the BBB 
Stereoselective absorption, disposition, metabolism and elimination can result 
from stereoselective transport and/or receptor activity (Table 1.7). Similarly, the 
difference in sedative effects of K and N atropisomers could also be due to their 
different affinities for BBB transporters and/or CNS H1 receptors.  
P-gp plays an important role in minimizing the sedative effects of second-
generation antihistamines including fexofenadine, cetirizine, loratadine, ebastine 
(Ecker and Chiba, 2009; Miura et al, 2007; Miura and Uno, 2010). Moreover, P-gp 
has been reported to be stereoselective for some second-generation 
antihistamines (fexofenadine) and other drugs (citalopram, mefloquine, 
loperamide, tacrolimus, pioglitazone and ivermectin) (Chang et al, 2015; Choong 
et al, 2010; Miura et al, 2007; Miura and Uno, 2010). S-Fexofenadine has been 
reported to have a higher P-gp affinity than the R-enantiomer (Miura et al, 2007). 
Sakugawa et al indicated that in the presence of verapamil (a P-gp inhibitor), the 
pharmacokinetics of S-fexofenadine showed a greater change than that of R-
fexofenadine. With verapamil, the AUCs of the S- and R-enantiomers were 3.5- 
and 2.2-fold higher respectively compared with the AUCs without verapamil 
(Sakugawa et al, 2009). Interestingly, P-gp can be regulated stereoselectively by 
cetirizine enantiomers (Shen et al, 2007).  
Not only P-gp, but the MCT has also been reported to be highly stereospecific for 
substrates and show evidence of selectivity for amino acids (Bickel et al, 2001). 
The glucose transporter (GLUT)-1 is stereoselective for the D-glucose 
stereoisomer (McAllister et al, 2001).  
However, some publications indicate that investigating stereoselective transport 
using total brain-to-plasma (B/P) ratio could be misleading. Gupta et al reported 
that the stereoselective transport of S-cetirizine results from stereoselective 
plasma protein and brain tissue binding (Gupta et al, 2006). This suggests it is 
important and necessary to determine the free B/P ratio to study stereoselective 
transport (Chapter 7). 
Stereoselective transporters and enzymes contribute to chiral drug delivery and 
stereoselective receptors also play an important role. For instance, Gustavo et al 
reported stereoselectivity of the H3 receptors based on the different affinity and 
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potency of the ligand enantiomers of R-α-methylhistamine (H3 receptor agonist) 
and thioperamide (H3 receptor antagonist) (Gustavo et al, 2016). More examples 
are shown in Table 1.11 (Smith and Jakobsen, 2007). 
Table 1.11 Examples of stereoselective receptors in the central nervous 
system. Data were summarised from a review paper. 




[123I]4-iododexetimide was a high affinity 
antagonist whereas [123I]4-
iodolevetimide was inactive 
Muller-Gartner 




Accumulation of S-[11C]mirtazapine was 
greater than that of R-[11C]mirtazapine  
 




D1-dopamine receptor was selectively 
inhibited by R-NNC 122 whereas S-NNC 
122 lacks affinity for this receptor. 




The (5R,6R)-cyclofoxy has high affinity at 
μ- and κ- receptors (in vitro), whereas 
(5S,6S)-cyclofoxy has virtually no affinity 
for opiate receptors.  
Ostrowski et al, 
1987 
Smith and Jakobsen, 2007 
1.8 Aim of this thesis 
Enzymes, transporters, receptors and protein binding can contribute to the 
stereoselective delivery of chiral compounds through the BBB. In this thesis, the 
reason for the lower sedative effect of SN than of SK, RK and RN was 
investigated. The following questions were posed and consequent investigations 
performed. 
Is there stereoselective transport of K and/or N into/through brain capillary 
endothelial cells? Immortalized rat brain endothelial (RBE4) and Caco-2 cell 
models were used for uptake and permeability studies respectively (Chapter 5);  
Is there stereoselective binding of K and/or N to the CNS H1 receptor? CNS H1 
receptor occupancy assay was used (Chapter 6);  
Is there stereoselective transport at the BBB? Rat tail vein injection technique 
was used to investigate the total and free B/P ratios of K and N (Chapter 7). 
To aid understanding and interpretation of in vitro and in vivo results, log P, log D 
of racemic K and N by different systems at different temperatures (4, 25 and 
37°C) were determined (Chapter 3). 
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To analyse samples in bio-matrices from in vitro and/or in vivo studies, chiral 
and nonchiral high-performance liquid chromatography (HPLC) assays were 
developed and validated (Chapters 2 and 4). 
 34 
 
Chapter 2 Nonchiral HPLC assay development and validation 
2.1 Introduction  
As HPLC is one of the most robust and widely used analytical techniques, it was 
chosen to be the basis for both a nonchiral assay to simultaneously determine 
racemic K and N and chiral assays to determine K and N atropisomers. Previous 
publications have reported nonchiral assays to determine racemates of K by 
HPLC (Le Bigot et al, 1983, 1987; Yagi et al, 2002; Nnane et al, 1998) and LC–MS 
(Tashiro et al, 2005) and nonchiral LC–MS assays to determine K and N (Mey et 
al, 1999; Milner et al, 2012) in various matrices. Although the LC–MS assay of 
Milner et al. (2012) determined both K and N in mouse plasma, it was decided to 
develop a less complex HPLC assay for their determination in RBE4 cell 
homogenate.  
In developing an HPLC assay to simultaneously determine K and N racemates, 
the choice of stationary phase (SP) is crucial. In this regard Yagi et al, (2002) 
reported a C8 SP gave better separation of K from endogenous peaks in plasma 
than a C18 SP despite having little effect on its retention time (Rt). Thus, a C8 
column was used here to develop the nonchiral HPLC assay for simultaneous 
determination of K and N. 
2.2 Materials  
2.2.1 Chemicals and reagents 
RBE4 cells were kindly provided by Professor Michael Aschner (Vanderbilt 
University, Nashville, TN, USA). Sodium dihydrogen phosphate monohydrate 
(99%) and potassium dihydrogen orthophosphate (≥ 99.5%) were purchased 
from BDH Laboratory Supplies (England). Racemic K and N fumarates (> 98%) 
were provided by GL Synthesis Inc. (MA, USA) through the kind offices of Dr 
Gunnar Aberg, BridgePharma, Sarasota, FL, USA. Acetonitrile (ACN), methanol, 
isopropanol and n-hexane were purchased from Merck (Darmstadt, Germany). 
HEPES (≥ 99.6%), anhydrous calcium chloride (≥ 96%) and Krebs-Ringer 
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bicarbonate buffer were obtained from Sigma (Auckland, New Zealand). The 
BCA™ protein assay kit was purchased from PIERCE (Rockford, IL, USA). 
2.2.2 Instrumentation (HPLC system) 
The HPLC system (Shimadzu Prominence series) consisted of a degasser (DGU- 
20A5), pump (LC-20AD), autosampler (SIL-20AC), C8 column (Luna 5 μm, 150 × 
4.6 mm, Phenomenex), column oven (CTO-20A) and diode array detector (SPD-
M20A). The software used for data analysis was CLASS-VP7.4 SP4. C18 guard 
cartridges, 0.45 μm nylon filter membranes, 100 μl HPLC inserts (PP LV, 5 × 32 
mm) and liners (PTFE/SIL, 8 mm) were purchased from Grace Davison 
Discovery Science (Deerfield, IL, USA). 
2.3 Assay development and validation 
2.3.1 Chromatagraphy 
Separation of K and N was assessed in terms of the separation factor α, a higher α 
value indicating better separation. The α value was calculated using Equation 
2.1:  
α = (Rt2 − Dt) / (Rt1 − Dt)                                                                                            2.1 
where Rt1 and Rt2 are the retention times of the first and second peak 
respectively, and Dt is the column dead time (time to the solvent front).  
As part of assay development, factors potentially affecting the separation of K 
and N including mobile phase composition, mobile phase pH, column 
temperature and flow rate were investigated as follows:  
Mobile phase composition: Flow rate 1 ml/min, column temperature 30°C, mobile 
phase ACN:50 mM phosphate buffer pH 6; 30:70, 40:60 and 50:50.  
Mobile phase pH: Flow rate 1 ml/min, column temperature 30°C, mobile phase 
30:70 ACN:50 mM phosphate buffer; pH 4, 5 and 6.  
Column temperature: Flow rate 1 ml/min, mobile phase 30:70 ACN:50 mM 
phosphate buffer pH 6; column temperature 20, 25, 30 and 40°C. 
Flow rate: Mobile phase 30:70 ACN:50 mM phosphate buffer pH 6, column 
temperature 30°C; flow rate 1.0, 1.2 and 1.5 ml/min. 
Detection was at 310 nm despite the fact that the wavelength of maximum 
absorption of both K and N is at 295 nm (Yagi et al, 2002). This is because the 
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peak due to K was subject to interference from an endogenous peak, which was 
not detected at 310 nm. In addition, the absorption of K and N at 310 nm was 
only slightly lower than at 295 nm. Quantitation was based on determination of 
peak areas.  
Another factor considered was whether to include an internal standard (IS). It 
was decided an IS was not necessary because sample preparation involved 
simple protein precipitation, recovery was consistently > 90% and accuracy and 
precision were acceptable based on the Bioanalytical Method Validation, 
Guidance for Industry of U.S. Food and Drug Administration (FDA) (2001). 
2.3.2 Sample preparation 
RBE4 cell monolayers in 75 cm2 collagen coated cell culture flask (BD BioCoat™, 
England) were washed with 5 ml Ringer-HEPES buffer (10 mM HEPES 1.2 mM 
calcium chloride, pH 7.4). Milli-Q water (5 ml) was added to each flask and 
incubated at 4°C overnight to lyse cells. Cell suspensions were collected by 
pipetting up and down several times and transferred to 1.7 ml centrifuge tubes. 
Glass beads were added and sample mixtures homogenised at speed 7 for 3 min 
using a Bullet Blender® (NEXT >>>ADVANCE, NY, USA). All homogenates were 
mixed together and protein concentration determined using 50 μl aliquots of 
homogenate in the BCA™ protein assay. The final protein concentration in quality 
control (QC) samples was approximately 250 μg/ml. 
Sample preparation of RBE4 cell homogenate (or calibration standards or QC 
samples) involved protein precipitation using 2 volumes ACN (180 μl sample 
plus 360 μl ACN) followed by vortexing and centrifuging (Eppendorf AG, 
Hamburg, Germany) at 10,000 rpm for 10 min. Supernatant (510 μl) was 
transferred into a clean tube and dried under vacuum at room temperature 
(Speed Vac Concentrator and Refrigerated Vapor Trap RVT4104, SAVANT) 
overnight. The residue was reconstituted in mobile phase (60 μl) followed by 
vortexing and centrifuging at 10,000 rpm for 10 min. Finally 55 μl supernatant 
was transferred into an HPLC insert and 50 μl injected into the HPLC system.  
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2.3.3 Validation  
Stock and standard solutions: K and N racemates (1 mg/ml) were dissolved in 
methanol. Further dilutions were made using Milli-Q water to give standard 
solutions with concentrations in the range 1 − 5 µg/ml. 
Calibration standards and QC samples: Mixed calibration standards containing 20, 
40, 80, 125 and 200 ng/ml K and N racemates (Table 2.1) and low, medium and 
high mixed QC samples (QCL, QCM and QCH) containing 25, 50 and 100 ng/ml K 
and N racemates respectively (Table 2.2) were freshly prepared on each assay 
day by spiking RBE4 cell homogenate with K and N standard solutions. 
Table 2.1 Preparation of mixed calibration standards for K and N racemates in 








Standard solution (μl) 







20 1 16 84 700 
40 1 32 68 700 
80 2 32 68 700 
125 2 50 50 700 
200 5 32 68 700 
 













25 1 225 8775 
50 2 225 8775 
100 4 225 8775 
 
Linearity and lower limit of quantitation (LLOQ): Linearity was determined based 
on construction of three calibration curves in the concentration range 20 − 200 
ng/ml. The LLOQ was taken as the concentration with a signal-to-noise ratio of 5 
to 1 (FDA 2001). 
Recovery: Recovery (%) was determined using triplicate QC samples as the peak 
area of the compound after sample preparation compared with the peak area of 
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the compound at the same concentration in mobile phase without sample 
preparation. 
Accuracy and precision: Intra- and inter-day accuracy (as percent relative error, 
RE) and precision (as percentage coefficient of variation, CV) were determined 
by analysis of 5 replicates of QC samples on 3 different days. Intra- and inter-day 
values are calculated according to Equations 2.2 and 2.3 respectively: 
Accuracy (%) = (∑ |Di − S| × 100) / N                                 2.2 
Precision (%) = (SD / mean) × 100                                                                    2.3 
where Di is the determined concentration, S is the nominal concentration, SD is 
the standard deviation and N is the number of determinations. 
For intra-day accuracy and precision, calculation was based on data from 
individual days (n = 5) while for inter-day values, a combination of data for all 
three days (n = 15) were used. 
Stability: Stability of racemic K and N in QC samples and in processed samples in 
the autosampler were investigated. The storage conditions are shown in Table 
2.3.  The remaining concentration (recovery) after storage was calculated using 
Equation 2.4. 
R (%) = (Di/C0) × 100       2.4 
where R is the percentage of remaining stable compound, Di is the determined 
concentration after storage and C0 is the determined concentration of fresh made 
QC sample. 
Table 2.3 Conditions of storage to determine stability of racemic K and N in 





Bench top 25 ± 1 4 h 
Autosampler (processed samples) 4 24 h 
3 Freeze-thaw cycles (- 80 to 25°C) N/A N/A 
Long-term storage - 80 2 months 
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2.4 Results and discussion  
2.4.1 Assay development 
Different HPLC conditions were tested to achieve the best separation of K and N, 
in addition, intensity of responses of these two compounds were also considered.  
Figure 2.1 showed the elution order of K and N on a C8 column in the optimized 
conditions. The tested HPLC conditions are shown in the following sections. 
Minutes










































Figure 2.1 Chromatograph of 125 ng/ml racemic ketotifen (6.25 min) and 
norketotifen (4.47 min) in mobile phase. 
Mobile phase composition: Increasing the ACN percentage in the mobile phase 
from 30% to 50% decreased the Rt of both K and N but had no effect on α (Figure 
2.2 a). 
Mobile phase pH: Increase in mobile phase pH from 4 to 6 increased the Rts of 
both K and N and, because the Rt of K increased more than that of N, increased α 
particularly from pH 5 to 6 (Figure 2.2b). 
Column temperature: Increasing the column temperature from 20 to 40°C 
decreased the Rts of both K and N but had little effect on α (Figure 2.2c). 
Effect of flow rate: Increasing the flow rate from 1.0 to 1.5 ml/min decreased the 




Figure 2.2 Effects of changing HPLC conditions on the separation factor (α) of 
racemic K and N; (a) mobile phase composition, (b) mobile phase pH, (c) 
column temperature and (d) flow rate (for conditions of each chromatograph 
see Section 2.3). 
The factor causing most change in the separation of K and N in RBE4 cell 
homogenate was the mobile phase pH. With increasing pH (from 4 to 6), the Rt of 
K increased from 5.43 min to 6.98 min while that of N increased only slightly 
from 4.76 min to 4.89 min such that separation between K and N increased. This 
is presumably because of the increasing difference in degree of ionization 
between K and N as pH increases from 4 to 6. The result is contrary to the 
findings of Galaon and David (2012) who found that as pH increased from 7 to 
8.5, the retention of N increased more than that of K such that their separation 
decreased.  
This discrepancy arises because, in changing form pH 4 to 6, the percent 
unionized K (pKa 8.8) increases from 0.002% to 0.2% whereas that of N (pKa 
10.4) increases from 0.00004% to 0.004%. In changing from pH 7 − 8.5, the 
percent unionized K increases from 1.6% to 33.4% whereas that of N increases 




















































The optimized conditions for the assay were mobile phase 30:70 ACN:50 mM 
phosphate buffer pH 6 delivered at a flow rate of 1 ml/min through a column 
maintained at 30°C. A chromatograph of K and N under these conditions is 
shown in Figure 2.3.  
Minutes


































Figure 2.3 HPLC of 80 ng/ml racemic ketotifen (6.98 min) and norketotifen 
(4.89 min) in RBE4 cell homogenate (α = 1.6) using the optimized condition 
for the assay.  
2.4.2 Assay validation 
Linearity and LLOQ: The assay was linear (R2 > 0.999) for both K and N (Figure 
2.4) in the concentration range tested. The LLOQ for both K and N was 20 ng/ml. 
 
y = 203.85x + 451.51
R2 = 0.9997 (N)
y = 205.7x - 240.26


















Figure 2.4 Calibration curves of racemic K and N in RBE4 cell homogenate 
(data are means ± SD, n = 3). 
Recovery: The recovery was > 90 % at all three QC concentrations. 
Accuracy and precision: Intra- and inter-day accuracies were satisfactory with 
concentrations ± 8 % of the nominal values at all QC concentrations. Intra- and 
inter-day precisions were < 19% for QCL and < 9% for QC M and QC H samples 
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(Table 2.4). These results indicate that the accuracy and precision of the assay 
meet the requirements of the FDA guidelines (2001). 
Stability: Under all storage conditions (Table 2.5), the concentrations of K and N 
racemates in QC samples remained ± 10 % of the nominal concentrations (Table 
2.5). This shows K and N are stable in RBE4 cell homogenate under the tested 
storage conditions. 
In conclusion, the nonchiral HPLC assay is a simple, reliable and accurate tool to 
determine racemic K and N in RBE4 cell homogenate and buffer solutions in log 
P and log D determinations. 
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Table 2.4 Accuracy and precision of the HPLC assay for racemic ketotifen (K) 
and norketotifen (N) in RBE4 cell homogenate (data are means ± SD for assay 












L (25) 25.1 6.0 6.6 
M (50) 50.1 0.9 3.5 Intra-day 1 
H (100) 96.4 4.0 4.9 
L (25) 26.1 4.8 12.1 
M (50) 51.2 3.5 5.4 Intra-day 2 
H (100) 104.7 4.7 3.0 
L (25) 24.8 4.0 15.2 
M (50) 48.9 4.0 8.9 Intra-day 3 
H (100) 101.3 2.0 2.5 
L (25) 25.3 5.1 10.6 
M (50) 50.1 2.8 5.7 
K 
Inter-day 
H (100) 100.8 3.8 3.5 
L (25) 22.8 7.3 18.0 
M (50) 49.1 2.3 4.3 Intra-day 1 
H (100) 101.2 4.3 2.6 
L (25) 24.4 4.8 12.9 
M (50) 51.1 3.5 5.4 Intra-day 2 
H (100) 103.3 4.7 3.1 
L (25) 25.2 4.7 18.7 
M (50) 49.8 4.0 8.7 Intra-day 3 
H (100) 101.2 2.0 2.5 
L (25) 24.1 5.7 15.6 
M (50) 50.0 3.3 5.6 
N 
Inter-day 
H (100) 101.9 3.9 2.8 
 
Table 2.5 Stability of racemic ketotifen (K) and norketotifen (N) in RBE4 cell 
homogenate stored under different conditions (data are means ± SD, n = 3 for 
percent compound remaining). 




(ng/ml) 25°C (4 h) 






25 91.3 ± 3.8 109.2 ± 5.5 101.6 ± 4.7 106.4 ± 3.3 
50 90.8 ± 2.5 103.9 ± 2.8 98.5 ± 3.2 100.9 ± 3.0 K 
100 94.6 ± 5.0 102.7 ± 2.4 106.2 ± 1.8 102.8 ± 2.7 
25 92.7 ± 4.5 99.6 ± 1.3 101.1 ± 1.3 97.0 ± 2.7 
50 95.2 ± 2.1 102.1 ± 3.5 97.7 ± 3.9 99.5 ± 0.4 N 
100 99.9 ± 4.5 100.1 ± 2.8 105.5 ± 2.0 105.2 ± 2.4 
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Chapter 3 Partition and distribution coefficients of ketotifen 
and norketotifen  
3.1 Introduction  
The partition coefficient P of a drug is usually determined in octanol/water (log 
P) as a measure of its relative lipophilicity. If the compound is ionised at or close 
to physiological pH (7.4), the distribution coefficient D is determined in 
octanol/buffer (log D). Log D at a particular pH is a measure of the relative 
lipophilicty of the compound at that pH. Generally log D < log P since the ionised 
form of the drug has low solubility in octanol. This is the case with K and N which 
exist as equilibrium mixtures of free base and positively charged conjugate acid. 
The calculated log P values of K and N (Table 3.1) from SciFinder Scholar (CAS) 
indicate K is less lipophilic than N, which is contrary to expectation based on 
their structures. However, the calculated log D values (octanol/buffer pH 7) are 
in the opposite order and are much lower than the corresponding log P values. 
Table 3.1 Calculated log P and log D (pH 7) of ketotifen and norketotifen at 
25°C obtained from SciFinder Scholar (CAS). 
 Log P Log D (pH 7) 
K 2.19 ± 0.73 0.37 
N 2.65 ± 0.51 -0.26 
 
Log P and log D values are useful in predicting the passive diffusion of drugs 
through cell membranes in cell uptake and permeability studies. However, effect 
of temperature on log D measurement is a complex interplay between multiple 
factors, such as distribution, pKa of drug and buffer. Therefore, to better 
interpret results from cell experiments (Chapter 5), it is important to determine 
log P and log D at certain temperatures, at which experiments were carried out.  
This chapter reports the determination of log P and log D of K and N at 
temperatures (4°C, 25°C and 37°C) relevant to such studies in Chapter 5 (REB4 
cell uptake at 4°C and 37°C and Caco-2 cell permeability at 37°C).  
Although log D in an octanol/buffer system is a convenient measure of relative 
lipophilicity, it does not necessarily reflect distribution across a cell membrane. A 
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more valid measure of this distribution can be obtained using liposomes because, 
like cells, they possess lipid bilayers with similar negative charges on their 
surfaces. This chapter also reports log D values of K and N in the 
liposome/Ringer-HEPES buffer pH 7.4 system at 37°C. 
3.2 Materials  
Soy lecithin phospholipid was obtained from Lipoid (GmbH, Ludwigshafen, 
Germany). Cholesterol (approx. 95%) was obtained from Sigma (USA). Other 
materials and chromatographic conditions are described in Section 2.2. 
3.3 Methods 
3.3.1 Assay 
The nonchiral HPLC assay (Chapter 2) was used to analyse samples from 
partition and distribution studies. Samples from octanol/water and 
octanol/buffer systems were dried under vacuum at room temperature to 
remove any residual octanol after which residues were reconstituted in mobile 
phase and analysed by HPLC. Both buffer and octanol phases were analysed 
whereas in the liposome/buffer system, only the buffer was analysed. 
3.3.2 Log P octanol/water: Effect of temperature 
For log P measurements, octanol-saturated water and water-saturated octanol 
were equilibrated at 4°C, 25°C and 37°C in a cold room (4°C), at room 
temperature and in a water bath (37°C) respectively. To obtain K and N free 
bases, 150 μl racemic K and N stock solutions (fumarate salt equivalent to 1 
mg/ml K and N in methanol) were evaporated at room temperature and 1.5 ml 
NaOH solution in water (pH 13) added. K and N free bases were then extracted 
into 3 ml water-saturated octanol after which aliquots (0.3 ml) of these solutions 
(50 μg/ml) together with 3 ml octanol-saturated water were added to a Mixor 
(Wu et al, 2004; Yang et al, 2009) (5 ml) and mixed 30 times to reach 
equilibrium. Finally aliquots (180 μl) of both the aqueous and octanol phases 
were collected, evaporated at room temperature, reconstituted in 60 μl mobile 
phase (30:70 ACN:50 mM phosphate buffer, pH = 6) and injected into the HPLC 
system.   
Log P was calculated using Equation 3.1: 
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Log P = Log 10 (Coct / Cwat)         3.1 
where Coct and Cwat are the concentrations of K or N in octanol phase and in 
aqueous phase at equilibrium respectively. 
3.3.3 Log D octanol/buffer: Effect of temperature 
Log D of K and N in octanol/Ringer-HEPES buffer pH 7.4 (10 mM HEPES and 1.2 
mM calcium chloride) was also determined at 4°C, 25°C and 37°C. In this case, 
150 μl racemic K and N stock solutions (fumarate salts equivalent to 1 mg/ml K 
and N in methanol) were evaporated to dryness and reconstituted in 30 ml 
octanol-saturated Ringer-HEPES buffer. An aliquot (3 ml) of this solution 
together with Ringer-HEPES buffer-saturated octanol (0.3 ml) were added to a 
Mixor (5 ml) and mixed 30 times to reach equilibrium. The two phases were then 
analysed for K and N as described above. Log D was calculated using Equation 
3.1 where Cwat was replaced by the concentration of K or N in buffer (Cbuf). 
3.3.4 Log D liposome/buffer 
3.3.4.1 Liposome preparation 
Liposomes were prepared by the thin film hydration method and extruded to 
decrease particle size and obtain a narrow size distribution. Soy lecithin 
phospholipid (100 mg) and cholesterol (25 mg) were dissolved in 5 ml 
chloroform-methanol (3:1, v/v) in a round-bottomed flask. The thin film was 
formed by rotary evaporation (Rotavapor R110) at 35°C under vacuum for 30 
min, then kept under vacuum overnight to remove traces of organic solvent. 
Ringer-HEPES buffer pH 7.4 (5 ml) and 0.5 g glass beads were added and the film 
hydrated by rotary evaporation without vacuum for 30 min. After hydration the 
liposomal suspension was sonicated (bath sonicator, RK100H) for 10 min and 
then extruded sequentially ten times through 200 nm Nucleopore Track-Etch 
membranes using a liposome extruder (Lipex Extruder, NORTHERN LIPIDS INC, 
Burnaby, Canada). Finally liposomes were suspended in Ringer-HEPES buffer pH 
7.4 containing 1.5 × 10-3 mg/ml (5 μM) racemic K or N to a concentration of 10 
mg/ml lipid.  
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3.3.4.2 Liposome characterization 
The concentration of phospholipid in the liposomal suspension was determined 
using the Stewart assay (Stewart, 1980). Particle size was determined by 
dynamic light scattering (DLS) using a Zetasizer (ZS90, Malvern Instrument, 
Worcestershire, UK). The liposomal suspension (20 µl) and Ringer-HEPES buffer 
pH 7.4 (1980 µl) were mixed in the cuvette and placed in the Zetasizer using a 
refractive index (RI) of 1.335, viscosity of 1.02 mPa.s and temperature of 25°C.  
3.3.4.3 Log D determination 
The liposome suspension containing 5 μM racemic K or N (0.5 ml) was injected 
into the donor side of an equilibrium dialysis device (10000 Da) and Ringer-
HEPES buffer pH 7.4 (0.5 ml) injected into the receptor side. The device was 
switched on and maintained at 37°C for 4 h to reach equilibrium. A sample (180 
μl) was removed from the receptor side and analysed for K or N.  
Liposome/Ringer-HEPES buffer apparent distribution coefficient (D) was 
calculated using Equation 3.2 (Plemper van Balen et al, 2004): 
D = VB × (Cini – 2CB) / (Vlipo × CB) + 1                                                                      3.2 
where Cini and CB are the concentrations of K or N on the receptor side initially 
and at equilibrium respectively, VB is the volume in buffer compartment and Vlipo 
is the volume of phospholipid used (calculated using the lipid concentration 
assuming a density of 1 g/ml). 
3.3.5 Statistic analysis 
Statistical analysis was carried out using GraphPad Prism (GraphPad Software, 
San Diego, CA, USA). One-way ANOVA with post-hoc Bonferroni testing was used 
to compare selected data sets for log P and log D values at different 
temperatures. Unpaired two-tailed t-test (with Welch’s correction) was used to 
compare the difference in log D values between liposome/buffer and 
octanol/buffer systems. Results are presented as means ± SD. Differences for 
which p < 0.05 were taken as significant. 
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3.4 Results 
3.4.1 Log P octanol/water: Effect of temperature 
The experimental log P values are larger for K than for N at all temperatures 
contrary to the calculated values in Table 3.1. Experimental Log P values of K and 
N increase significantly with increasing temperature (from 4°C to room 
temperature)(Table 3.2 and Figure 3.1) indicating K and N partition more 
extensively into octanol with increasing temperature. Although the differences in 
log P values of neither K nor N between room temperature and 37°C was 
significant, this could be due to insufficient sample number used in the 
experiment. As power of statistical analysis increases with increasing sample 
size, by using more replicates in determination in future studies, a significant 
difference might be found in K and N log P values between room temperature 
and 37°C. 
Table 3.2 Log P of ketotifen (K) and norketotifen (N) in the octanol/water 
system at different temperatures (data are means ± SD, n= 5). 
 Log P in the octanol/water system 
 4°C Room Temperature* 37°C 
K 2.24 ± 0.13 2.89 ± 0.33 3.23 ± 0.16 
N 1.48 ± 0.21 1.78 ± 0.06 1.92 ± 0.06 
  *25 ± 2°C  
 
Figure 3.1 Log P values of ketotifen (K) and norketotifen (N) measured in the 
octanol/water system at different temperatures (data are means ± SD, n = 5, 
**P<0.002, ***P<0.001, ****P<0.0001). 
According to the π system for calculating log P values, K with one more methyl 



















approximately 0.5. However, the results (Table 3.2) indicate the difference is 
more than 0.5 at all temperatures. This is presumably because the π system does 
not fully take into account the structural differences between the two 
compounds. More recent methods for estimating log P take into account other 
factors such as atomic contributions and topological indices (Erica et al, 2011).   
The effect of temperature on log P is elucidated as follows (Equation 3.3): 
Log P = ΔS°/2.303R − ΔH°/2.303RT     3.3 
where T is temperature (Kelvin), ΔHo and ΔS° is the enthalpy and entropy change 
in distribution respectively, and R is the gas constant. 
It suggests with increasing temperature, log P can be increasing or decreasing 
depending on whether the distribution procedure is endothermic (H > 0) or 
exothermic (H < 0). According to our result (Table 3.2 and Figure 3.1), log P 
increased with increasing temperature thus the distribution procedure of K and 
N between octanol and water is endothermic. 
3.4.2 Log D octanol/buffer: Effect of temperature 
As found with log P values, Log D values in the octanol/buffer pH 7.4 system 
show K distributes more extensively into octanol at all temperatures. As 
expected, the log D values are always less than their corresponding log P values 
and increase with increasing temperature although at a slower rate than the log 
P values. However, only the difference log D values between 4°C and 37 °C is 
significant (Table 3.3 and Figure 3.2), which may be due to insufficient sample 
number used in determination as discussed in Section 3.4.1. 
Table 3.3 Log D of ketotifen (K) and norketotifen (N) in the octanol/Ringer-
HEPES buffer pH 7.4 system at different temperatures (data are means ± SD, n 
= 5). 
 Log D in the octanol/buffer pH 7.4 system 
 4°C Room Temperature * 37°C 
K 2.08 ± 0.43 2.49 ± 0.07 2.68 ± 0.02 
N 0.99 ± 0.02 1.01 ± 0.43 1.62 ± 0.45 
* 25 ± 2°C  
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Figure 3.2 Log D values of ketotifen (K) and norketotifen (N) measured in the 
octanol/ Ringer-HEPES buffer pH 7.4 system at different temperatures (data 
are means ± SD, n = 5, **P<0.002). 
The changes with temperature presumably reflect the complex interplay 
between log P, which increases with temperature and pKa, pH of buffer, which 
are discussed in the following paragraphs. 
Effect of temperature on partition coefficient was discussed in last section 
(Section 3.4.1); however, temperature affects not only log P but also pKa.  
The effect of temperature on pKa can be elucidate using the following equation 
(Equation 3.4): 
pKa = ΔH°/2.303RT - ΔS°/2.303R           3.4 
where T is temperature (Kelvin), ΔHo and ΔS° is the enthalpy and entropy change 
in disassociation respectively, and R is the gas constant. 
Effect of temperature on pKa, similar to log P, depends on ΔHo. With increasing 
temperature, pKa increases when the dissociation is exothermic but decreases 
when dissociation procedure is endothermic.  
This effect of temperature on pKa not only applies to K and N but also applies to 
buffer used in log D measurement. As a result of temperature-dependent pKa, 
the pH of buffer solution used decreases with increasing temperature for 
exothermic dissociation, vice versa. It has been reported that for bases generally 
decrease by 0.3 pH units for every 10°C rise in temperature (Perrin et al, 1981).  
As a result, effect of temperature on log D measurement is a complex interplay 
between multiple factors, such as distribution, pKa of drug and buffer. Therefore, 
to better interpret results from cell experiments (Chapter 5), it is important to 
















carried out. In our case, we are going to use these log P and log D values at 4 and 
37° to interpret REB4 cell uptake and Caco-2 cell permeability results of K and N 
in Chapter 5. 
3.4.3 Log D liposome/buffer 
Log D values were found to differ between the octanol/buffer (log Do/b) and 
liposome/buffer (log Dl/b) systems (Table 3.4). Log Do/b values indicate K 
distributes more extensively into octanol than N, whereas log Dl/b values indicate 
K distributes less extensively into liposomes.  
Table 3.4 Summary of calculated and experimental (data are means ± SD) log D 
values for ketotifen and norketotifen at 37°C (There was a significant 
difference in log D values of N between liposome/buffer and octanol/buffer 
systems (***P<0.0002)). 
Log D 
 Liposome/buffer pH 7.4  
(n = 3) 
Octanol/buffer pH 7.4  
(n = 5) 
Octanol/buffer 
pH 7.4* 
K 2.63 ± 0.04 2.68 ± 0.02 2.15 
N 3.64 ± 0.01 1.62 ± 0.45 0.92 
*Unpublished results from Aberg A. K. G. using phosphate-buffered saline (PBS) buffer pH 7.4. 
Compared with the octanol/aqueous system, the liposomes/aqueous system is a 
better model to determine the interaction between compound and cells. This is 
because the drug-membrane interaction involves both partitioning and binding 
(Plemper van Balen et al, 2004). Instead of using octanol as lipid phase, 
liposome/aqueous system uses liposomes, to be specific, phospholipid bilayers 
as lipid phase. These lipid bilayers are similar to cell membranes and contribute 
to the partitioning part of the drug-membrane interaction. In addition, the polar 
head of phospholipid on liposome bilayers carries charges, which depend on 
phospholipids used to make liposomes. The charge on liposomes provides a 
chance for ionic bonds or ion exchange between membrane and ionized 
compounds to take place, thus contribute to the binding part of the drug-
membrane interaction (Plemper van Balen et al, 2004). Therefore, compared 
with octanol/aqueous system, distribution of drug between liposome/aqueous 
system helps to better elucidate the behaviours of a compound at the target 
membrane. 
In our log Dl/b determination, liposomes (mean particle size approximately 200 
nm) used were made from soy lecithin phospholipid and cholesterol. This 
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combination produces a negative surface charge (zeta potential ~-2 mV) at lipid 
bilayers. Both K and N at pH 7.4 are positively charged but K (pKa = 8.8) is less 
ionized than N (pKa = 10.3), such that liposomes would be expected to interact 
and bind more strongly to N than to K. A similar result has been described 
elsewhere where binding was probably due to ion exchange or ionic bond on 
lipid membranes (Klein et al, 2001, Plemper van Balen et al, 2004; Yang et al, 
2011). Future work could be done to investigate the effect of physiochemical 
properties liposome to log D measurement by using a positively charged 
liposomes/buffer system to determine log D of K and N. The electric force 
between positively charged liposome membrane and positively charged 
compound may result in a lower log Dl/b. 
3.5 Discussion  
Experimental log Dl/b and log Do/b values at 37°C for K and N trend in opposite 
directions. Thus whereas log Dl/b values indicate that K distributes less into 
liposomes than N, the log Do/b and Aberg A. K. G log Do/b values both indicate K 
distributes more into octanol than N (Table 3.4). As discussed in Section 3.4.3, 
the difference may be related to binding between K and N and liposomes.  
Log P results showed the temperature effect on partition of K and N between 
octanol and water. Log D o/b results demonstrated the complex interplay between 
multiple factors for K and N partitioning between octanol and Ringer-HEPES 
buffer at 4°C and 37°C. These results are useful for interpretation of cell culture 
work, which were carried out under the same conditions (Section 5.4.3). Log Dl/b 
results represent drug-membrane interaction in both distribution and binding 
aspects, which elucidated the K and N interactions with cell membranes at 37°C 
(Section 5.4.3 and 5.4.4).  
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Chapter 4 Chiral HPLC assay development and validation 
4.1 Introduction  
There are a number of separation techniques by which chiral separation can be 
achieved: capillary electrophoresis (CE) (Alessandro et al, 2014; Beibei et al, 
2014; Elena et al, 2016; Gerald and Martin, 2000; Salvatore, 2009), gas 
chromatography (GC) (Beibei et al, 2014; Malgorzata and Alina, 2014; Schurig, 
1994), supercritical fluid chromatography (Eric and Caroline, 2015; Kveta et al, 
2014; Michael et al, 1994), counter-current chromatography (Xin-Yi and Duo-
Long, 2015), LC−MS (Sian and Barbara, 2014), HPLC and ultra-high performance 
liquid chromatography (UHPLC) (Beibei et al, 2014; Jun et al, 2014; Ola et al, 
2010; Szabolcs et al, 2014). LC−MS methods are known to be highly sensitive and 
selective, and asymmetric molecules with different m/z values do not require 
separation. However, for atropisomers or enantiomers which have the same m/z 
values, they do require separation which tends to extend chromatographic run 
times.  LC−MS also suffers from high maintenance cost and the need for volatile 
buffers. Given that in this study anticipated levels of K and N in biological 
samples are above the detection limit of HPLC, it was used to develop chiral 
assays to determine K and N atropisomers in RBE4 cell homogenate, rat plasma 
and rat brain homogenate.  
A chiral HPLC assay has been reported for the determination of K atropisomers 
in liver microsomes (Breyer-Pfaff and Nill, 2000) but no studies have reported 
the separation of N atropisomers using HPLC alone. 
In this thesis, a chiral HPLC was carried out on a column containing a β-
cyclodextrin-bound silica chiral stationary phase (CSP). The assay was validated 
and used to determine single atropisomers of K and N in different matrices, such 
as buffer, cell homogenate, human plasma and rat brain homogenate. In addition, 
it was used to determine atropisomers in racemates and in the single 
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atropisomers where it allowed assessment of atropisomeric purity and detection 
of any racemization or inversion in the presence of RBE4 cells and Caco-2 cells.  
4.2 Materials  
Human plasma was kindly provided by SCL lab, Dunedin hospital. Caco-2 cells 
were purchased from European Collection of Cell Culture (Sigma Aldrich, New 
Zealand). RS-Metoprolol (±)-tartrate (≥ 98%), RS-atenolol (≥ 98%), 
cyproheptadine hydrochloride (100%), (R)-(+)-propranolol hydrocloride (≥ 
98%), sodium bicarbonate (cell culture tested) and Hank’s Balanced Salt Solution 
(HBSS) were purchased from Sigma (Auckland, New Zealand). Methanol were 
purchased from Merck (Darmstadt, Germany). Sodium dihydrogen 
orthophosphate monohydrate (99%) and potassium dihydrogen orthophosphate 
(≥ 99.5%) were purchased from BDH Laboratory Supplies (England). Anhydrous 
disodium hydrogen orthophosphate (99%) was purchased from Asia Pacific 
Specialty Chemicals Ltd. RS-pizotifen was provided by GL Synthesis Inc. (MA, 
USA) through the kind offices of Aberg, A. K. G  BridgePharma, Sarasota, FL, USA. 
Other materials are given in Chapters 2 (Section 2.2) and 3 (Section 3.2). 
4.3 Assay development 
4.3.1 Methods of assay development 
4.3.1.1 Chiral separation 
First attempts were made to develop a chiral HPLC method for the simultaneous 
determination of the atropisomers of K and N. However, this was not successful 
because it was impossible to obtain baseline separation of all four peaks of K and 
N. Thus, separate chiral HPLC methods were developed for K and N 
atropisomers.  
A β-cyclodextrin-bonded silica chiral column (CDB-453 HQ, 4.6 × 150 mm, 
Phenomenex) maintained at 30°C was used for the chiral assay with the 
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remainder of HPLC system being the same as for the nonchiral assay (Chapter 2). 
The separation of K atropisomers was used to optimize the conditions for chiral 
resolution based on the following investigations. 
Mobile phase composition: Flow rate 0.5 ml/min, mobile phase ACN:50 mM 
phosphate buffer pH 6 10:90, 20:80 and 30:70.  
Mobile phase pH: Flow rate 0.5 ml/min, mobile phase 10:90 ACN:50 mM 
phosphate buffer; pH 3.5, 5 and 7. 
Flow rate: Mobile phase 10:90 ACN:50 mM phosphate buffer pH 6; flow rates 0.4, 
0.5 and 0.6 ml/min. 
Buffer concentration: Flow rate 0.5 ml/min, mobile phase 10:90 ACN:phosphate 
buffer pH 6; buffer concentration 50 mM and 100 mM. 
Figure 4.1 Chiral HPLC of 50 ng/ml racemic ketotifen (K) and norketotifen 
(N) showing separation of (a) K atropisomers and (b) N atropisomers in RBE 
cell homogenate at 310 nm.  
Matrices used for method development and validation were prepared as follow: 
RBE4 cells (Yang et al, 2011) and Caco-2 cells (Yang et al, 2009) were grown, 
detached from the incubation flask, and homogenized using a Bullet Blender® 
tissue homogenizer (Next Advance, NY, USA) (refer to Section 2.3.2 for details). 
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The homogenate was further diluted with Milli-Q water to a final protein 
concentration of 250 μg/ml (measured using the BCA™ protein assay kit). 
Wistar rats for brain matrix were purchased from the animal facility of Otago 
University. Rat brains were collected, weighed and homogenized in two volumes 
of Milli-Q water (w/v). The brain homogenate was further diluted to 1 in 10 
diluted brain homogenate to prepare calibration standards and QC samples. The 
unused aliquots of 1 in 3 diluted brain homogenate samples were stored at -80°C 
until required. 
For RBE4 cell homogenate samples prepared as for the nonchiral assay, SN 
which has the shortest Rt was subject to interference from an early eluting peak 
but this was eliminated by simply changing the detection wavelength from 295 
nm to 310 nm (Figure 4.1). No IS was needed for the assay of RBE4 cell 
homogenate for the same reasons as for the nonchiral assay (refer to Section 
2.3.1). 
However, liquid-liquid extraction (LLE) was an absolute requirement for assay of 
plasma and brain homogenate, and detection at 295 nm was then free of 
interference. An IS was included in this assay. 
4.3.1.2 Selection of IS 
The IS was selected on the basis of an investigation into the suitability of the 
following five compounds: pizotifen, atenolol, metoprolol, cyproheptadine and 
propranolol (Figure 4.2). The compounds were examined in terms of their MW, 
calculated partition coefficient (Clog P), pKa, and Rt (Table 4.1). There was no 
clear correlation between the clog P and Rt of the compounds tested (r2 = 0.35) 
suggesting separation by the CSP depends less on hydrophobicity and more on 
the size of the compound and electrostatic interactions in the cavity of the β-
cyclodextrin (Lammerhofer, 2010). The deeper a compound inserts into the 
cavity, the stronger the interaction (Chankvetadze et al, 2000). It has been 
reported that, to some extent, a compound with a chiral centre (enantiomer) 
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gains a better separation than one without chiral centre (atropisomers) on the β-
cyclodextrin matrix stationary phase. However, the separation also depends on 
interaction with the cavity mouth of the β-cyclodextrin (Armstrong et al, 1986; 
Stalcup et al, 1991). Therefore, the interactions of β-cyclodextrin and K and N 
may be come from the interaction of the β-cyclodextrin cavity mouth, as K and N 
do not have a chiral centre.  
 
Figure 4.2 Structures of ketotifen, norketotifen and the five compounds tested 
as internal standards in the chiral assays of ketotifen and norketotifen. 
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Table 4.1 Properties of ketotifen, norketotifen and the five compounds 
evaluated as internal standards in the chiral assays of ketotifen and 
norketotifen (clog P and pKa were obtained from SciFinder Scholar). 
 MW clog P pKa Rt (min) 
6.9 (SK) 
K 309 2.19 ± 0.73 8.84 ± 0.20 
9.1 (RK) 
5.6 (SN) 
N 295 2.65 ± 0.51 10.4 ± 0.2 
6.5 (RN) 
Pizotifen 295 2.71 ± 0.67 9.04 ± 0.20 > 100 
Atenolol 266 0.34 ± 0.28 9.43 ± 0.10 3.3 
Metoprolol 267 1.63 ± 0.26 9.43 ± 0.10 4.9 
Cyproheptadine 287 5.82 ± 0.76 8.95 ± 0.20 > 100 
Propranolol 259 2.90 ± 0.25 9.50 ± 0.30 61 
 
Although pizotifen and cyproheptadine are similar to K in structure and pKa, 
their values of Rt are much longer than those of both K and N. Again this cannot 
be due to hydrophobicity since the clog Ps for the compounds are very similar. 
The only explanation is that the ketone group in K and N reduces greatly the 
interaction with the CSP but the detailed reason for the difference is unknown. 
RS-Metoprolol was finally chosen as IS because (a) it eluted before K and N 
atropisomers with an Rt long enough to avoid interference from matrix peaks 
but still baseline resolved from the first atropisomer peaks of SK and SN and (b) 
as metoprolol elutes before K and N atropisomers, it results in a shorter total 
run-time without any separation of its enantiomer peaks. The maximum 
absorbance of metoprolol was at 220 nm and, accordingly, the diode array 
detector was programmed to switch from 220 nm to 295 nm after its elution. 
4.3.1.3 Sample preparation 
Sample preparation of RBE4 cell homogenate was as described in Chapter 2 
(Section 2.3.2). For human plasma and rat brain homogenate samples, 10 μl IS 
solution (10 μg/ml) was added to 0.5 ml sample (or calibration standard or QC 
sample) to give a final concentration of 200 ng/ml. An aliquot of 1M NaOH (30 
μl) was added after which 1 ml 60:40 diethyl ether:n-hexane was added to 
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plasma samples and 1 ml 10:90 dichloromethane:n-hexane added to brain 
homogenate samples. Mixtures were vortexed for 30 s and centrifuged at 10,000 
g for 10 min. The upper organic phase (0.95 ml) was then transferred into clean 
tubes and 0.3 ml 0.0036% HCl added for back extraction. Tubes were vortexed 
for 30 s and centrifuged for 10 min at 10,000 g after which 0.27 ml aliquots of 
aqueous phase were transferred to clean tubes and evaporated to dryness under 
vacuum at room temperature overnight. Dried samples were reconstituted in 60 
μl mobile phase followed by vortexing and centrifuging at 10,000 g for 10 min. 
Finally, 55 μl supernatant was transferred into HPLC inserts and 50 μl injected 
into the HPLC system. 
4.3.2 Results and discussionof assay development 
Mobile phase composition: Increasing the ACN percentage in the mobile phase 
above 20% decreased the Rt of K atropisomers and decreased the separation 
factor (Figure 4.3a).  
Mobile phase pH: Increasing the mobile phase pH increased the Rt of K 
atropisomers and decreased the separation factor (Figure 4.3b). 
Flow rate: Increasing the flow rate decreased the Rt of K atropisomers but had no 
effect on the separation factor (Figure 4.3c). 
Phosphate buffer concentration: Increasing the phosphate buffer concentration 
caused a slight decrease in the Rt of K atropisomers and a slight increase in the 




Figure 4.3 Effects of changing chiral HPLC conditions on the separation factor 
of K atropisomers: (a) mobile phase composition, (b) mobile phase pH, (c) 
flow rate, and (d) phosphate buffer concentration (for conditions of each 
chromatograph, see Section 4.3.1). 
The factors causing most change in the separation of K atropisomers were the 
mobile phase composition and pH. The effect of increasing ACN in the mobile 
phase to decrease Rt and separation arises because ACN reduces the affinity 
between CSP and analytes (Ferguson et al, 1996). The effect of increasing mobile 
phase pH to increase Rt and decrease separation is presumably due to the 
change in ionization degree of K. Cyclodextrin predominantly interacts with 
uncharged molecules (Lutka and Golda, 2006) so that, as the proportion of 
unionized K increases with increasing of pH, the interaction between both 
atropisomers and CSP increases. This may increase the retention of both 
atropisomers thereby reducing the separation between K atropisomers.  
Similar procedures were carried out to obtain the optimized conditions for 
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The optimized conditions for the chiral HPLC assays were mobile phases of 
ACN:100 mM phosphate buffer pH 3.2 6:94 for K and 12:88 for N delivered at a 
flow rate of 0.5 ml/min through the column maintained at 30°C. Chromatographs 
of K and N racemates rat plasma and rat brain homogenate under these 
conditions are shown in Figure 4.4.  
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Figure 4.4 Chiral HPLC of racemic ketotifen (K) and racemic norketotifen (N) 
showing separation of (a) K atropisomers and (b) N atropisomers in human 






Assay of plasma and brain homogenate included an internal standard (RS-
metoprolol) which elute first and is detected at 220 nm after which detection 
wavelength is changed to 295 nm at the time indicated by the arrow. 
4.4 Assay validation  
4.4.1 Methods of assay validaiton 
4.4.1.1 Human plasma versus rat plasma 
In this chapter, plasma QC samples were prepared using human plasma instead 
of rat plasma. This was due to following reasons:  
First, the LLOQ of chiral assay requires a 0.5 ml plasma sample for sample 
extraction. Consequently a relatively large amount of rat plasma is needed for QC 
sample preparation. However, one rat (200 g body weight) only has 12 ml blood, 
which is approximately 6 ml of plasma. Moreover, it is impossible to collect all of 
the 6 ml plasma from a rat. In this case, plasma from one rat is just enough to 
make a standard curve let alone all of the QC samples for precision and accuracy 
tests and stability tests. Thus to validate this assay using rat plasma requires 
killing too many rats, which is not ethical. 
Second, although there was no proper cross-validation done between human 
plasma and rat plasma in this thesis, tests were performed to compare these two 
plasma samples. Results from human plasma and rat plasma were very similar, 
in both chromatograph and standard curve. 
Third, species difference of esterase expression and activity do happen between 
human and rat plasma (Bahar et al, 2012), however, different esterase 
expression does not affect K and N metabolic route (Figure 1.2). 
As discussed above, there was no clear evidence that suggesting difference 
between using rat plasma and human plasma occurs during K and N HPLC assay 
validation. Moreover, using human plasma avoids ethical issue caused by using 
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rat plasma. As a result, human plasma was used in this validation instead of rat 
plasma. 
4.4.1.2 Preparation of calibration standards and QC samples  
Calibration standards were prepared freshly each assay day by spiking RBE4 cell 
homogenate or plasma or rat brain homogenate (diluted 1 in 10 with Milli-Q 
water) with aqueous solutions of K or N racemates to give final atropisomer 
concentrations in the range 20 − 500 ng/ml. Low, medium and high QC samples 
were prepared in the same way at concentrations of 30, 60 and 120 ng/ml.  
4.4.1.3 Linearity, LLOQ, recovery, accuracy and precision 
Linearity, LLOQ, recovery, accuracy and precision: These were determined as 
described for the nonchiral assay (Chapter 2, Section 2.3.3). 
4.4.1.4 Stability  
This was assessed using QC samples of racemates (in REB4 cell homogenate, 
human plasma, and rat brain homogenate) stored under the same conditions as 
for the nonchiral assay (Section 2.3.3, Table 2.3) except that long-term stability 
at -80°C was for one month.  
Stability of atropisomers in racemate K and N in RBE4 cells, human plasma and 
rat brain homogenate was calculated using Equation 2.4. 
4.4.2 Results and discussion of assay validation 
4.4.2.1 Linearity  
The assays for both K and N atropisomers in all matrices were linear (R2 > 0.999) 
in the concentration range used (Figure 4.5) and in all cases the LLOQ was 20 
ng/ml. 
 65
Figure 4.5 Calibration curves for (a) K atropisomers and (b) N atropisomers 
in TOP RBE4 cell homogenate, MIDDLE human plasma, and BOTTOM rat 
brain homogenate (data are means ± SD, n = 3). Assay of RBE4 cell 
homogenate used external standards, whereas assays of plasma and rat brain 
homogenate used an internal standard. 
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R2 = 0.9995 (SK)
y = 350.21x - 1348.2
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4.4.2.2 Recovery  
The recovery was > 90% for assay of RBE4 cell homogenate and > 80% for 
human plasma and rat brain homogenate. 
4.4.2.3 Accuracy and precision  
Intra-day and inter-day accuracy of K and N atropisomers in RBE4 cell 
homogenate, human plasma and rat brain homogenate were within ± 15% at all 
QC concentrations. The corresponding intra-day and inter-day precisions were < 
10% at all QC concentrations (Table 4.2 to 4.7). These results indicate the assays 
fully meet the requirements of the FDA Guidelines (2001).  
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Table 4.2 Accuracy and precision of the chiral HPLC assays for ketotifen (K) 
















L (30) 28.4 ± 1.0 5.5 3.5 
M (60) 60.6 ± 2.8 3.6 4.6 Inter-day 1 
H (120) 117.6 ± 5.0 3.7 4.3 
L (30) 27.9 ± 2.2 8.2 7.8 
M (60) 63.2 ± 1.7 5.3 2.8 Inter-day 2 
H (120) 119.6 ± 8.3 6.1 7.1 
L (30) 29.6 ± 0.5 1.5 1.6 
M (60) 61.2 ± 1.9 2.9 3.2 Inter-day 3 
H (120) 116.0 ± 5.9 4.4 5.1 
L (30) 28.6 ± 1.5 5.1 5.2 
M (60) 61.7 ± 2.4 4.0 5.8 
SK 
Intra-day 
H (120) 116.8 ± 6.1 4.7 5.2 
L (30) 31.4 ± 1.0 4.6 3.2 
M (60) 68.8 ± 2.3 14.6 3.4 Inter-day 1 
H (120) 137.5 ± 1.8 14.5 1.3 
L (30) 28.7 ± 1.8 6.5 6.4 
M (60) 65.4 ± 2.4 9.0 3.6 Inter day 2 
H (120) 122.1 ± 8.5 5.6 7.0 
L (30) 27.7 ± 1.0 7.8 3.4 
M (60) 63.0 ± 2.8 5.3 4.5 Inter-day 3 
H (120) 119.3 ± 3.8 2.4 3.2 
L (30) 29.2 ± 2.0 6.3 7.0 
M (60) 65.7 ± 3.4 11.0 5.2 
RK 
Intra-day 
H (120) 126.3 ± 9.7 10.1 7.0 
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Table 4.3 Accuracy and precision of the chiral HPLC assays for norketotifen 















L (30) 29.4 ± 1.5 4.6 5.2 
M (60) 58.6 ± 2.1 3.2 3.6 Inter-day 1 
H (120) 121.7 ± 5.7 4.0 4.7 
L (30) 25.9 ± 0.4 13.6 1.5 
M (60) 55.6 ± 2.3 7.3 4.1 Inter-day 2 
H (120) 116.4 ± 2.7 3.0 2.3 
L (30) 30.8 ± 0.7 2.9 2.3 
M (60) 63.4 ± 1.4 5.7 2.2 Inter-day 3 
H (120) 127.3 ± 3.1 6.1 2.4 
L (30) 28.7 ± 2.3 7.0 7.0 
M (60) 52.9 ± 3.8 5.4 5.4 
SN 
Intra-day 
H (120) 121.8 ± 5.9 4.4 4.4 
L (30) 31.2 ± 2.0 6.4 6.5 
M (60) 59.1 ± 2.1 2.8 3.6 Inter-day 1 
H (120) 127.8 ± 2.5 6.5 2.0 
L (30) 25.5 ± 0.8 14.9 3.3 
M (60) 53.3 ± 2.0 11.2 3.8 Inter-day 2 
H (120) 113.4 ± 3.5 5.5 3.1 
L (30) 29.6 ± 2.6 6.3 8.7 
M (60) 60.5 ± 3.0 4.2 4.9 Inter-day 3 
H (120) 114.3 ± 3.6 4.8 3.1 
L (30) 28.8 ± 3.0 9.2 9.2 
M (60) 57.6 ± 3.9 6.1 6.1 
RN 
Intra-day 




Table 4.4 Accuracy and precision of the chiral HPLC assays for ketotifen (K) 














L (30) 31.5 ± 1.5 5.7 4.9 
M (60) 60.5 ± 1.6 2.1 2.6 Inter-day 1 
H (120) 117.2 ±1.7 2.4 1.4 
L (30) 30.9 ± 1.7 5.2 5.6 
M (60) 61.1 ± 4.5 6.1 7.3 Inter-day 2 
H (120) 120.5 ± 2.0 1.3 1.7 
L (30) 31.3 ± 0.6 4.3 1.8 
M (60) 62.6 ± 2.0 4.3 3.1 Inter-day 3 
H (120) 116.0 ± 1.1 3.3 1.0 
L (30) 31.2 ± 1.3 5.1 4.1 
M (60) 61.4 ± 2.9 4.2 4.7 
SK 
Intra-day 
H (120) 117.9 ± 2.5 2.3 2.1 
L (30) 30.1 ± 1.7 4.1 5.6 
M (60) 62.3 ± 0.7 3.9 1.1 Inter-day 1 
H (120) 116.7 ± 3.6 3.5 3.1 
L (30) 29.0 ± 1.3 5.1 4.6 
M (60) 61.7 ± 4.7 6.9 7.5 Inter-day 2 
H (120) 120.0 ± 3.2 1.9 2.7 
L (30) 31.4 ± 0.7 4.8 2.2 
M (60) 61.2 ± 1.5 2.6 2.5 Inter-day 3 
H (120) 115.3 ± 0.2 3.9 1.7 
L (30) 30.2 ± 1.6 4.6 5.3 
M (60) 61.7 ± 2.7 4.5 4.3 
RK 
Intra-day 




Table 4.5 Accuracy and precision of the chiral HPLC assays for norketotifen 















L (30) 30.9 ± 1.6 4.1 5.2 
M (60) 60.8 ± 4.4 6.0 7.3 Inter-day 1 
H (120) 120.1 ± 3.0 1.9 2.5 
L (30) 29.2 ± 1..6 4.3 5.6 
M (60) 57.9 ± 2.3 4.5 4.0 Inter-day 2 
H (120) 116.3 ± 1.9 3.0 1.6 
L (30) 34.0 ± 0.6 13.2 1.6 
M (60) 61.4 ± 3.1 3.2 5.0 Inter-day 3 
H (120) 111.4 ± 6.8 7.2 6.1 
L (30) 31.0 ± 2.8 6.3 7.4 
M (60) 59.8 ± 2.5 4.7 5.9 
SN 
Intra-day 
H (120) 116.6 ± 4.9 3.6 4.2 
L (30) 29.2 ± 1.0 3.6 3.5 
M (60) 61.4 ± 3.4 5.0 5.6 Inter-day 1 
H (120) 120.7 ± 4.2 2.3 3.4 
L (30) 31.1 ± 0.8 3.9 2.5 
M (60) 59.4 ± 2.0 2.8 3.4 Inter-day 2 
H (120) 118.4 ± 4.1 1.4 0.9 
L (30) 33.2 ± 1.3 10.5 4.0 
M (60) 60.7 ± 2.9 3.8 4.8 Inter-day 3 
H (120) 111.1 ± 8.8 7.5 7.9 
L (30) 30.9 ± 1.8 5.3 5.9 
M (60) 60.5 ± 2.8 3.9 4.6 
RN 
Intra-day 




Table 4.6 Accuracy and precision of the chiral HPLC assays for ketotifen (K) 
atropisomers in rat brain homogenate (Brain) (1 to 10 diluted with Milli-Q 
water) (data are means ± SD for assay of 5 replicates). 











L (30) 29.2 ± 1.8  4.9 6.1 
M (60) 57.3 ± 1.4 4.5 2.4 Inter-day 1 
H (120) 114.6 ± 2.4 4.5 2.1 
L (30) 31.2 ± 2.3 6.4 7.3 
M (60) 62.8 ± 4.1 4.7 6.5 Inter-day 2 
H (120) 126.1 ± 7.4 5.6 5.9 
L (30) 29.2 ± 1.8  4.9 6.1 
M (60) 57.4 ± 1.3 4.4 2.2 Inter-day 3 
H (120) 114.6 ± 2.4 4.5 2.1 
L (30) 29.9 ± 2.1 5.4 6.9 
M (60) 59.2 ± 3.6 4.5 6.1 
SK 
Intra-day 
H (120) 118.4 ± 7.1  4.9 6.0 
L (30) 31.4  ± 1.4 6.0 4.6 
M (60) 61.4 ± 2.8 3.3 4.6 Inter-day 1 
H (120) 118.6 ± 2.8 2.0 2.3 
L (30) 30.3 ± 0.6 1.7 1.9 
M (60) 61.8 ± 3.6 4.3 5.8 Inter-day 2 
H (120) 126.8 ± 7.7 6.2 6.1 
L (30) 31.2 ± 1.5 5.4 4.8 
M (60) 61.7 ± 2.5 2.9 4.1 Inter-day 3 
H (120) 118.6 ± 2.8 2.0 2.3 
L (30) 30.9 ± 1.2 4.4 4.0 
M (60) 61.6 ± 2.8 3.5 4.5 
RK 
Intra-day 




Table 4.7 Accuracy and precision of the chiral HPLC assays for norketotifen 
(N) atropisomers in rat brain homogenate (Brain) (1 to 10 diluted with Milli-














L (30) 31.0 ± 1.7 5.5 5.4 
M (60) 61.4 ± 1.7 3.3 2.8 Inter-day 1 
H (120) 120.7 ± 4.1 2.9 3.4 
L (30) 31.7 ± 1.0 5.7 3.2 
M (60) 60.3 ± 2.5 3.0 4.1 Inter-day 2 
H (120) 119.1 ± 5.1 3.6 4.3 
L (30) 29.9 ± 1.6 4.1 5.4 
M (60) 58.0 ± 2.3 4.1 3.9 Inter-day 3 
H (120) 118.0 ± 3.9 2.9 3.3 
L (30) 30.8 ± 1.6 5.1 5.1 
M (60) 59.9 ± 2.5 3.4 4.2 
SN 
Intra-day 
H (120) 119.3 ± 4.2 3.2 3.6 
L (30) 31.1 ± 1.0 4.5 3.3 
M (60) 58.5 ± 2.3 3.5 3.9 Inter-day 1 
H (120) 116.6 ± 4.3 3.5 3.7 
L (30) 30.5 ± 2.4 5.9 8.0 
M (60) 60.9 ± 2.0 3.0 3.2 Inter-day 2 
H (120) 121.1 ± 6.2 4.2 5.2 
L (30) 30.5 ± 0.8 2.8 2.8 
M (60) 59.8 ± 2.1 2.7 3.5 Inter-day 3 
H (120) 1117.4 ± 2.5 2.4 2.2 
L (30) 30.7 ± 1.5 4.4 5.0 
M (60) 59.7 ± 2.2 3.1 3.7 
RN 
Intra-day 
H (120) 118.4 ± 4.7 3.4 4.0 
4.4.2.4 Stability in plasma and rat brain homogenate 
For racemates in human plasma (Table 4.8) and rat brain homogenate (Table 
4.9), the changes in K and N atropisomer concentrations indicate the 
atropisomers are stable under all the tested storage conditions. 
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Table 4.8 Stability of ketotifen (K) and norketotifen (N) atropisomers to 
decomposition in human plasma under different storage conditions (data are 
means ± SD, n = 5). 




(ng/ml) 25°C (4 h) 4°C (24 h) 
Freeze-thaw 
(3 cycles) 
 -80°C  
(1 month) 
L (30) 96.0 ± 2.9 104.0 ± 0.7 97.0 ± 5.1 102.3 ± 3.6  
M (60) 95.5 ± 1.5 95.8 ± 4.1 95.4 ± 2.1 96.3 ± 1.1 SK 
H (120) 100.2 ± 4.2 93.6 ± 3.6 95.1 ± 2.5 96.3 ± 3.2 
L (30) 100.2 ± 2.2 104.7 ± 3.1 102.4 ± 4.8 98.7 ± 1.7 
M (60) 96.3 ± 4.8 92.2 ± 4.8 98.0 ± 1.6 101.2 ± 2.1 RK 
 H (120) 98.7 ± 2.9 98.5 ± 4.9 95.7 ± 1.3  97.4 ± 2.1 
L (30) 101.0 ± 3.9 94.4 ± 7.5 107.8 ± 5.4 98.0 ± 0.2 
M (60) 100.5 ± 5.7 98.4 ± 1.5 95.5 ± 7.8 105.0 ± 6.0 SN 
H (120) 103.4 ± 2.7 97.1 ± 1.7 101.4 ± 4.12 103.2 ± 4.2 
L (30) 101.1 ± 3.8 96.2 ± 1.4 102.5 ± 8.4 104.6 ± 6.3 
M (60) 98.8 ± 4.9 95.3 ± 2.8 92.7 ± 4.2 100.1 ± 6.7 RN 
H (120) 100.4 ± 3.0 96.6 ± 2.5 95.2 ± 2.4 106.5 ± 1.7 
 
Table 4.9 Stability of ketotifen (K) and norketotifen (N) atropisomers to 
decomposition in rat brain homogenate (1 in 10 diluted with Milli-Q water) 
(data are means ± SD, n = 5). 




(ng/ml) 25°C (4 h) 4°C (24 h) 
Freeze-thaw 
(3 cycles) 
 -80°C     
(1 month) 
L (30) 99.1 ± 4.1 102.8 ± 6.4 101.7 ± 3.8 101.2 ± 7.0 
M (60) 95.2 ± 2.5 100.7 ± 1.6 101.7 ± 1.5 104.4 ± 4.1 SK 
H (120) 95.2 ± 2.0 104.7 ± 2.4 100.1 ± 5.6 100.8 ± 6.5 
L (30) 103.9 ± 5.2 101.9 ± 8.5 102.5 ± 5.5 107.2 ± 7.0 
M (60) 95.3 ± 3.7 100.3 ± 1.8 98.5 ± 2.3 107.0 ± 1.3 RK 
H (120) 93.7 ± 1.6 104.0 ± 2.1 99.7 ± 6.3 102.7 ± 8.4 
L (30) 96.3 ± 8.5 99.6 ± 4.6 103.2 ± 3.2 94.1 ± 4.0 
M (60) 97.7 ± 1.6 97.8 ± 2.0 98.9 ± 2.7 104.7 ± 6.2 SN 
H (120) 100.3 ± 5.2 97.4 ± 1.2 97.0 ± 1.6 95.2 ± 3.4 
L (30) 94.3 ± 9.3 95.3 ± 2.5 102.1 ± 2.5 101.9 ± 7.0 
M (60) 97.0 ± 1.0 105.3 ± 5.3 107.0 ± 1.9 103.1 ± 6.8 RN 




4.5 Atropisomeric purity of single atropisomers 
After validation of the chiral HPLC assay, atropisomeric purity of the single 
atropisomers was determined. Results (Figure 4.6) indicate that all atropisomers 
were contaminated to different extents with their antipodes. 
 
Figure 4.6 Chromatographs showing the presence of the antipode of the 
predominant atropisomer in single atropisomers of (TOP) ketotifen (K) and 
(BOTTOM) norketotifen (N) in Ringer-HEPES buffer (pH 7.4); (a) R in S, (b) S 
in R. 
The antipode of the predominant atropisomer was found to be present in all 
compounds, that is, the compounds are not atropisomerically pure. The 
atropisomeric purity of SK, RK, SN and RN are approximately 92%, 88%, 95% 
and 97% respectively. To ensure the absence of inversion during uptake and 
permeation studies, racemization of atropisomers in the presence of RBE4 and 
Caco-2 cells under different conditions was investigated  
4.5.1 Methods 
Racemization of single atropisomer was assessed in the presence of RBE4 and 
Caco-2 cells and their respective culture buffer to investigate cell-mediated 
racemisation or inversion. Ringer-HEPES buffer pH 7.4 was used for RBE4 cells 
Minutes




































































































































































and HBSS-HEPES buffer pH 7.4 for Caco-2 cells. In both cases, incubations were 
carried out in 12-well plates at 37°C under 5% CO2 for 6 h in (a) buffer only, (b) 
buffer pre-incubated with cell monolayers for 2 h, and (c) buffer in the presence 
of cell monolayers previously washed 3 times with 0.5 ml buffer. In all cases 2.2 
ml K or N atropisomer solutions (2 μM) were added to each well and incubations 
carried out in triplicate. Buffer samples (180 μl) were removed at times 0, 10, 30, 
60, 120, 240, 360 and 480 min and then dried under vacuum at room 
temperature. Dried samples were reconstituted with 60 μl mobile phase and 
subjected to chiral assay.  
Racemization of single atropisomers of K and N in the presence of RBE4 and 
Caco-2 cells and their respective culture buffer was calculated using Equation 
4.1. 
A (%)= (Canti/Cnor)×100       4.1 
where A is the percentage from the antipode, Canti is the determined 
concentration of the antipode and Cnor is the nominal concentration of the 
atropisomer used for stability test. 
4.5.2 Results and discussions 
4.5.2.1 Racemization of single atropisomers in RBE4 cell culture medium 
As shown in Figure 4.7, the single atropisomers of K and N were stable to 
racemization or inversion (a) in Ringer-HEPES buffer pH 7.4, (b) Ringer-HEPES 
buffer pH 7.4 pre-incubated with RBE4 cell monolayers and (c) in Ringer-HEPES 




Figure 4.7 Stability of single atropisomers of ketotifen (K) and norketotifen 
(N) at 37°C over 6 h in (a) Ringer-HEPES buffer pH 7.4 (b) Ringer-HEPES 
buffer pre-incubated with RBE4 cell monolayers for 2 h, and (c) Ringer-
HEPES buffer in the presence of RBE4 cell monolayers (data are means ± SD, n 
= 3). 
4.5.2.2 Racemization of single atropisomers in Caco-2 cell culture medium 
As shown in Figure 4.8, the single atropisomers of K and N were stable to 
racemization or inversion in (a) HBSS-HEPES buffer pH 7.4, (b) HBSS-HEPES 
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buffer pH 7.4 pre-incubated with Caco-2 monolayers for 2 h, and (c) in HBSS-
HEPES buffer in the presence of Caco-2 cell monolayers. 
 
Figure 4.8 Stability of single atropisomers of ketotifen (K) and norketotifen 
(N) at 37°C over 6 h in (a) HBSS-HEPES buffer pH 7.4, (b) HBSS-HEPES buffer 
pre-incubated with Caco-2 cell monolayers for 2 h, and (c) HBSS-HEPES 
buffer in the presence of Caco-2 cell monolayers (data are means ± SD, n = 3). 
As shown above, atropisomers of K and N were stable to racemization or 
inversion under different conditions (Figure 4.7 and 4,8) but the existing counter 
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atropisomers (5 to 10%) could be a potential problem when we assume pure 
atropisomers were used. Thus it is necessary to investigate the uptake of K and N 
into RBE4 cells using both atropisomers (with antipodes) and racemates (50% of 
each atropisomers) by using both nonchiral (Chapter 2) and chiral assays to 
investigate the effect of existing antipodes on the uptake of K and N atropisomers 
in RBE4 cells. 
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Chapter 5 Uptake and permeation studies of ketotifen and 
norketotifen in cell models of the BBB 
5.1 Introduction 
The isolation of cerebral capillaries by Joo and Karnushina (1973) initiated a 
new generation of in vitro studies of the BBB. Recently, investigation of the 
barrier functions at the cellular and molecular levels has involved in vitro models 
of the BBB such as primary and immortalised capillary endothelial cell lines of 
human, bovine, porcine and rat brain (Naik and Cucullo 2012; Roux and Couraud 
2005) . 
The immortalized rat brain endothelial cell line, RBE4, is one of the most well 
characterized models of the BBB. The cells, immortalized using a plasmid 
containing the E1A adenovirus gene (Yang et al, 2001), retain many 
characteristics of their in vivo capillary endothelial cells including enzymes, glial 
factors (Calhau et al, 2002; Roux et al. 1994)  and a wide range of  transporters. 
These include P-gp (Babakhanian et al, 2007; Begley et al, 1996), BCRP (Lee et al, 
2007), MRP (Regina et al, 1998), GLUT (Regina et al, 1997, 2001) OCTN-2 
(Friedrich et al, 2003) and L-amino acid transporter (LAT) (Reichel et al, 2002). 
For this reason, RBE4 cells are widely used to investigate drug transport across 
the BBB. 
Early studies of K transport in RBE4 cells implicated an influx transporter 
(Ishiguro et al, 2004), later shown to be a common transporter of cationic H1 
antagonists (Suzuki et al, 2010). This suggests that both K and N are substrates 
of this transporter but nothing is known about whether it is stereoselective. The 
first aim of the work reported in this chapter was to determine whether the 
uptake of K and N by RBE4 cells is stereoselective using single atropisomers 
(nonchiral assay) and racemates (chiral assays). A non-linear fitting model 
(Michaelis-Menten), which consists both passive (linear) and active (non-linear) 
components, was used to estimate kinetic parameters in the uptake. 
Although the RBE4 cell line has been widely used for uptake studies, it cannot be 
used for transendothelial permeability studies because monolayers of REB4 cells 
do not form complete tight junctions thus do not generate the necessary 
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restrictive paracellular barrier properties (Rist et al, 1997; Tsukita and Furuse, 
2000). Barrier properties can be improved by co-culture of RBE4 cells with 
astrocytes (or astrocyte-conditioned medium) (Balbuena et al, 2010; 2011) or 
cortical neurons (Cestelli et al, 2001) but the integrity of the membranes 
produced remains poor.  
An alternative strategy is to use the Caco-2 cell line, an immortalized 
heterogeneous human epithelial adenocarcinoma cell line which forms complete 
tight junctions and shares some transporters with rat brain endothelial cells. It 
has been reported that as endothelial and epithelial cells share similarity in 
organization and regulation, cultured epithelial cell lines such as Caco-2 are 
appropriate to investigate generic regulatory mechanisms (Abbott, 2005). 
The second aim of the work reported in this chapter was to investigate whether 
transport of K and N across Caco-2 cell monolayers is stereoselective. This was 
done using racemates (chiral assays). 
5.2 Materials 
TrypLE™ Express, MEM non-essential amino acids, F-10 nutrient mixture (Ham) 
(1×), MEM alpha (1×) minimum essential medium, Dulbecco’s Modified Eagle 
Medium, L-glutamine 200 mM, penicillin-streptomycin (10,000 U/ml), fetal 
bovine serum (FBS), selective antibiotic (Geneticin® G418 Sulphate) and 
Dulbecco’s phosphate buffered saline were purchased from Gibco® (Invitrogen, 
New Zealand). Basic bovine fibroblast growth factor (FGF) (156Aa) was 
purchased from Roche (Mannheim, Germany). Cell proliferation assay using 
CellTiter 96® AQueous One solution was obtained from Promega Corporation 
(USA). [14C]Mannitol (58.8 mCi/mmol (2.176 GBq/mmol), OPTIPHASE ‘HISAFE’ 
2 scintillation cocktail and miniature 6 ml polyethylene vials were purchased 
from PerkinElmer (Waltham, USA). DMSO was purchased from Merck (New 
Zealand). 
12-well, 24-well (MULTIwell™), and 96-well (MICROTEST™) plates, 15 ml and 50 
ml high-clarity polypropylene conical tubes, 10 ml and 25 ml serological pipettes 
were obtained from BD FALCON™ (USA). Collagen coated 12-well plates and 75 
cm2 flasks were purchased from BD BioCoat™ (England). VacuCap® 60 filter units 
(0.2 μm) were purchased from PALL Life Sciences (Auckland, New Zealand). Cell 
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culture flasks (25 cm2) and Transwell® permeable supports (0.4 μm 
PCmembranes, COSTAR®), were purchased from Corning Inc. (NY, USA). Rapid 
equilibrium dialysis devices (8K MWCO) (RED, Pierce) were purchased from 
ThermoFisher Scientific (Taiwan). 
Other materials were obtained and described in Section 2.2 and 4.2. 
5.3 Methods 
5.3.1 Studies in RBE4 cells 
5.3.1.1 RBE4 cell culture techniques 
Medium preparation: RBE4 cell culture medium was prepared by mixing MEM-
alpha and F-10 (1× Hams) medium in a 1:1 ratio and adding 10% FBS, 2 mM L-
glutamine, 300 μg/ml G418, 1% penicillin-streptomycin and 1 ng/ml FGF. The 
medium was sterilized by filtering through a 0.2 μm filter (Aspiration Station 
GILSON, Switzerland) in a laminar flow hood (HERA Safe KS 12, Thermo Electron 
Corp. Germany). 
Cell thawing: Frozen cells were thawed in a 37°C water bath (Julabo TW20, John 
Morris Scientific Pty Ltd, Austria) and transferred to a 15 ml centrifuge tube 
containing 8 ml culture medium. The suspension was centrifuged (KUCOTA 
5930, Japan) at 1000 rpm for 5 min, the supernatant removed and the cells 
resuspended in 10 ml culture medium. The cell suspension was then added to a 
75 cm2 flask along with another 5 ml culture medium and incubated at 37°C 
under 95% O2, 5% CO2 (HERA cell 150, Thermo Electron Corp., Germany). 
Medium (15 ml) was renewed every two days until confluence.  
Cell subculture: After carefully removing culture medium, 1.5 ml TrypLE™ was 
added and the flask left in the laminar flow hood at room temperature for 10 min 
to allow cells to detach. Cell culture medium (12 ml) was added and pipetted up 
and down several times to retrieve most cells. Finally, the cell suspension was 
equally divided into three clean flasks to which more cell culture medium was 
added to ensure 15 − 20 ml medium was present in each mlask. 
Cell freezing: RBE4 cells were detached as described above after which 10 ml cell 
culture medium was pipetted up and down several times to retrieve most cells. 
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The cell suspension was transferred to a 15 ml tube and centrifuged at 1000 rpm 
for 5 min. The supernatant medium was then removed and 10 ml freezing 
medium (10% DMSO, 90% cell culture medium) added to the cell pellet. Cells 
were resuspended and divided into 5 freezing tubes, which were stored at -80°C 
for short-term storage and in liquid nitrogen for long-term storage.  
Seeding for uptake studies: RBE4 cells were seeded into a 12-well collagen-coated 
culture plate at a concentration of 50,000 cells/ml (1.5 ml cell suspension per 
well) and incubated at 37°C under 95% O2, 5% CO2. Medium was changed every 
2 days and cells reached confluence in 2 – 3 days.  
5.3.1.2 Binding to RBE4 cell membranes (chiral assays) 
In cell uptake, before being taken up into cells, compound binds specifically and 
non-specifically to cell membranes to different extents (Chapter 3). Since cell 
membranes are a chiral environment (with three-dimensional proteins such as 
receptors and transporters), it is possible for a chiral compound to 
stereoselectively bind to cell membranes. However, after homogenizing cells, it is 
impossible to tell whether the compound concentration determined is from cell 
membranes (binding) or inside cells (uptake). Therefore, in order to interpret 
the cell uptake result correctly, it is important to investigate (a) whether the 
compound binds to cell membrane, and (2) whether the compound binds 
stereoselectively to cell membranes. In this study, binding of K and N single 
atropisomers to RBE4 cell membranes was determined using RED. 
RBE4 cells were harvested and suspended in water for 4 h at 4°C to allow cells to 
swell before being subjected to three freeze-thaw cycles (from -80 to 25°C). The 
suspension was then probe-sonicated for 3 × 10 s with 10 s intervals and 
centrifuged at 1000 rpm for 10 min to remove unbroken cells and nuclei. The 
supernatant was further centrifuged (OPTMATM L Preparative Ultracentrifuge 
Class R, Beckman and 60 Ti Rotor, Backman, USA) at 22,300 rpm for 10 min 
(Anthes et al, 2002) and the pellet resuspended and centrifuged again. The final 
pellet was resuspended in 10 ml Ringer- HEPES buffer pH 7.4 with K or N 
atropisomers (2 or 10 μM). An aliquot (0.5 ml) of the suspension was added to 
the RED unit and subjected to orbital shaking (Orbital Mixer Incubator, Ratex) at 
250 rpm for 4 h. Aliquots (180 μl) from both the buffer and cell membrane sides 
 83
were collected for chiral analysis. Results were analysed and compared using 
one-way ANOVA with Bonferroni's multiple comparison post hoc test (GraphPad 
Prism5) to investigate whether the binding of K and N atropisomers to RBE4 cell 
membranes was stereoselective.  
Binding was calculated using Equation 5.1 
Binding (%) = (Ccell − Cbuffer) × 100 / Ccell                                         5.1 
where Ccell is the concentration of compound in cell compartment, Cbuffer is the 
concentration of compound in the buffer compartment.  
Mass balance (recovery) was calculated using Equation 5.2 
Mass balance (%) = (Mcell + Mbuffer) × 100 / Mloading                                          5.2 
where Mcell is the mass of compound in cell compartment, Mbuffer is the mass of 
compound in the buffer compartment, Mloading is the mass of compound loaded at 
the beginning of the experiment.  
5.3.1.3 Cytotoxicity to RBE4 cells 
The CellTiter 96® AQueous One Solution Cell Proliferation Assay, a colorimetric 
method for determining the number of viable cells, was used in this experiment. 
This assay reagent is bio-reduced to a coloured formazan product by reduced 
forms of nicotinamide adenine dinucleotide phosphate or nicotinamide adenine 
dinucleotide, which is produced by living cells. Therefore, the darker the colour 
after incubation indicates more formazan product, which is directly proportional 
to the number of living cells. 
RBE4 cells were seeded into 96-well plates at 50,000 cell/ml and allowed to 
reach confluence over 2 – 3 days. The monolayers were washed three times with 
0.2 ml Ringer-HEPES buffer pH 7.4 at 37°C before an experiment. 
Aliquots (100 μl) of K or N atropisomer solutions (0 – 100 μM) in Ringer-HEPES 
buffer pH 7.4 were added to the monolayers after which CellTiter 96® AQueous 
One Solution (20 μl) (reagent) was added into each well and the plate incubated 
at 37°C under 5% CO2 for 2 h. The absorbance of each well was then determined 
at 490 nm using a plate reader (SPECTRA MAX 340, Molecular Devices). 
The strongest colour was produced by wells with cell monolayers only (Acontrol), 
this absorbance representing 100% living cells. To exclude interference 
absorbance from reagent and buffer, absorbance of wells without cell monolayer 
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but with reagent and buffer were measured (ABlank) and subtracted from Acontrol. 
Thus, the percentage of living cells remaining after incubation with K and N can 
be calculated using Equation 5.3: 
Cell Proliferation (%) = Asample × 100 / (AControl – ABlank)                                 5.3 
where Asample is the absorbance of sample, AControl is the absorbance of the cell 
monolayer containing buffer and reagent (no drug) and ABlank is the absorbance 
of buffer and reagent (no cell monolayer or drug). 
5.3.1.4 Initial uptake studies 
Experiment 1: Time course of uptake of K and N atropisomers 
The first experiment involved incubation of single atropisomers of K or N at 
various time points with RBE4 cell monolayers and analysis of K and N using the 
nonchiral assay to determine the appropriate time for the concentration-
dependent uptake studies.  
RBE4 cell monolayers were washed with 0.5 ml Ringer-HEPES buffer pH 7.4 
after which 1.5 ml 5 μM solutions of SK, RK, SN or RN were added to wells in 
triplicate and incubated at 37°C for 1, 2, 3, 5, 10, 15, 20, 30, 60 and 120 min. 
Incubations were terminated by washing monolayers three times with 0.5 ml 
ice-cold Ringer-HEPES buffer after which 0.5 ml Milli-Q water was added to each 
well and incubated at 4°C overnight to detach and briefly lyse cells. The 
suspensions thus produced were collected by pipetting up and down several 
times and transferred to 1.7 ml centrifuge tubes. Glass beads were added and 
sample mixtures homogenised at speed 7 for 3 min using a Bullet Blender®. 
Finally, 180 μl aliquots of homogenates were processed and subjected to 
nonchiral analysis (Chapter 2). As each well contains different numbers of cells 
and compound concentration may vary during detaching and homogenization, 
all of which may affect measured K and N concentrations. To solve this problem, 
protein concentration of each homogenate sample was determined to normalise 
K and N atropisomer concentrations as nmol per mg of protein (nmol of 
compound per mg of protein in homogenate) instead of nmol. To determine 
protein concentration of each cell homogenate sample, 50 μl aliquots of 
homogenates were subjected to BCA™ protein assay. Normalised concentrations 
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of K and N atropisomers were plotted against time and the linear portion used to 
determine initial uptake rates. 
The time course of uptake of K and N atropisomers from 5 μM solutions at 37°C 
by RBE4 cells is shown in Figure 5.1. The results indicate that uptake was 
approximately linear over the first 2 min and this duration was used for 
subsequent uptake studies (Ishiguro et al, 2004). 
Figure 5.1 Time course of ketotifen (K) and norketotifen (N) atropisomer 
uptake from 5 μM solutions by RBE4 cells at 37°C (data are means ± SD, n = 3). 
 
Experiment 2: Effect of concentration on uptake of K and N atropisomers 
(incubating with single K or N atropisomers) 
The second experiment involved incubation of single atropisomers of K or N at 
various concentrations with RBE4 cell monolayers for 2 min (based on 
experiment 1) and analysis of K and N using the nonchiral assay to determine the 
effect of concentrations on uptake studies. 
RBE4 cell monolayers were washed three times with 0.5 ml Ringer-HEPES buffer 
pH 7.4 and then incubated with 1.5 ml of SK, RK, SN or RN solutions (0.2 − 50 
μM) in Ringer-HEPES buffer at 37°C for 2 min. Uptake was terminated, 
suspensions collected, homogenates prepared and analysed, as described above 
in Experiment 1. Results were plotted as loading concentration (μM) vs. 
normalised uptake rate (nmol/mg/min) over 2 min and fitted to a model 
incorporating passive and active transport (Equation 5.4) using GraphPrism 5. 
V = (Vmax × S)/(Km + S) + k × S                                                                            5.4  









































where V is the reaction rate, Km is the Michaelis-Menten constant, Vmax is the 
maximum reaction velocity of active transport, V contributes most at lower 
concentrations before the transporter is saturated as indicated by the Vmax 
plateau in the active transport curve. S is concentration and k, the rate constant 
for passive diffusion, becomes important at higher concentrations where Vmax is 
reached. The linear part of the curve at high substrate concentration gives the k 
value. The best-fit values of Vmax, Km and k were obtained from the model. 
Experiment 3: Effect of temperature and ATP depletion on concentration-
dependent uptake of K and N atropisomers (incubating with racemic K and N) 
The third experiment involved incubation of racemates of K and N at various 
concentrations with RBE4 cell monolayers for 2 min (based on experiment 1) 
and analysis of K and N by atropisomers using the chiral assays to determine the 
effect of concentrations, temperatures and ATP depletion on uptake studies 
(mechanism of uptake).  
At 4°C, the active transport was eliminated by cutting off the ATP required, as 
enzymes involved in ATP production are not functioning at 4°C. However, the 
lower temperature not only reduces the enzyme activity but also alters other 
parameters such as pH of buffer used during uptake studies, pKa and 
distribution coefficient of K and N (Chapter 3), cell membrane structures and, 
consequently, passive diffusion constant. Thus, the reduction of uptake at 4°C 
may not simply a result from reduced active transport. It is necessary to 
investigate the role of active transport played in cell uptake of K and N. To 
exclude the interference from passive diffusion, NaN3, an ATP depleter, was used. 
This is because as an ATP depleter, NaN3 eliminates active transport without 
changing other variables.  
Both the 4°C and ATP depleter methods provide information on uptake of K and 
N in different aspects under different conditions. As a result, comparing data 
from these studies may provide more information and help with interpreting 
uptake results.  
To investigate the effect of temperature, RBE4 cell monolayers were washed 
three times with 0.5 ml Ringer-HEPES buffer pH 7.4 and then incubated with 1.5 
ml of racemic K or racemic N solutions (0.5 − 100 μM) in Ringer-HEPES buffer for 
2 min.  
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For the uptake at 37°C, experiments were performed as described above in 
Experiment 2. For the uptake at 4°C, uptake of racemic K and N was investigated 
in a cold-room maintained at 4°C to eliminate active transport. Uptake rate 
(nmol/mg/min) over 2 min time versus concentration (μM) of K and N 
atropisomers was interpreted by linear regression (ie. Equation5.4 collapses to: 
V = k × S) and taken as the passive diffusion constant for the determined 
compound. 
To investigate the effect of ATP depletion, RBE4 cell monolayers were washed 
and incubated with 1.5 ml 10 mM NaN3 solution in Ringer-HEPES buffer pH 7.4 
at 37°C for 30 min. After removal of the NaN3 solution, 1.5 ml racemic K and N 
solutions at various concentrations (0.5 – 100 μM) containing 10 mM NaN3 in 
Ringer-HEPES buffer pH 7.4 were added and incubated for 2 min at 37°C. Uptake 
was terminated by washing three times with ice-cold Ringer-HEPES buffer, and 
samples subjected to chiral analysis. Uptake with or without 10 mM NaN3, rate 
(nmol/mg/min) at 37°C over 2 min versus concentration (μM) of K or N 
atropisomers was determined by nonlinear regression using GraphPrism 5 
(Equation 5.4). 
Statistical analysis was carried out by one-way ANOVA with post-hoc Bonferroni 
testing to compare selected data sets. Results are presented as means ± SD. 
Differences for which p < 0.05 were taken as significant. 
5.3.2 Studies in Caco-2 cells  
5.3.2.1 Caco-2 cell culture techniques 
Medium preparation: Caco-2 cell culture medium was prepared by mixing DMEM 
with 10% FBS, 1% penicillin-streptomycin and 1% MEM-NEAA in the laminar 
flow hood. 
Cell thawing: Frozen Caco-2 cells were equilibrated at 40°C and transferred into 
a 15 ml centrifuge tube containing 8 ml culture medium. The suspension was 
centrifuged at 1000 rpm for 5 min and the cells resuspended in 7 ml culture 
medium before being transferred to a 25 cm2 flask. Cells were then placed in an 
incubator at 37°C under 95% O2, 5% CO2 and 7 ml culture medium added every 
two days until reaching confluence.  
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Cell subculture: After removing medium from the flask, 0.5 ml TrypLE™ was 
added to cover the cell monolayer and the flask left in the laminar flow hood at 
room temperature for 10 min to allow cells to detach. Cell culture medium (6 ml) 
was added and pipetted up and down several times to retrieve most cells after 
which the cell suspension was divided into three clean flasks and cell culture 
medium added to ensure 7 – 8 ml medium was present in each flask. 
Cell freezing: Caco-2 cells were detached and collected by pipetting up and down 
several times. The cell suspension was transferred to a 15 ml tube and 
centrifuged at 1000 rpm for 5 min. After removal of supernatant, 6 ml freezing 
medium (10% DMSO, 90% cell culture medium) was added and cells 
resuspended and divided into three freezing tubes. Tubes were stored at -80°C 
for short-term storage and in liquid nitrogen for long-term storage.  
Cell seeding for permeability studies: Aliquots (0.5 ml) of Caco-2 cell suspension 
were added to a 12-well transwell plate at a concentration of 100,000 cells/well. 
Cell culture medium (1.5 ml) was added to each well and changed every two 
days. TEER was measured every two days until it reached a constant value of 
around 300 − 400 Ω*cm2 after about 21 days. 
5.3.2.2 TEER measurement 
The TEER instrument described was switched on and probes were equilibrated 
in warmed sterilized PBS (37°C) for 5 min in the laminar flow hood. The TEER 
probes were then carefully inserted into each well with the short probe in the 
insert and the longer probe in the well. After measurement, probes were left in 
PBS solution for short-term storage. 
5.3.2.3 Permeability of K and N atropisomers  
Solutions of K and N racemates (5 μM) were prepared containing 3 × 105 
dpm/ml [14C]mannitol in HBSS-HEPES buffer pH 7.4. Caco-2 cell monolayers 
were washed with HBSS-HEPES buffer at 37°C for 3 × 5 min before recording the 
TEER value.  
Caco-2 cell monolayers were incubated with test solutions in triplicate. For study 
of A (apical) to B (basolateral) transport, 0.5 ml drug solution was added to 
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inserts and 1.5 ml HBSS-HEPES buffer added into wells below inserts. For B to A 
studies, 1.5 ml drug solution was added to wells below inserts while 0.5 ml 
buffer was added to inserts. Plates were incubated at 37°C for 2 h during which 
0.4 ml samples were taken from the receptor side after 10, 20, 30, 60, 90 and 120 
min and immediately replaced with 0.4 ml 37°C HBSS-HEPES buffer. 
After collecting the last sample, TEER values were measured taking care to wash 
probes after use to remove radioactivity. All solutions from donor and receptor 
sides were transferred to labelled 1.7 ml centrifuge tubes and the filter 
membranes washed with ice-cold HBSS-HEPES buffer and cut off from inserts. 
Caco-2 cells on these membranes were transferred to 1.7 ml centrifuge tubes and 
homogenized in 0.5 ml Milli-Q water containing glass beads using a Bullet 
Blender® at speed 7 for 3 min. 
Samples from the donor and receptor sides as well as loading solutions and cell 
monolayer homogenates were subjected to chiral analysis. To determine 
permeability of [14C]mannitol, 100 μl samples were mixed with 5 ml scintillation 
cocktail for scintillation counting. Samples of cell monolayer homogenates were 
used to analyse protein concentration using BCA protein assay. Papp values of 
[14C]mannitol, K and N racemates were calculated using Equation 5.5: 
Papp= (dQ/dt) / (A × C0)                                                                                                5.5  
where dQ/dt is the rate of permeation (μmol/s) obtained from the slope of the 
linear portion of the Q versus time data, A is the surface area of the membrane 
(1.12 cm2) and C0 is the initial concentration in the donor solution (μM). The 
equation assumes that the donor concentration is essentially constant over the 
time of the study and Q versus t is linear. 
The mass recovered (%) of K and N atropisomers was calculated using Equation 
5.6: 
Mass recovered (%) = (MS + MD + MC+ MR) × 100/MT                               5.6 
where MS is the mass of compound in collected samples, MD is the mass of 
compound in the donor side after 2 h incubation, MC is the mass of compound in 
the cell monolayer homogenate, MR is the mass of compound in the receptor side 
after 2 h incubation and MT is the mass added to the donor side at beginning of 
the study (time 0). 
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Statistical analysis was carried out by one-way ANOVA with post-hoc Bonferroni 
testing to compare selected data sets using GraphPad Prism (GraphPad Software, 
San Diego, CA, USA). Results are presented as means ± SD. Differences for which 
p < 0.05 were taken as significant. 
5.4 Results  
5.4.1 Binding of K and N atropisomers to RBE4 cell membranes 
There was no significant difference between binding of SK and RK or between SN 
and RN to RBE4 cell membranes at the tested concentrations. The results suggest 
that binding of K and N atropisomers to RBE4 cell membranes is not 
stereoselective. However, binding of SN and RN was significantly higher than 
that of SK and RK at both concentrations (Figure 5.2). 
Mass balance of K and N atropisomers (Table 5.1) was in the range 78.5 – 110% 
of the concentration of the loading solution. 
The concentrations 2 μM and 10μM of K and N atropisomers were chosen as low 
and high concentrations of K and N before saturation of active transport (Figures 
5.5 and 5.6). That is, the concentration used for these binding studies was 
sufficient to detect binding but not high enough to saturate the binding sites.  
 
Table 5.1 Mass balance (recovery) for binding of ketotifen (K) and 
norketotifen (N) atropisomers to RBE4 membranes racemates as determined 
by rapid equilibrium dialysis at 37°C for 4 h (data are means, n = 3). 
 Loading (μM) Cell (%) Buffer (%) Recovery (%) 
SK 44.1 34.5 78.5 
RK 50.7 35.1 85.8 
SN 75.4 35.4 110.8 
RN 
2 
67.8 32.7 100.6 
SK 59.0 40.9 99.9 
RK 63.9 43.6 107.5 
SN 65.9 29.4 95.3 
RN 
10 




Figure 5.2 Binding of ketotifen (K) and norketotifen (N) atropisomers (a) 2 
μM and (b) 10 μM to RBE4 cell membranes after 4 hours at 37°C (data are 
means ± SD, n = 3) (* P < 0.05, ** P < 0.01 and *** P < 0.001). 
 
5.4.2 Cytotoxicity of K and N to RBE4 cell monolayers 
K and N were non-cytotoxic to RBE4 cells over 2 h in the tested concentration 
range (Figures 5.3 and 5.4) as the number of viable cells changed by < 10%. The 
slight increase in living cell percentage over time is probably due to medium 
evaporation during incubation. 
Based on these results, concentrations up to 100 μM were deemed safe to use in 
RBE4 uptake experiments. 
Figure 5.3 Cytotoxicity of ketotifen (K) atropisomers to RBE4 cell monolayers 
after 2  h at 37°C (data are means ± SD, n = 4). 
 
 

















































































































































Figure 5.4 Cytotoxicity of norketotifen (N) atropisomers to RBE4 cell 
monolayers after 2 h at 37°C (data are means ± SD, n = 4). 
5.4.3 Initial uptake experiments 
Concentration dependence (Experiment 2, loading single atropisomers):  
The concentration dependence of uptake of K (Figure 5.5) and N (Figure 5.6) 
atropisomers (loaded as single atropisomers) into RBE4 cell monolayers over 2 
min at 37°C shows a combination of both active and passive transport. The 
presence of active uptake is consistent with previous studies, which suggested K 
is transported by an unidentified influx transporter (Ishiguro et al, 2004; Suzuki 
et al, 2010).  
Figure 5.5 Initial rate of uptake of S-ketotifen (SK) and R-ketotifen (RK) 
atropisomers after loading single atropisomers into RBE4 cell monolayers 
over 2 min at 37°C (data are means ± SD, n = 3). The non-linear regression is 
based on Equation 5.4. 













































There are small differences between the rate of uptake of SK and RK (Figure 5.5) 
and SN and RN (Figure 5.6), but the differences are not significant (Table 5.2). 
The small differences may be due to inter-well variation arising from the loading 
of individual atropisomers into different wells. The results indicate that uptake 
of K and N atropisomers into RBE4 cell monolayers is not stereoselective under 
the tested conditions.  
Figure 5.6 Initial rate of uptake of S-norketotifen (SN) and R-norketotifen 
(RN) atropisomers after loading single atropisomers into RBE4 cell 
monolayers over 2 min at 37°C (data are means ± SD, n = 3). The non-linear 
regression is based on Equation 5.4. 
 
Table 5.2 Parameter estimates based on Equation 5.4 for uptake of ketotifen 
(K) and norketotifen (N) atropisomers loaded as single atropisomers over 2 








SK 1.02 ± 0.31 7.24 ± 2.69 
RK 1.55 ± 0.41 9.45 ± 2.68 
3.84 ± 6.10 
SN 5.78 ± 4.25 35.6 ± 19.5 
RN 4.15 ± 2.73 25.8 ± 12.3 
15.9 ± 36.5 
 
Although non-stereoselective, the results show that the uptake of N atropisomers 
is higher than that of K atropisomers by both active transport and passive 
diffusion (Table 5.2). The latter is unexpected since the Log D (octanol/buffer pH 
7.4) of K (2.68 ± 0.02) is higher than that of N (1.62 ± 0.45) (Table 3.4) but it is 
























consistent with the greater binding of N to RBE4 cells as revealed in the binding 
studies (Figure 5.2). In addition, the result is also consistent with the Log D 
(liposome/buffer pH 7.4 at 37°C) of K (2.63 ± 0.04), which is lower than that of N 
(3.64 ± 0.01) (Table 3.4). This provides further evidence that the higher 
concentration of N determined was a result from association with cell 
membranes. 
 
Concentration, temperature and ATP dependence (Experiment 3, loading 
racemates):  
The concentration dependence of the rates of uptake of K (Figure 5.7) and N 
(Figure 5.8) atropisomers loaded as racemates also shows a combination of 
active and passive transport.  
The data for SK and RK and for SN and RN are almost superimposable, indicating 
the uptake is not stereoselective. 
In addition, the uptake of N is much higher than that of K by both active and, 
especially, by passive transport mechanisms. 
Figure 5.7 Initial rate of uptake of S-ketotifen (SK) and R-ketotifen (RK) 
atropisomers into RBE4 cell monolayers after loading racemic ketotifen (K) 
over 2 min at 37°C (data are means ± SD, n = 3). 























Figure 5.8 Initial rate of uptake of S-norketotifen (SN) and R-norketotifen 
(RN) atropisomers into RBE4 cell monolayers after loading racemic 
norketotifen (N) over 2 min at 37°C (data are means ± SD, n = 3). 
The uptake rates of K atropisomers at 4°C and in the presence of NaN3 at 37°C 
are shown in Figures 5.9 and 5.10, and the corresponding uptake rates for N 
atropisomers are shown in Figures 5.12 and 5.13. 
Figure 5.9 Initial rate of uptake of S-ketotifen (SK) and R-ketotifen (RK) 
atropisomers after loading racemic ketotifen (K) into RBE4 cell monolayers 
over 2 min at 4°C (data are means ± SD, n = 3).  













































Figure 5.10 Initial rate of uptake of S-ketotifen (SK) and R-ketotifen (RK) 
atropisomers after loading racemic ketotifen (K) and 10 mM NaN3 into RBE4 
cell monolayers over 2 min at 37°C (data are means ± SD, n = 3).  
 
The rates of uptake of K atropisomers in the absence and presence of NaN3 is 
shown in Figure 5.11 and those for N atropisomers in Figure 5.14. 
Figure 5.11 Comparison of initial rate of uptake of S-ketotifen (SK) and R-
ketotifen (RK) atropisomers after loading racemic ketotifen (K) with and 
without 10 mM NaN3 into RBE4 cell monolayers over 2 min at 37°C (data are 
means ± SD, n = 3).  
Parameter estimates based on Equation 5.4 are given in Table 5.3, except at 4°C 
when only the passive component of Equation 5.4 was relevant.




























SK at 37°C with NaN3


















Table 5.3 Parameter estimates based on Equation 5.4 for uptake of ketotifen (K) and norketotifen (N) atropisomers (loading racemate) 
by RBE4 cell monolayers at 4°C and 37°C and in the presence of NaN3 (data are means ± SD, n = 3). 















SK 0.91 ± 0.19 3.33 ± 1.60 20.4 ± 2.2 0.45 ± 0.10 1.80 ± 1.11 
RK 0.91 ± 0.21 4.41 ± 2.18 
17.8 ± 4.0 
20.6 ± 2.1 0.42 ± 0.10 2.04 ± 1.33 
14.4 ± 2.2 
SN 5.68 ± 1.70 11.2 ± 4.8 110 ± 3 1.31 ± 0.15 3.14 ± 0.81 
RN 5.36 ± 1.90 13.9 ± 6.6 
53.6 ± 22.8 
120 ± 3 1.10 ± 0.13 2.26 ± 0.68 
52.1 ± 29.0 
 
Corresponding data for uptake of N atropisomers are shown in Figures 5.12, 5.13 and 5.14. 
Figure 5.12 Initial rate of uptake of S-norketotifen (SN) and R-norketotifen (RN) after loading racemic norketotifen (N) into RBE4 cell 
monolayers over 2 min at 4°C (data are means ± SD, n = 3).
























Figure 5.13 Initial rate of uptake of S-norketotifen (SN) and R-norketotifen (RN) 
after loading racemic norketotifen (N) and 10 mM NaN3 into RBE4 cell 
monolayers over 2 min at 37°C (data are means ± SD, n = 3).  
 
Figure 5.14 Comparison of initial rate of uptake of S-norketotifen (SN) and R-
norketotifen (RN) after loading racemic norketotifen (N) with and without 10 
mM NaN3 into RBE4 cell monolayers over 2 min at 37°C (data are means ± SD, n = 
3).  
Uptake at 4°C and 37°C  (with NaN3) showed a reduced active transport for both K 
and N comparing with estimated parameters at 37°C. For passive diffusion, at 4°C k 
increased significantly for both K and N. This is possibly due to the effect of 
temperature on pKa, logD and other factors discussed before (Chapter 3). At 37°C 
(with NaN3), for both K and N, k values were found similar to those at 37°C without 
NaN3 (Table 5.3). This is because NaN3 only depletes ATP to reduce active transport 















































instead of affecting other parameters, which alter passive diffusion. In addition, the 
uptake of K and N at 4°C were almost linear profiles (Figure 5.9 and 5.12). In 
contrast, uptake of K and N at 37°C (with NaN3) were still non-linear, which 
suggested a reduced but still present active transport (Figure 5.10 and 5.13, Table 
5.3). 
5.4.4 Permeability of Caco-2 cell monolayers (loading racemates) 
TEER value measured before and after the permeability study were all within the 
range of 300 − 400 Ω*cm2. In addition, the Papp of [14C]mannitol (< 10-6 cm/s) agreed 
with TEER result. Both results indicated the Caco-2 monolayers were intact all 
through the study. For RBE4 cells, on the other hand, the TEER value of monolayers 
has been reported to be approximately 100 Ω*cm2 or even less (Faria et al, 2010). 
Moreover, Papp of sucrose through RBE4 cell monolayer has been reported to be 214 
× 10-6 cm/s, which is much higher than that through in vivo rat BBB (less than 0.1 × 
10-6 cm/s) (Gumbleton and Audus, 2001). These results indicated that compared 
with the “leaky” RBE4 cell monolayers, the Caco-2 monolayers are “tight and intact”, 
thus providing a good barrier model to assess transcellular permeation. 
Papp values for transport of K and N atropisomers across Caco-2 cell monolayers in 
the A to B and B to A directions are shown in Figure 5.15. 
Results show there is no stereoselective transport of K or N atropisomers in either 
direction through Caco-2 cell monolayers after 2 h at 37°C. However, about twice 
as much of both K and N is transported from B to A than from A to B (Table 5.4). 
This may indicate an efflux mechanism involved in the transport of K and N 




Figure 5.15 Papp values for transport of ketotifen (K) and norketotifen (N) 
atropisomers (loaded as racemates) across Caco-2 monolayers after 2 h at 37°C in 
the (a) apical to basolateral and (b) from basolateral to apical direction; (c) 
compares the two sets of data (data are means ± SD, n = 3, * P< 0.05) 
 
Table 5.4 Papp values for transport of ketotifen (K) and norketotifen (N) 
atropisomers across Caco-2 cell monolayers after 2 h at 37°C (data are means ± 
SD, n = 3). 
Compound Direction Papp (10-5 cm/s) Efflux ratio 
A to B 1.52 ± 0.29 
SK 
B to A 2.69 ± 0.24 
1.77 
A to B 1.89 ± 0.24 
RK 
B to A 3.12 ± 0.39 
1.65 
A to B 1.59 ± 0.04 
SN 
B to A 3.61 ± 0.13 
2.27 
A to B 1.42 ± 0.07 
RN 
B to A 3.37 ± 0.40 
2.37 
 
Mass balance for this study (Table 5.5) shows the recovery of K and N atropisomers 

















































































Table 5.5 Mass balance for transport of K and N atropisomers across Caco-2 cell 












SK 3.56 1.87 0.76 0.05 75.4 
RK 3.67 1.90 0.99 0.05 80.2 
SN 2.66 1.14 0.70 0.09 72.8 
A to B 
RN 2.62 1.21 0.62 0.11 74.1 
SK 9.69 5.68 1.24 0.08 72.3 
RK 10.03 5.90 1.50 0.11 74.9 
SN 7.77 4.49 1.45 0.22 79.3 
B to A 
RN 7.87 4.27 1.35 0.22 74.3 
 
Interestingly, despite the fact that the total recovery of K and N atropisomers is 
similar, the mass of K and N recovered from the Caco-2 cell monolayers was 
significantly different (Figure 5.16) in both the A to B and B to A directions, with the 
Caco-2 cells containing approximately twice as much N as K. This is consistent with 
the results from RBE4 cell uptake and log Dl/b studies (Table 3.4). As discussed 
before (Section 3.5 and 5.4.3), it indicates the association of compounds with cell and 
liposome membranes. N associated more with Caco-2 membranes compared with K, 
therefore the recovered mass of N was more than K on Caco-2 cell monolayers. The 
difference was not affected by stereoselective binding to Caco-2 cell membranes 
because there was no significant difference between K atropisomers or N 
atropisomers (Table 5.5). 
Figure 5.16 Mass percentage of ketotifen (K) and norketotifen (N) associated 
with Caco-2 cell monolayers after permeability study at 37°C for 2 h (data are 



































5.5.1 Effect of ATP depletion 
The uptake of K and N at 37°C in the presence of 10 mM NaN3 should occur 
predominantly by passive diffusion. Theoretically, 10 mM NaN3 depletes ATP 
production to 30% by inhibiting mitochondrial oxidative phosphorylation (Kang et 
al, 2001; Togami et al, 2013). Although more efficient ATP depletion can be achieved 
using a combination of ATP depleters (Mandel et al, 1994; Wilson et al, 1990) this 
was not necessary in this study where the aim was to simply establish that active 
transport is involved.  
5.5.2 Uptake and association 
As discussed in Chapter 3, the difference between log Do/b and log Dl/b could also be 
related to the interaction between K and N and liposomes. Both K and N at pH 7.4 are 
positively charged but K (pKa = 8.8) is less ionized than N (pKa = 10.3), such that 
negatively charged liposomes interact and bind more strongly to N than to K. The 
binding studies of K and N atropisomers to RBE4 cell membranes indicated binding 
of N to cell membranes was more than that of K (Figure 5.2). It was also consistent 
with cell experiments where for RBE4 cells there was more N associated with cells 
then K (Table 5.2 and 5.3). In addition, results from Caco-2 cell studies also indicate 
that more N is associated with Caco-2 cell monolayers during permeability 
experiments than that of K (Figure 5.16). The above results suggest that the higher 
“uptake” of N by RBE4 cells is due to association with cell membranes rather than 
uptake into cells.  
5.5.3 Effect of temperature on RBE4 cell uptake 
Active transports are reduced at 4°C but changing temperature can also affect 
passive distribution of ionic drugs into lipid bilayers, as discussed in Chapter 3.  
In these uptake studies, among many factors changed by temperature, the 
association with membranes was the main factor (Table 5.3). This is because RBE4 
cell uptake at 37°C with and without NaN3 had similar passive diffusion coefficients 
for both K and N, whereas at 4°C, N had a much higher k than both K and N at 37°C 
and K at 4°C.  
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In addition, a reduction of temperature leads to a reduction of membrane fluidity, 
which would reduce passive diffusion across cell membranes.  
Moreover, according to the Strokes-Einstein equation, a decrease in temperature 
decreases the diffusion coefficient of compounds due to decreased thermal motion; 
also, there is an increase in water viscosity with decreasing temperature. This means 
that at lower temperature, the diffusion constant is reduced for both K and N.  
Besides all the above reasons, a reduction of temperature also may alter the binding 
profile of compounds to cell membranes. It is not possible, therefore, to simply 
conclude that a decrease in uptake at 4°C is due to elimination of active transport. 
5.5.4 RBE4 uptake and Caco-2 monolayer permeability studies 
RBE4 cell uptake and binding was not stereoselective for either K or N at 37°C 
(Tables 5.2). In addition, there was no stereoselective uptake (or association) of K or 
N atropisomers at 4 or 37°C with or without an ATP depleter (Tables 5.3).  
For both K and N, the uptake (or association) was a combination of active transport 
and passive diffusion. This was suggested by the good fit (R2 ≥ 0.96) of the equation 
containing both active and passive components (Equation 5.4). It was also supported 
by results of the studies with ATP depleter, NaN3, as uptake was reduced and more 
linear with NaN3 (Figure 5.11 and 5.14).  
In the Caco-2 cell permeability studies, with intact Caco-2 monolayers throughout 
experiments (based on TEER value and [14C]mannitol result), there was no 
stereoselective transport of K or N atropisomers across Caco-2 cell monolayers after 
2 h at 37°C. For both K and N, the B to A Papp was higher than the A to B Papp, an 
indication of the presence of an efflux mechanism. However, there was no evidence 
of a stereoselective efflux mechanism for either K or N atropisomers, as the 
respective efflux ratios for SK and RK were 1.77 and 1.65, and for SN and RN were 
2.27 and 2.37 (Table 5.4). Mass balance was similar for both K and N (Table 5.5) but 
N was found to associate with Caco-2 cell membranes to a greater extent than K 
(Figure 5.16). This is consistent with the RBE4 cell uptake result showing N is more 
associated with cell membranes than K. 
As discussed before, RBE4 cells do not express occluding and only express very low 
level of claudin, thus they do not form restrictive paracellular barrier (TEER = 64 ± 5 
Ω*cm2) (Rist et al, 1997; Tsukita and Furuse, 2000; Veszelka et al, 2018), which is 
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critical for investigate permeability for small molecular compounds, such as K and N. 
Even co-culture with other cells, such as astrocytes, does not improve the 
paracellular barrier enough for permeability studies (Veszelka et al, 2018). As a 
result, to ensure the paracellular barrier, Caco-2 cells were used as a transcellualr 
permeability model in this thesis. 
Although there are no reports of stereoselective transporters on RBE4 cells, there 
are many reports of stereoselective transport mechanisms on Caco-2 cells. These 
apply to P-gp (cetirizine, fexofenadine, ginsenoside Rh2, methadone) and MRP 
transporters (cetirizine, nerapamil) (Gu et al, 2010; He et al. 2010; Shen et al, 2007). 
The stereoselective transport of fexofenadine by P-gp has also been reported in 
human (Miura et al, 2007). As P-gp and some of the MRPs are also expressed by 
REB4 cells, it is likely that stereoselective transport also occurs in RBE4 cells. This 
supports the use of both RBE4 and Caco-2 cells as screening models. 
However, as RBE4 and Caco-2 cells are from different origins (endothelial and 
epithelial cells), they do differ in transporter expressions. 
Although RBE4 cells express both P-gp (Babakhanian et al, 2007) and BCRP (Lee et 
al, 2007), BCRP level has been reported to be very low (Veszelka et al, 2018). In 
addition, MRP 1, 3 and 5 have been found at RBE4 cell but at much lower level 
compared to the Caco-2 cells. 
In Caco-2 cell monolayers, both BCRP and P-gp are expressed, at a much higher level 
compared to that in RBE4 cells (Veszelka et al, 2018). Moreover, an overexpression 
of P-gp at the Caco-2 cell monolayer has been reported (Lohmann et al, 2002). It was 
concluded these cells can be used to investigate if a compound is a substrate of efflux 
transporters (Rodrigues et al, 2009; Wilhelm and Krizbai, 2014).  
As discussed, Caco-2 cell express a much higher level of efflux transporters 
compared to RBE4 cells. The efflux mechanism indicated by the Caco-2 cells could be 
overestimated compared to that in rat BBB. 
In summary, using both cell lines as BBB models, there was no stereoselective 
transport of K or N across and no stereoselective association with cell membranes. 
The lower sedative effect of SN is therefore unlikely due to stereoselective transport 
across the BBB. However, there are more possibilities such as poor correlation 
between in vitro and in vivo studies and stereoselective binding to H1 receptors in 
the CNS after crossing the BBB. It is important, therefore, to investigate the binding 
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Chapter 6  In vitro studies of the binding of ketotifen and 
norketotifen atropisomers to CNS H1 receptors in rat 
6.1 Introduction 
Histamine plays an important role in the CNS where it is involved in regulation of 
arousal, the sleep-wake cycle, memory and cognition. This is mainly through 
interaction with histamine H1 receptors (Brown et al, 2001; Tashiro et al, 2005, 
2008). Therefore when an antihistamine crosses the BBB and reaches the CNS, it 
may block CNS H1 receptors and gives rise to sedative effects and cognitive deficits.  
Research has indicated that the severity of sedative effects produced by H1 
antagonists is correlated to their CNS H1 receptor occupancy (Gupta et al, 2007; 
Tashiro et al, 2005, 2008; Yanai et al, 2011). This is illustrated in Figure 6.1. 
Antihistamines are classified as sedative, less sedative or non-sedative according to 
whether their H1 receptor occupancy is 50 − 100%, 20 − 50% or 0 − 20%, 
respectively (Yanai and Tashiro, 2007). On this basis, K is clearly a highly sedative 
antihistamine. 
Although CNS H1 receptor occupancy of many antihistamines has been well studied 
and although many antihistamines are chiral, there is no information on whether H1 
receptor occupancy is stereoselective and, in particular, no information on whether 
H1 receptor occupancy of K and N atropisomers is stereoselective. As discussed in 
Chapter 5, one hypothesis to explain the different sedative effects of K and N 
atropisomers is that they cross the BBB to a similar extent but bind to CNS H1 
receptors to different extent. 
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Figure 6.1 H1 receptor occupancy by various antihistamines.  
Yanai and Tashiro, 2007, reproduced with permission  
Different methods have been used to determine the sedative effects of 
antihistamines. Some have involved statistical analysis of proportional impairment 
ratio (PIR) (McDonald et al, 2008; Shamsi and Hindmarch 2000) based on 
psychomotor performance tests and visual analogue scale (VAS) questionnaires 
(Izumi et al, 2008). Others have inferred sedative effects of antihistamines through 
determination of their relative H1 receptor occupancy by techniques such as 
positron emission tomography (PET) (Tashiro et al, 2008; Yanai et al, 2011; Zhang et 
al, 2010) or binding of radiolabelled antihistamines to tissues rich in H1 receptors. 
The latter have included rodent brain membranes ex vivo (Chang et al, 1979; Gupta 
et al, 2007; Malany et al, 2009) brain cells from cows (Yamashita et al, 1991), insects 
transfected by human genes (Appl et al, 2012) and rodent cells in vitro (Anthes et al, 
2002; Moguilevsky et al, 1994).  
Although PET is a non-invasive technique to determine binding of antihistamines 
(Yanai and Tashiro 2007), it requires special equipment for imaging and 
preparation. A traditional binding assay using brain tissue is a more convenient way 
to investigate the affinity of K and N atropisomers as it is easy to set up, well-
validated and poses fewer ethical issues. 
This Chapter reports the use of a traditional receptor occupancy assay as described 
by Chang et al, (1979) to investigate the affinity of antihistamines for H1 receptors. It 
involved determining the extent of inhibition of [3H] mepyramine binding to H1 
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receptors in rat brain membranes. The ability to compete with mepyramine binding 
assesses the affinity of K and N atropisomers for brain H1 receptors and is therefore 
an indirect measure of their relative sedative effects.  
6.2 Materials 
Male Wistar rats (age 6 weeks, 130-150 g) were purchased and housed in the animal 
facility of Otago University until required. [3H] Mepyramine (pyridinyl 5-3H, 250 μCi, 
58.8 mCi/mmol in 0.5 ml ethanol:water (9:1)) and triprolidine hydrochloride (> 99 
%) were purchased from Sigma (USA). Disodium hydrogen phosphate (anhydrous, 
99%) was purchased from Asia Pacific Specialty Chemicals Ltd. Potassium 
dihydrogen phosphate (≥ 99.5 %) was purchased from BDH Laboratory Supplies 
(UK). Glass fibre filters (GF/B) were purchased from Whatman (Maidstone, England) 
and pipettes from Eppendorf® (Hamburg, Germany). OPTIPHASE ‘HISAFE’ 2 
scintillation cocktail, miniature 6 ml Pony polyethylene scintillation vials, Tricarb® 
2910TR Liquid Scintillation Analyzer and QuantaSmartTM software (version 4.00) 
were all purchased from PerkinElmer (Waltham, MA, USA).  
All other materials were obtained as described in Sections 2.2, 4.2 and 5.2. 
6.3 Methods 
6.3.1 Preparation of rat brain membrane suspensions 
Five rats were sacrificed by decapitation and three brains were removed for the H1 
receptor occupancy test. These brains were placed on ice and frozen at -80°C until 
required. The following method of sample preparation was based on Chang et al. 
(1979). Briefly, rat brains were weighed and homogenized in 30 volumes (w/v) ice-
cold 50 mM phosphate buffer (prepared by diluting 30.16 ml 1 M sodium hydrogen 
orthophosphate and 19.84 ml 1 M potassium dihydrogen phosphate to 1 Liter and 
adjusting pH to 7.4) using a glass homogeniser tube with a manual Teflon pestle. 
Brain homogenate was centrifuged at 50,000 g for 10 min and the pellet 
resuspended in the same volume of ice-cold fresh phosphate buffer using the 
homogenizer. The suspension was centrifuged as described above and the washing 
procedure repeated 3 times. The final pellet was resuspended in the same volume of 
ice-cold fresh phosphate buffer. All suspensions from three rat brains were pooled 
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and mixed thoroughly to ensure a sufficient amount to carry out all inhibition 
studies. The pooled suspension was used within 24 h to reduce variability in results.  
6.3.2 Determination of Kd of [
3
H] mepyramine binding to H1 receptors  
In order to estimate inhibition constants (KI) for K and N, the equilibrium 
dissociation constant (Kd) for specific binding of [3H] mepyramine to H1 receptors 
was first determined. To an aliquot of rat brain membrane suspension (0.45 ml 
containing 15 mg tissue), [3H] mepyramine (final concentration 0.2 − 10 nM) was 
added to give a final volume of 0.5 ml. A parallel incubation was carried out 
containing triprolidine (final concentration 2 μM). Incubations were carried out in 
triplicate. Suspensions were thoroughly mixed and incubated at 25°C for 30 min 
after which 4 ml ice-cold fresh phosphate buffer was added. The suspensions were 
rapidly filtered through glass fibre filters under vacuum and filters washed with 3 × 
4 ml ice-cold fresh phosphate buffer taking no more than 15 s in total to reduce the 
loss of [3H] mepyramine. After washing, the filters were transferred to 6 ml Pony 
scintillation vials followed by 5 ml scintillation cocktail. Vials were vortexed for 30 s 
and radioactivity counted using the scintillation counter over 5 min.  
6.3.3 Determination of K and N concentration ranges for KI determination 
A concentration range of 0.01 − 10000 nM of racemic K and N was investigated to 
determine the optimum range for accurate determination of KI values. To an aliquot 
of rat brain membrane suspension (0.45 ml containing 15 mg tissue), [3H] 
mepyramine (final concentration 2 nM) was added followed by a solution of racemic 
K or N to a final concentration in the range 0.01 − 10000 nM in a minal volume of 0.5 
ml. Subsequent steps were as described in Section 6.3.2. Incubations were carried 
out in duplicate. 
6.3.4 Total binding (TB), non-specific binding (NB) and specific binding (SB) of K and N 
atropisomers to H1 receptors  
In order to determine TB of K and N atropisomers, incubations were carried out as 
previously described in the presence of individual K and N atropisomers at final 
concentrations in the range 0.01 − 2500 nM and 0.01 − 1000 nM respectively (based 
on the results of Section 6.3.3). [3H] Mepyramine solution was added to each sample 
to give a final concentration of 2 nM in a final volume of 0.5 ml. A parallel incubation 
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was carried out in the presence of triprolidine (final concentration 2 μM) to measure 
NB and to allow calculation of SB of K and N atropisomers. Subsequent steps were as 
described in 6.3.2. Incubations were carried out in triplicate. 
6.3.5 Data processing  
6.3.5.1 Kd of [
3
H] mepyramine binding 
GraphPad Prism 5 was used to analyse data from Section 6.3.2. The Kd was 
calculated by fitting a “One site-total and non-specific binding” model (Figure 6.2) 
which is based on Equations 6.1 and 6.2: 
SB = Bmax × X/ (X + Kd)                                                                                                     6.1 
NB = NS × X + Background                                                                                             6.2 
where NS is the slope of the NB plot, Bmax is the maximum number of receptor 
binding sites and X is the concentration of [3H] mepyramine. Simulation is shown 
below (Figure 6.2): 
Figure 6.2 Simulation for the “One site-total and non-specific binding” model in 
GraphPad Prism 5 (TB, SB and NB are total, specific and non-specific binding 
respectively). 
 











6.3.5.2 SB of K and N atropisomers 
SB of [3H] mepyramine to rat brain H1 receptors in 15 mg brain tissue in the 
presence of K and N atropisomers was calculated using data from section 6.3.4 and 
Equation 6.3: 
SB / 15 mg brain tissue (%) = (TB – NB) × 100/ B0                                                  6.3 
where TB and NB are substituted as counts per min (CPM) for the respective binding 
of [3H] mepyramine and B0 is the CPM for binding in the absence of inhibitor. 
6.3.5.3 Calculation of KI of K and N atropisomers 
The KI values for K and N atropisomer inhibition of [3H] mepyramine binding were 
determined using GraphPad Prism 5 using the model called “One site-fit KI”. By 
entering the concentration of radioligand (X) and its Kd as constants, the model 
estimated KI as described in Equations 6.4 and 6.5. 
 
Figure 6.3 Simulation of the “One site-fit KI” model in GraphPad Prism 5 (TB, SB 
and NB are total, specific and non-specific binding respectively). 
 
Log EC50 = log 10log KI × (1 + X / Kd)       6.4 
Y = NB + (TB − NB) / (1 + 10(Log X – Log EC50))                        6.5 
where EC50 is the concentration of inhibitor causing 50% inhibition, KI is the 
inhibition constant of the inhibitor, Kd is in nM units and X is the concentration of 
[3H] mepyramine in nM units, Y is binding in percentage unit. 
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This model assumes that the (a) binding is reversible and at equilibrium and (b) Hill 
coefficient is 1. It fits the KI of the unlabelled ligand directly. After entering the 
concentration of radioligand and its Kd as constants, Prism directly fits the KI of 
unlabelled ligand without reporting EC50.  
6.3.5.4 Statistical analysis: 
Data were analysed by one-way ANOVA with post-hoc Bonferroni testing to compare 
selected data sets. Results are presented as means ± SD. Differences for which p < 
0.05 were taken as significant. 
6.4 Results 
6.4.1 Determination of Kd of [
3
H] mepyramine binding to H1 receptors  
Fitting of the data for TB and NB of [3H] mepyramine in the absence and presence of 
triprolidine respectively is shown in Figure 6.4. The Kd of [3H] mepyramine binding 
was estimated to be 7.8 ± 3.8 nM which is close to the published value of 9.4 ± 0.67 
nM for binding of [3H] mepyramine to Wistar rat brain cortex (Inagaki et al, 1989) 
but differs from the value of 4.0 ± 1.1 nM for binding to Sprague-Dawley rat brain 
membranes (Chang et al, 1979). The difference presumably reflects the different 
species of rat (Wistar male rats were used here).  
 
Figure 6.4 Total (open circles) and non-specific (closed squares) binding of [3H] 
mepyramine ([3H] M) to H1 receptors in rat brain membrane suspensions. 
Nonspecific binding is determined in the presence of 2 μM triprolidine (T) (data 
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Given the high value of Kd, it could have been preferable to conduct experiments 
using an extended concentration range of [3H] mepyramine. However, evidence 
shows that, in addition to the higher affinity sites, a lower affinity binding 
component becomes apparent when the [3H] mepyramine concentration is higher 
than 10 nM (Hill and Young, 1980). As a result, the concentration range of 0 − 10 nM 
was appropriate for this study. 
6.4.2 Determination of K and N concentration ranges for KI determination 
TB of [3H] mepyramine to rat brain H1 receptors in the presence of 0.01 − 10000 nM 
K and N racemates is shown in Figure 6.5. K inhibited [3H] mepyramine binding to a 
greater extent than N but the inhibition curves levelled off at similar concentrations. 
There is some indication that binding of [3H] mepyramine decreases further at high 
inhibitor concentration presumably because both SB and NB decrease at high 
concentrations of inhibitor. In fact, there is the potential to overestimate the affinity 
of an inhibitor if the upper limit of the concentration range is too high. This is why it 
is necessary to evaluate an optimum inhibitor concentration range before the actual 
inhibition study. Based on these results, the selected concentration ranges for K and 
N atropisomers were 0.01 − 2500 nM (-11 to -5.6 M in log scale) and 0.01 − 1000 nM 
(-11 to -6.0 M in log scale) respectively. 
Figure 6.5 Total binding of 2 nM [3H] mepyramine to rat brain membrane H1 
receptors in the presence of K and N racemates (data are presented in individual 
date point, n = 2).  
 



























6.4.3 TB of [
3
H] mepyramine in the presence of K and N atropisomers 
TB of [3H] mepyramine in the presence of SK and RK is shown in Figure 6.6 a. There 
was a small but not significant difference between the TB of [3H] mepyramine in the 
presence of SK and RK. This indicates the affinity of RK for rat brain membrane H1 
receptors is lower than that of SK, however, this difference is not significant. 
 
Figure 6.6 Calculated total binding of [3H] mepyramine to rat brain membrane H1 
receptor in the presence of (a) K and (b) N atropisomers (data are means ± SD, n 
= 3). 
Corresponding data for SN and RN is shown in Figure 6.6 b. In this case, the affinity 
of RN is lower than that of SN, but this difference was not significant probably 
because of the higher variability in the N data.  
 






























































6.4.4 Determination of NB of [
3
H] mepyramine in the presence of K and N 
atropisomers 
There was concern that K and N could affect NB. Therefore, the effect of K and N on 
NB was determined by measuring binding of K and N in the presence of 2 μM 
triprolidine. The [3H]mepyramine bound was approximately 50% of that in the 
absence of triprolidine as shown in Figure 6.7. This 50% NB presumably results from 
non-specific binding of K and N to brain tissue. The data show that the NB of 
[3H]mepyramine was independent of K and N concentration indicating that K and N 
atropisomers do not change the NB of [3H]mepyramine over the concentration range 
tested. However, the relatively high NB probably reduces the accuracy and precision 
of the measurements of SB since it is calculated by subtracting NB from TB. 
Figure 6.7 Non-specific binding of 2 nM [3H] mepyramine to rat brain membrane 
in the presence of K and N atropisomers and 2 μM triprolidine (data are means ± 
SD, n = 3). 
6.4.5 SB of [
3
H] mepyramine to H1 receptors in the presence of K and N atropisomers 
SB of [3H] mepyramine to rat brain membrane H1 receptors in the presence of K and 
N atropisomers was calculated from the TB and NB results using Equation 6.3. The 
SB data were analysed using “One site-fit KI” model in GraphPadPrism5 based on 
Equation 6.4 and 6.5. Parameters including logKI and KI were estimated by software 
by non-linear fitting. The results show a significant difference in the inhibition of SB 
of [3H] mepyramine between SK and SN, between RK and SN, moreover between SN 
and RN (Figures 6.8 and 6.9, Table 6.1). Among the four atropisomers, SK was the 





























most potent inhibitor of SB of [3H] mepyramine to rat brain membrane H1 receptors 
while SN was the weakest.  
Table 6.1 Estimated log KI (M) and KI (nM) for specific binding of [3H] 
mepyramine to rat brain membrane H1 receptors in the presence of S-ketotifen 
(SK), R-ketotifen (RK), S-norketotifen (SN) and R-norketotifen (RN) (data are 
means ± SD, n = 3). 
 SK RK SN RN 
Log KI (M) -9.03 ± 0.16 -8.81 ± 0.16 -8.33 ± 0.18 -8.73 ± 0.17 
KI (nM) 1.03 ± 0.42 1.65 ± 0.58 5.10 ± 2.00 2.08 ± 0.75 
 
Figure 6.8 Calculated SB of [3H] mepyramine to rat brain membrane H1 receptor 
in the presence of (a) K and (b) N atropisomers (data are means ± SD, n = 3). 
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Figure 6.9 Comparison of the inhibition (KI) of SB of [3H] mepyramine to rat 
brain membrane H1 receptors by K and N atropisomers (data are means ± SD, n = 
3; * P< 0.05, ** P< 0.01). 
6.5 Discussion 
The H1 receptor affinity in this work is determined by a classic method using cell 
membranes (Chang et al, 1979). It is based on competitive inhibition of a highly 
selective H1 receptor substrate (mepyramine). While there are advantages to using 
purified H1 receptors, it would significantly increase the cost of experiments 
significantly.  
For curve fitting, the one-site model (Equations 6.4 and 6.5) is used. It assumes Hill 
coefficient is 1. However, it is possible that the value of Hill coefficient is not 1. In this 
work different Hill coefficient values were put into equation and the “goodness of fit” 
retested. The results indicate there was no improvement in R2 using Hill coefficients 
other than 1. As a result, a Hill coefficient of 1 is appropriate to interpret our data. 
Based on previous studies of cell membrane binding and functional assays (Appl et 
al. 2012; Bakker et al. 2007; Gallois-Bernos and Thurmond, 2012; Seifert et al. 2003), 
the log KI of racemic K (in M) varies from -9.02 ± 0.01 to -10.4 ± 0.1, similar with the 
values of log KI for K atropisomers found here (Table 6.1). The KI value for K, taken 
as the average of the values for SK and RK (1.34 nM), is similar to a published KI 
value for inhibition of [3H]mepyramine binding by K to guinea pig H1 receptors (1.26 
nM) (Sharif et al. 1994). 
K and N atropisomers showed similar profile on NB (approximately 50% for all 


















atropisomers. For the atropisomers of K and N, the inhibition of SB of [3H] 
mepyramine to rat brain membrane H1 receptors suggests the affinity of SK was the 
highest while SN was the weakest (Tables 6.1, Figures 6.9) and there are some 
stereoselective bindings between SK and SN, RK and SN, more over, SN and RN. SK 
gives the most negative log KI for SB whereas SN gives the least negative log KI for SB 
(Tables 6.1). Although the differences are not great, they are larger than that 
between the enantiomers of fexofenadine (2.3 times greater for S-fexofenadine) 
(Kusuhara et al, 2013) and sufficient to conclude that binding to CNS H1 receptors 
contributes to the lower sedative effect of SN. Although no significant difference was 
found between SK and RK, based on the current sample number (n = 3), the power 
calculated using Mini-tab (one way ANOVA, CI 95%) is 26%. This is not enough to 
detect a significant difference in the H1 receptor affinity between SK and RK. 
However, the initial sample number was chosen as the literature indicates n = 3 is 
adequate (Anthes et al, 2002). By using the variation and mean value found in this 
work, in order to detect a significant difference with 80% power, n = 10 is required. 
As a result, in future studies comparing the H1 receptor affinity of K atropisomers, at 
least 10 measurements would be required. 
To investigate another possibility to explain the different sedative effects, which is 
the stereoselective transporter hypothesis, the total and free B/P ratios were 
determined using rat tail vein injection combined with RED technique in the next 
chapter (Chapter 7).  
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Chapter 7 Determination of total and free brain-to-plasma ratio 
of K and N atropisomers by injecting racemic K and N through rat 
tail vein 
7.1 Introduction 
The last two chapters were focused on the stereoselectivity of K and N in vitro. The 
uptake and permeability of K and N atropisomers in and through cell monolayers 
were investigated in Chapter 5. In Chapter 6, the binding of K and N atropisomers to 
H1 receptors in rat brain homogenates was studied. This chapter describes the 
results of a study that investigated the stereoselective uptake of K and N into the 
brain of the live animal. 
To investigate compound distribution in the live animal brain, several models can be 
used: in situ brain perfusion (Alata et al, 2014; Smith and Allen, 2003), in vivo carotid 
artery injection technique (brain uptake index, BUI) (Yamazaki, 1994a), 
microdialysis (Hammerlund-Udenaes, 2016; Gupta et al, 2006), PET (Honer et al, 
2014; Tashiro et al, 2005) and rat tail vein injection method (Kato et al, 1997; 
Wohlfart et al, 2011; Zhou et al, 2016). Advantages and disadvantages of these 
techniques are discussed in the following sections. 
7.1.1 In situ brain perfusion technique 
In situ brain perfusion is performed by inserting a cannula into the heart or major 
arteries that lead to the brain (such as carotid artery) of an anaesthetized animal. A 
perfusate, such as a buffer, containing a compound of interest, is then pumped 
through the cannula, in such a way the brain circulation of a live animal is taken over 
for a certain period. After the perfusion, brain tissue is collected and analysed to 
access the BBB permeability of the compound of interest (Smith and Allen, 2003). 
It is a widely used method because by modifying perfusate composition, the 
technique provides controllable conditions to investigate individual factors that 
affect the permeability of the BBB, which are difficult to achieve in in vivo conditions. 
Examples of conditions are adding certain ions to the perfusate to determine the 
effect of ions on the BBB permeability; adding albumin to the perfusate to 
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investigate the effect of binding to plasma proteins on the BBB permeability; adding 
transporter inhibitor or substrate to perfusate to study the effect of a certain 
transporter on the BBB permeability. It also minimizes drug metabolism by 
bypassing metabolizing organs (Alata et al, 2014; Hammerlund-Udenaes, 2014).  
However, there are limitations to using this technique. First, this method requires 
surgical procedures that are technically challenging to perform. In addition, it 
measures the initial rate of brain uptake. As a result, for a single time point 
experiment, when a compound equilibrates faster than the chosen time point, 
significant back flux from brain back to the perfusate occurs. Therefore, the result 
does not reflect the initial rate thus may not be accurate (Zhao et al, 2009). 
Moreover, unless combined with other methods such as ultrafiltration, this method 
by itself does not provide information on the unbound drug concentration in the 
brain (Di et al, 2008).   
7.1.3 In vivo techniques 
Microdialysis: 
The microdialysis method is a well-established and widely used in vivo model. It 
plants a dialysis probe (s) in brain of a living animal by surgical procedures. There 
are two ways of implanting probe (s). A single probe only is implanted in the brain of 
conscious animals whereas for the dual probe method, probes are implanted in 
blood and brain but only in anaesthetized animals. The real-time unbound drug 
concentration can be measured by determining the drug concentration in the 
dialysate from the probe (s) (Erdo et al, 2017).  
Although the microdialysis technique is time-, labour- and resource-demanding, it is 
still a “gold standard” to investigate the extent and rate of drug transport through 
the BBB. There are advantages of this technique. First, it presents the real-time 
profile of a compound in brain and/or blood over a short or relatively long period. 
Second, it measures free concentration in a specific brain region and/or blood where 
the probe is implanted (Hammerlund-Udenaes, 2016). However, it damages brain 
tissue including the BBB to a certain extent during surgery (Morgen et al, 1996). In 
addition, this method is not suitable for all compounds. For instance, lipophilic 
compounds, such as ketotifen, may non-specifically bind to the dialysis probe 
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membrane, which consequently leads to poor recovery (Di et al, 2008; Hammerlund-
Udenaes, 2014), but this can be tested by appropriate in vitro studies. 
PET 
PET is a non-invasive imaging technique that measures both extent and rate of 
radiolabelled drug distribution in a living animal or human (Bauer et al, 2016; Gunn 
and Rabiner, 2017; Hammerlund-Udenaes, 2014). By injecting a compound of 
interest labelled with [11C] or [18F], drug distribution and concentration in tissue can 
be measured (Gunn and Rabiner, 2017). It has been used for various areas, such as 
determination of drug distribution, target engagement (receptor occupancy and 
transporter affinity), pharmacologic activity and biomarker development (Bauer et 
al, 2016; Gunn and Rabiner, 2017). Because of its non-invasive and quantitative 
nature, PET has been widely used to determine H1 receptor occupancy and sedative 
effects of antihistamines (Tagawa et al, 2001; Yanai et al, 2011; Yanai et al, 2017) in 
both animals and humans. However, equipment for making radiolabelled drugs, 
determination of labelled drugs, and software and experience of data analysis and 
modelling are required. Consequently, PET is an extremely resource-demanding and 
expensive technique. In addition, PET cannot distinguish between free and bound 
drugs. As a result, it measures the concentration and distribution rate of both bound 
and free drugs instead of free drugs (Hammerlund-Udenaes, 2014). 
Carotid artery injection: 
In the carotid artery injection method a single injection of a drug together with a 
reference standard is administered through the carotid artery of an animal. The 
animal is then killed 5 to 15 seconds after the injection and brain is collected for 
analysis. BUI is calculated based on the relation of the brain uptake rates between 
the drug and the reference compound (Aschner and Gannon, 1994). Thus, it requires 
co-administration of a reference compound, and the use of this technique is limited 
by the permeability surface area product (PA, no less than 10 μl/min) value of the 
test compound (Pardridge, 1995). In addition, it is not applicable for compounds that 
do not readily cross the BBB, because a 5 – 15 s post-injection time is sometimes not 
long enough for compounds to accumulate in brain to be detectable (Hammerlund-
Udenaes, 2014).  
Rat tail vein injection: 
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The rat tail vein injection (intravenous injection) and carotid artery injection 
techniques are both easy to perform, relatively cheap, straightforward techniques, 
thus they are simple and useful tools to investigate drug uptake by brain. Unlike the 
carotid artery injection technique, the rat tail vein injection method does not require 
a reference compound to calculate the brain uptake rate of the compound of interest.  
The rat tail vein injection technique requires injection of drug solution through the 
rat tail vein. Blood and brain tissue are collected at a certain time point (from less 
than a minute to 60 min). It investigates the unidirectional uptake rate of compound 
into brain with the assumption that there is no elimination from brain during the 
experiment. (Hammerlund-Udenaes, 2014; Patlak et al, 1983; Smith, 2003). The 
longer post-injection time (compared to carotid artery injection method) results in 
enough drug accumulation in brain. However, it also leads to the greater risk of 
metabolism in the brain, in addition to increased risk of violation of the assumption 
that there is only a unidirectional transport occurring during the experiment. 
Therefore, an optimized time should be established to secure detection and reduce 
metabolism (Hammerlund-Udenaes, 2014). The method is widely used to measure 
the total B/P ratio that describes the distribution of a compound between brain and 
plasma (Kato et al, 1997; Wohlfart et al, 2011; Zhou et al, 2016). Another reason for 
choosing this technique is that research has been published using this method to 
investigate central effects of several antiallergy agents including K racemate (Kato et 
al, 1997). These researchers, however, only focused on the total concentrations of 
racemic K in brain tissue homogenate and plasma and the total B/P ratio.  
Gupta’s group suggested the importance of investigating free enantiomer 
concentrations in brain and plasma and consequently the free enantiomer B/P ratio 
(Gupta et al, 2006). According to their results, the total B/P ratio of enantiomers 
could be misleading. This occurs when there is stereoselective non-specific binding 
of enantiomers to plasma and/or brain tissue. Thus, total enantiomer concentrations 
and B/P ratios cannot be used to distinguish stereoselective uptake of enantiomers 
into the brain (Gupta et al, 2006). Therefore, it is more useful to determine free B/P 
ratio in addition to the total B/P ratio of K and N atropisomers to investigate if there 
is stereoselective transport on the BBB or a stereoselective binding to plasma 
protein and/or brain tissue. However, the rat tail vein injection method only 
provides total concentrations and total B/P ratio; as a result, RED was introduced as 
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a further sample treatment to determine the free compound in brain tissue and 
plasma collected from the rat tail vein injection experiment. Di et al suggested a 
similar experimental procedure to determine free B/P ratio using combined 
methods (Di et al, 2008). 
In this chapter, after injecting racemic K or N solution through rat tail vein, the total 
and free brain and plasma concentrations of K and N atropisomers are quantified 
using the chiral HPLC assay (Chapter 4) and then the corresponding B/P ratios are 
calculated. The aim of the research in this chapter was to compare the total and free 
concentrations and B/P ratios of K and N atropisomers to investigate if there is 
stereoselective transport across the BBB and/or stereoselective binding to brain 
tissue and/or plasma proteins. 
7.2 Materials 
Wistar rats (15 males, 6 weeks, 130 – 150 g) were housed in the animal facility of 
Otago University. This study had ethics approval from the Animal Ethics Committee 
of University of Otago (ethics approval number: 32/2013). Saline solution (0.9%), an 
animal balance, decapitation cones, a rodent guillotine, scissors, forceps and other 
surgical appliances were provided by the Animal Welfare Office, University of Otago. 
Funnels (15 glass funnels) were purchased from the Glassblowing Unit, University of 
Otago. Syringes (0.3 ml BD Ultra-fine 0.3 ml 30 G insulin syringe) and BD 
Vacutainer® (K2 EDTA 7.2 mg, 4 ml) were purchased from BD (Auckland New 
Zealand).  
All other materials were obtained and described in Section 2.2, 4.2 and 5.2. 
7.3 Methods 
7.3.1 Rat tail vein injection 
Stock solutions of K and N racemic fumarates were prepared by dissolving 27.5 mg 
of K fumarate or 27.8 mg of N fumarate in 5 ml of 0.9% saline solution, which is 
equivalent to 4 mg/ml of K and N solutions. Volumes of K and N injection solutions 
were calculated individually based on body weight of rats (Equation 7.1). The 
injected dose was 3 mg/kg K or N in all non-control groups. 
Injection volume (in ml) = 0.75 × body weight (in kg)                                7.1 
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Wistar rats were divided into three groups (five rats per group), and different 
injection solutions were administered through rat tail vein as follows: (1) the control 
group (drug-free saline as injection solution); (2) the K group (4 mg/ml K as 
injection solution); and (3) the N group (4 mg/ml N as injection solution).  
Although N is a trace metabolite of K in human, it accounts for 62% metabolized K at 
4 h in cultured rat hepatocytes (Le Bigot et al, 1987). As a result, it is possible that K 
can be metabolized into N in rats if the post-injection time is long enough. In 
addition, the concentration of K in both brain and plasma is reducing 2 min after the 
tail vein injection (Kato et al, 1997). To minimize the concentration of N from 
metabolized K and get a reasonable concentration of K and N in brain and plasma, 2 
– 6 min is the best end-point range for this experiment (Kato et al, 1997). 
Considering the applicability to perform the technique in reality, the decapitation 
time was chosen at 5 min after the tail vein injection. 
To perform the rat tail vein injection, a rat was wrapped in a towel leaving the rat 
tail out. The rat tail was left in a warm water bath for 5 min to make the tail vein 
more visible.  An aliquot of K, N or saline solution was injected through the rat tail 
vein. The rat was transferred into a decapitation cone 4 min after injection and 
decapitated at 5 min post injection.  Blood was collected from thoracic cavity into 
labelled BD Vacutainer tubes through a glass funnel. Tubes were inverted several 
times gently to mix the blood and the anticoagulant (EDTA) and then placed on ice.  
The rat head was dissected and the brain was collected in a Petri dish on ice for 
processing or stored at -80°C until required. 
Blood samples were centrifuged at 2000 rpm for 10 min at 4°C.  Plasma was 
separated from blood cells and then aliquot (0.5 ml) into labelled 1.7 ml centrifuge 
tubes. Rat plasma from the control group (a pool of five rats) was used as a blank 
matrix for the standard curve for the chiral HPLC assay (Chapter 4). An aliquot (0.5 
ml) of plasma sample was subjected to chiral analysis to determine the total 
concentration of K or N in plasma, while another aliquot of plasma sample was used 
for RED assay (Section 7.3.2) to investigate the free K or N concentration in plasma. 
The unused plasma aliquots were stored at -80°C until required.  
Rat brains from control group (three out of five brains) were kept for the CNS H1 
receptor binding study (Chapter 6). The other two brains from the control group 
were used as the blank matrix to prepare standard curves for the chiral HPLC assay. 
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The blank matrices of brain and brain samples in K and N groups were prepared the 
same way as stated below. Rat brains were weighed and homogenized in two 
volumes of Milli-Q water (w/v). The brain homogenate was divided into two 
aliquots, one of which was further diluted with Milli-Q water from 1 in 3 diluted to 1 
in 10 diluted brain homogenate and the other aliquot was stored at -80°C. The 1 in 
10 diluted brain homogenate was aliquot (0.5 ml) into labelled 1.7 ml centrifuge 
tubes. Aliquots (0.5 ml) of the 1 in 10 diluted brain homogenate samples were 
subjected to chiral analysis to determine the total concentration of K and N in brain 
while another aliquot was used for the RED assay (Section 7.3.2) to investigate the 
free K and N concentrations in brain. The unused aliquots of 1 in 10 diluted brain 
homogenate samples were stored at -80°C until required. 
The total B/P ratio was calculated using Equation 7.2. 
Total B/P ratio (BT/PT) = TCbrain × 10 / TCplasma                                               7.2 
where the TCbrain and TCplasma are total concentration of K or N atropisomers in brain 
homogenates (1 in 10 diluted) and plasma respectively. 
7.3.2 RED assay 
Plasma (0.5 ml) and brain homogenate (0.5 ml) samples were placed into the sample 
chamber (indicated by the coloured retainer ring) of the RED unit, and 0.75 ml of 
dialysis buffer (Ringer-HEPES buffer pH 7.4) solutions were placed into the buffer 
chamber. A higher volume of buffer was used to avoid sample volume change during 
the dialysis procedures. Units were covered and sealed with para film before 
incubating at 37°C in an orbital shaker at approximately 250 rpm for 4 h at which 
time K and N reached equilibrium in the RED units. 
Aliquots (0.49 ml) of plasma and brain homogenate samples were removed from 
sample side while 0.5 ml of dialysis buffer solutions were removed from buffer side 
of RED units after incubation. Rat plasma, rat brain homogenate or dialysis buffer 
(0.49 ml) was mixed with 10 μl of internal standard (10 μg/ml metoprolol) to make 
a final concentration of 200 ng/ml metoprolol in 0.5 ml of sample. 
These samples were subjected to the chiral HPLC assay to determine the free 
concentrations of K and N atropisomers in rat plasma and brain homogenate. 
The free B/P ratio, which is independent of effects of binding of drug to brain tissue 
and plasma, was calculated using Equation 7.3. 
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Free B/P ratio (BF/PF) = FCbrain × 10 / FCplasma                                                         7.3 
where the FCbrain (1 in 10 diluted) and FCplasma are free concentration of K or N 
atropisomers in brain homogenates and plasma respectively. 
Another B/P ratio, which is independent of effect of drug plasma binding, was 
calculated as follows: 
BT/PF = TCbrain × 10 / FCplasma                                                                                           7.4 
This BT/PF ratio is calculated using the total brain concentration (TCbrain, 1 in 10 
diluted) and the free plasma concentration (FCplasma). By comparing the BT/PF, the 
BF/PF and the BT/PT ratios, a difference between BT/PF and the BF/PF is indicative of 
binding to brain tissue, and a difference between BT/PF and the BT/PT is indicative of 
binding to plasma protein. 
Non-specific binding of K and N atropisomers to RED unit membrane was 
determined by filling the sample sides of the RED units with 0.5 ml buffer containing 
10 μM K or N atropisomers and 0.5 ml of drug-free buffer was filled in the buffer 
side. Samples were analysed using the same procedures as those used to analyse 
plasma and brain homogenate samples. Buffer (0.49 ml) solutions from both sides 
were mixed with 10 μl of internal standard (10 μg/ml metoprolol) and subjected to 
the chiral HPLC assay to determine percentage of K or N atropisomers bound to RED 
membrane. Results showed the nonspecific binding of K and N atropisomers to the 
RED membranes were all at about the same level (10%) as recommended in the 
instructions for the assay (no more than 10% nonspecific binding). In addition, there 
was no evidence of stereoselective binding to the RED membranes for atropisomers 
of K or N. 
7.3.3 Data processing and statistics 
GraphPad Prism 5 was used to analyse data and calculate B/P ratios from Section 
7.3.1 and 7.3.2. Data were analysed by one-way ANOVA with post hoc Bonferroni 
test to compare selected sets. Results are presented as means ± SD. Differences for 
which p < 0.05 were taken as significant. 
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7.4 Results and Discussion 
7.4.1 Total and free of K and N atropisomer concentrations in rat brain homogenate 
The total and free concentrations of K (Figure 7.1) atropisomers in rat brain 
homogenate showed there was no significant difference between SK and RK 5 min 
after injecting racemic K through rat tail vein. Similar results (Figure 7.2) indicated 




















































Figure 7.1 Total and free concentrations of ketotifen atropisomers (SK and RK) in 
rat brain homogenate 5 min after injecting 3mg/kg racemic ketotifen through rat 
tail vein (n = 3*, data are means ± SD). 
* One rat was dead before the endpoint (possibly due to the stress from the procedures) and 
another one showed very low concentration of SK and RK in both brain and plasma, which 
may be because the K solution was not injected into tail vein). These two rats were excluded 























































Figure 7.2 Total and free concentration of norketotifen atropisomers (SN and RN) 
in rat brain homogenate 5 min after injecting 3mg/kg racemic norketotifen 
through rat tail vein (n = 5, data are means ± SD).  
The total concentration of K and N in brain homogenate, however, were 
approximately 2-fold and 3-fold of the free concentrations of K and N respectively. 
This suggests there was binding of K and N to brain tissues (Figure 7.1 and 7.2). This 
agrees with the results from RBE4 and Caco-2 cell studies, which indicated that N is 
more likely to associate with cell membranes (Chapter 5, Figures 5.2 and 5.16). It 
explains, to some extent, the higher binding fraction of N to brain tissues (Figures 7.1 
and 7.2). 
There are significant differences (P < 0.0001) between the free fractions of K (0.61 ± 
0.03) and N (0.26 ± 0.07) in brain homogenate. Results also indicate, both total and 
free fraction of N, that N penetrates the brain much less than K (Figures 7.1 and 7.2). 
Consequentially, there is less free N than K available in the interstitial fluid (ISF), 
which would result in less interaction between N and H1 receptors in the CNS. 
According to H1 receptor occupancy results (Chapter 6), affinity of K and N 
atropisomers for the CNS H1 receptors from the lowest to the highest are SN, RN, RK 
and SK. Therefore, lower free concentrations in the ISF in addition to lower affinity 
for the CNS H1 receptors suggested less sedative effects caused by N (especially SN). 
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7.4.2 Total and free concentrations K and N atropisomers in rat plasma 
The total and free concentrations of K (Figure 7.3) atropisomer in rat plasma 
showed no significant difference between SK and RK 5 min after injecting racemic K 
through rat tail vein. Similar results (Figure 7.4) indicated that in rat plasma there 
was no significant difference between SN and RN 5 min after injecting racemic N 
through rat tail vein. This suggests that there was no stereoselective binding of K or 
N atropisomers to plasma proteins. However, the bound fraction of N (90% bound) 
in rat plasma is more than that of K (75% bound) 5 min after the tail vein injection 
(Figures 7.3 and 7.4). As a result, the free concentrations of N atropisomers were 
slightly lower than those of K. The degree of binding of K to plasma protein agrees 














































Figure 7.3 The concentration of ketotifen atropisomers (SK and RK) in rat plasma 
5 min after injecting 3 mg/kg racemic ketotifen through rat tail vein (n = 3, data 

















































Figure 7.4 The concentration of norketotifen atropisomers (SN and RN) in rat 
plasma 5 min after injecting 3 mg/kg racemic norketotifen through rat tail vein (n 
= 5, data are mean ± SD). 
In plasma, the free concentration of N is lower than that of K. This suggests less free 
N is available in the blood stream to cross the BBB in both passive and active 
mechanisms. This may also contribute, to the lower total concentration of N in rat 
brain (Figure 7.2), although it has been reported that transport of compounds 
through the BBB may not only depend on the free fraction but also the total 
concentration (Pardridge et al, 1983; Tanaka and Mizojiri, 1998). 
In plasma, the total concentrations of N atropisomers were higher than those of K. It 
may be the result from N being less lipophilic than K, therefore, N accumulates less 
in tissues (and brain), and thus more is left in blood (Figures 7.3 and 7.4). Similar to 
the results from rat brain homogenate, the total plasma concentrations of K and N 
atropisomers were much higher than those of free plasma concentrations suggesting 
binding of K and N atropisomers to plasma proteins.  
Different from the plasma results, in brain homogenate the concentrations of K 
atropisomers were higher than those of N. The difference between K and N 
concentrations in brain could be a result of the following possibilities. First, as 
discussed, after binding to plasma protein, there is less free N available in blood to 
cross the BBB. Second, K is more lipophilic than N, thus it passively penetrates the 
BBB more readily than N.  Third, an active influx transporter was reported for 
lipophilic cationic antihistamines, which transports K though the rat brain 
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endothelial cell monolayers (Yamazaki, 1994b). Nevertheless, according to the 
structure of N, it is also a possible substrate of this cationic transporter. This was 
supported by the RBE4 cell uptake results (Tables 5.2 and 5.3). An active influx 
mechanism was found, which contributed to actively transport both K and N into 
brain. This is supported by the results for free concentrations of K and N in brain and 
plasma (Figures 7.1 to 7.4). The free concentrations of both K and N atropisomers in 
brain homogenate were higher than the free concentrations in plasma. This indicates 
an active influx mechanism at the BBB for both K and N, because if there is only a 
passive mechanism, no matter before or at the equilibrium stage, the free 
concentrations of K and N in brain would be less or equal to the free concentrations 
in plasma. Interestingly, the B/P ratios (both BT/PT and BF/PF) of K atropisomers 
were much higher than those of N (Figure 7.5). The assumption is that at 
equilibrium, without the effects of active transport, the free concentration in brain 
equals the free concentration in plasma. However, according to results (Figure 7.5), 
the ratio of free concentrations of K atropisomers in brain over those in plasma (free 
B/P ratios) was about 40, whereas the values of N atropisomers were only about 10. 
This suggests the following: (a) an active influx mechanism present at the BBB; (b) 
this active transporter transports K more than N from plasma to the brain.  
In addition to the active transport mechanism and nonspecific binding, a trace of 
residual blood left in the brain capillaries may also contribute to the difference 
between total and free concentration of K and N to some extent. This is because K 
and N may bind to the plasma protein left in the brain, as there was no experimental 
procedure to remove blood remaining in the brain. However, it has been published 
that in male adult Wistar rats (250 g), the cerebral blood volume is 3.4 ± 0.4 ml/100g 
of brain, which equals 0.034 ml/g of brain (Shockley and LaManna, 1988). According 
to total concentrations in plasma, the effects of residue blood on free concentrations 
of K and N in brain homogenate were approximately 0.3 and 5.1% respectively. 
Therefore, the effect of residual blood in brain is negligible.   
7.4.3 Comparison of different B/P ratios of K and N atropisomers 
The relatively high total B/P ratio of K (18-20, Figures 7.5) is consistent with the 
result from Kato et al (Kato et al, 1997), who reported the total B/P ratio of K was 
approximately 26 at 6 min after tail vein injection of 3 mg/kg ketotifen in mice. The 
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total B/P ratio of K was approximately four times that of N; a similar trend was seen 
in the free B/P ratios of K and N (Figures 7.5 and 7.6). It suggests both total and free 
concentrations of K are four times that of N in the CNS versus peripheral. Moreover, 
H1 receptor occupancy results (Figure 6.9 and Table 6.1) suggested the affinity of SN 
to the CNS H1 receptor were lower than that of RN, SK and RK. The H1 receptor 
inhibition constants of the four atropisomers from the lowest to the highest were SN 
(KI = 5.10 ± 2.00 nM), RN (KI = 2.08 ± 0.75 nM), RK (KI = 1.65 ± 0.58 nM) and SK (KI = 
1.03 ± 0.42 nM) (Table 6.1). As a result, there may be at least four-times higher 
sedative effect of K compared to that of N because the sedative effect is related to the 
ability of compound to reach the CNS and interact with the H1 receptors (Yanai et al. 
2011). However, no significant stereoselectivity between SK and RK or SN and RN 

























































Figure 7.5 Different brain-to-plasma ratios of ketotifen atropisomers (SK and RK) 
5 min after tail vein injection (n = 3, data are means ± SD). 
Comparison between BT/PT, BT/PF and BF/PF ratios for K atropisomers showed there 
was no significant stereoselective transport between SK and RK through the BBB 
(Figure 7.5). In addition, there was no stereoselective binding of SK and RK to 
plasma protein and/or brain tissue.  
The highest BT/PF ratios were a result of (a) the effect of binding of K to plasma 
proteins (reduces PF) and (b) the active mechanism transports K from plasma to 
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brain which increases the BF (also BT). As a result, there is a further increase of the 
BT/PF ratio of K.  
Similar to K, there was no stereoselective transport of N atropisomers when they 
cross the BBB. In addition, there was no stereoselective binding of N atropisomers to 
plasma proteins and/or brain tissues. The BT/PT, BT/PF and BF/PF ratios of N 
























































Figure 7.6 The brain-to-plasma ratios of norketotifen atropisomers (SN and RN) 5 
min after tail vein injection (n = 5, data are means ± SD). 
There is no stereoselective transport of K or N atropisomers across the BBB or 
stereoselective binding to plasma proteins and/or brain tissues 5 min after injecting 
racemic K or N through rat tail vein. Although both K and N partition into brain, the 
free BF/PF ratio of K is 4 times that of N. Moreover, affinity of K atropisomers for the 
CNS H1 receptors are higher than that of N atropisomers (especially SN). These 
suggest K is four times more likely to get into brain and lead to a greater sedative 
effect compared to N.  
As a much lower sedative effect was observed (Aberg A. K. G, Patent US9439895 B2) 
for SN than RN, SK and RK, at this stage, we can conclude only that N atropisomers 
penetrate the BBB in a similar manner but to a lesser extent than K. The difference 
between SN and RN may be because of their stereoselective affinity to CNS H1 
receptors (Chapter 6, Table 6.1).   
 134
7.4.4 Equation used to calculate concentrations of K and N atropisomers in undiluted 
brain homogenate samples 
Brain homogenate samples (1 in 10 diluted) were used to determine the free and 
total concentrations of K and N atropisomers in the CNS. To calculate the undiluted 
concentrations, the dilution factor “10” was used in Equations 7.2 to 7.4. This, 
however, may not be appropriate as diluting brain homogenate samples could affect 
the equilibrium between binding sites and K or N atropisomers. 
To determine the concentrations of K and N atropisomers in undiluted brain 
homogenate, it is appropriate to use the dilution factor directly when drug 
concentration ([DT]) >> binding sites ([BST]). In contrary, when [DT] << [BST] and 
[DT] = [BST], it may be not accurate to simply use the dilution factor as the actual 
factor between concentration of the diluted and undiluted samples could vary. This 
is because dilution does not affect binding equilibrium much when binding sites 
were saturated with a much higher drug concentration.  
In this work, although Equations 7.2 to 7.4 could be affected by inappropriate 
dilution factor, in the worst scenario as long as the BF/PF > 10, an active influx 
transport was indicated. That is, by simply multiplying the dilution factor to 
calculate the undiluted concentration may lead to an over estimated BF/PF when [DT] 
≤ [BST], but it did not affect the final conclusion that there was an active influx 
mechanism involved in transport K and N into the CNS. Moreover, many other 
researchers have used the same way to back calculate for undiluted concentration 
(Bao et al, 2019; Friden et al, 2011; Li et al, 2011; Maurer et al, 2005; Melander et al, 
2016; Wan et al, 2007). Therefore, in this work, dilution factor “10” was used to back 
calculate K and N atropisomer concentrations in 1 in 10 diluted brain homogenate. 
7.5 Conclusion 
Based on the results, there was no stereoselective transport of K or N atropisomers 
through the BBB. Although K and N bound to plasma and brain tissue to different 
extents, there was no indication of stereoselective binding. An active influx transport 
mechanism, though not stereoselective, is probably present at the BBB for both K 
and N, which transports more K than N into brain. However, there was four times 
less N than K in brain homogenate, which indicates less N penetrates the BBB. 
Moreover, the CNS H1 receptor occupancy results (Chapter 6) suggested the affinities 
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for the H1 receptor from the lowest to the highest were SN, RN, RK and SK. 
Therefore, the lower sedative effect observed for SN compared with RN may be a 
result of stereoselective affinity to CNS H1 receptors. On the other hand, the lower 
sedative effect of SN compared to SK and RK may be due to (a) the lower BF of SN 
than K atropisomers and (b) the lower stereoselective affinity of SN for the H1 
receptor, compared with the K atropisomers. 
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Chapter 8 Discussion 
K (Figure 1.1), a chiral compound, is a first-generation antihistamine with 
antiinflammatory properties. The antiinflammatory potency attributes to the 
inhibition of histamine release from mast cells and reduction of mast cell activity by 
stabilizing their membranes (Dimkovic et al, 1992; Zhang et al, 2016). It was 
suggested that the stabilization effect on mast cells is antihistaminic independent, 
but may be attributed to inhibition of platelet-activating factor (PAF) (Grant et al, 
1990).  
Clinically, K is used, as the racemate, by both oral and ocular routes. Because of the 
antihistaminic and antiinflammatory potency of K, it is widely used as an antiallergic 
and antianaphylactic agent in both adults and children (Hsu et al, 2016; Kabra et al, 
2000; Sokol et al, 2013). Oral K has been used in patients with allergic rhinitis, 
allergic conjunctivitis, atopic dermatitis, urticaria, asthma, mastocytosis, and food 
allergy in some countries including Canada, Europe, and Mexico (Sokol et al, 2013). 
However, only the ocular administration has been approved for patients with 
allergic conjunctivitis in the United States, which is due to the CNS side effects, 
especially the sedative effect. 
N is an active metabolite of K (by the oxidative N-demethylation metabolic pathway) 
(Le Bigot et al, 1987). It is similar to K, not only in its structure but also in 
antihistaminic and antiinflammatory potency, which makes N a potential compound 
to treat allergic and anaphylactic conditions, such as pruritus (Aberg et al, 2015). In 
addition, N is a chiral compound, having S- and R-atropisomers. Moreover, the S-
atropisomer of N was reported to show much less sedative effect compared to RN 
and K (Chapter 1, Section 1.1). This indicated SN could be a useful and potent 
antihistaminic as well as antiinflammatory agent with a much less sedative side 
effect compared to K. Therefore, it is important to understand how the sedative 
effect is induced by antihistamines and why SN is lacking of sedative effect.  
As discussed (Section1.1), in the CNS, histamine is involved in regulation of sleep and 
wakefulness (Table 1.1), thus sedative side effect occurs when antihistamine binds 
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to the CNS H1 receptor. In order to explain why SN lacks the sedative side effect, the 
following hypotheses have been posited and tested in this thesis: 
 
1. Stereoselective transporter hypothesis: 
At the BBB, there is a stereoselective transporter involved in transporting K and N 
atropisomers. This transporter functions (a) as an influx transporter, which 
selectively transports less SN than RN, SK and RK into brain or (b) as an efflux 
transporter, which selectively pumps more SN than RN, SK and RK out of brain. As a 
result, there is less SN in the CNS available to bind to the H1 receptor, thus less 
sedative effect. 
2. Stereoselective specific binding hypothesis: 
In the CNS, SN has lower affinity for the H1 receptor compared to RN, SK and RK. As a 
result, there is less SN bound to the H1 receptor than RN, SK and RK. Consequently, 
SN causes less sedative effect. 
3. Stereoselective non-specific binding hypothesis: 
There are non-specific bindings of SN, RN, SK and/or RK to plasma proteins and/or 
brain tissue. The stereoselective non-specific bindings result in more SN binding to 
plasma proteins and/or brain tissues compared to RN, SK and RK. Consequently 
there is less SN available in the plasma and/or in the CNS than RN, SK and RK thus 
less sedative effect.  
The lack of sedative effect from SN could be a result of one or combination of the 
above hypotheses, which are discussed in the following sections. 
8.1 Stereoselective transporter hypothesis 
Many research groups have reported stereoselective transporters, such as the P-gp, 
MCT and GULT-1 (Bickel et al, 2001; Chang et al, 2015; McAllister et al, 2001), which 
were also found at the BBB. Among these, P-gp has been found to be involved in 
transporting some of the second-generation antihistamines (cetirizine and 
fexofenadine) (Table 8.1) (Miura et al, 2007; Miura and Uno, 2010) and other drugs 
(citalopram, ivermectin, loperamide, mefloquine, pioglitazone and tacrolimus) 
(Chang et al, 2015; Choong et al, 2010; Miura et al, 2007; Miura and Uno, 2010).  
However, to date, there was no stereoselective influx or efflux transporters reported 
in transporting K or N atropisomers. As a result, the stereoselective transporter, 
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which may contribute to transport of K and N atropisomers across the BBB, was 
investigated in this thesis. 
Table 8.1 Stereoselective transporters and antihistamines 
Antihistamines Transporter Enantiomer/atropisomers 
preference 
Literature 
P-gp Efflux S-enantiomer more 
than R-enantiomer  
Akamine and 
Miura, 2018; 
Miura et al, 2007; 
Miura and Uno, 
2010 
Fexofenadine 
OATP2B1 Uptake more R-
enantiomer than S-
enantiomer 
Akamine et al, 
2014; Akamine 
and Miura, 2018 
p-gp Efflux more R-enantiomer 
than S-enantiomer 
Cetirizine 
MRPs Efflux more R-enantiomer 
than S-enantiomer 
He et al 2010 
 
8.1.1 Stereoselective influx transporter hypothesis 
The stereoselective influx transporter hypothesis was mainly based on an 
unidentified influx transporter, which has been reported to actively transport 
cationic first-generation antihistamines (including K) into RBE cell monolayer 
(Ishiguro et al, 2004; Suzuki et al, 2010). Similar to the reported influx mechanism, 
an influx transporter was found in our RBE4 cells studies (Chapter 5, Section 5.4.3), 
which indicates an active mechanism was involved in uptake of both K and N into 
RBE4 cell monolayers.  
In addition to the influx transporter at the REB4 cell monolayers, the in vivo work 
suggested a similar influx mechanism existing in rat BBB. The BF/PF of K (over 40) 
and N (approximately 10) further suggested the existence of an active influx 
mechanism is involved in transporting K and N to rat brain via the BBB (Figure 7.5 
and 7.6).  
As transporter-substrate interactions occur in chiral environments, the transporter 
found at the RBE4 cell monolayer and the active mechanism indicated in the BF/PF 
results, could be a potential candidate, which participates in stereoselective 
transport of K and N atropisomers through the BBB. 
However, despite the active influx transporter found both in vitro and in vivo, 
according to current results, none of these active influx mechanisms showed 
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significant stereoselectivity on transporting K or N atropisomers across the BBB. 
Although K and N atropisomers were transported by an active influx mechanism into 
the REB4 cell monolayers and across the rat BBB, the mechanism was not 
stereoselective. As a conclusion, the stereoselective active influx transporter 
hypothesis is not supported.  
8.1.2 Stereoselective efflux transporter hypothesis 
Another hypothesis based on stereoselective transporter is the stereoselective efflux 
transporter hypothesis. That is, at the BBB, a stereoselective efflux transporter 
selectively pumps more SN out of brain and consequentially leads to less sedative 
effects compared to RN, SK and RK.  
As discussed (Section 1.6.1), there are three main efflux transporters expressed at 
the BBB (P-gp, BCRP and MRPs). Although MRP 1, 2 and 4 were confirmed to be 
located on the luminal membrane of the human BBB (Dallas et al, 2006), only MRP4 
is expressed in quantifiable levels at the human and rodent BBB (Agarwal et al, 
2012; Kalvass et al, 2013; Shawahna et al, 2011). Therefore, in this thesis, only 
MRP4, p-gp and BCRP were discussed as potential candidates of stereoselective 
efflux transporter involved in transporting K and N atropisomers.  
Among these three efflux transporters, BCRP is expressed 1.6-fold higher than p-gp 
whereas MRP4 is 10 times less abundant than p-gp (Shawahna et al, 2011). In 
addition to the lower expression at the BBB, MRP4 is an organic anion transporter, 
which is unlikely to be involved in transporting K or N, as both are cationic 
compounds. As a result, only BCRP and p-gp were considered the possible 
stereoselective efflux transporters for K and N atropisomers. 
Although RBE4 cells express both P-gp (Babakhanian et al, 2007) and BCRP (Lee et 
al, 2007), RBE4 cells do not form complete tight junctions thus do not generate the 
necessary restrictive paracellular barrier properties (Tsukita and Furuse, 2000). As 
a result, to investigate these potential stereoselective efflux transporters, Caco-2 cell 
monolayers were used. As both BCRP and P-gp are expressed in Caco-2 cell 
monolayers, it was concluded these cells could be used to investigate if a compound 
is a substrate of efflux transporters (Rodrigues et al, 2009; Wilhelm and Krizbai, 
2014).  
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Papp results from the Caco-2 cell monolayer permeability study (Table 5.4) showed 
the Papp ratios of K and N from B to A side over the A to B side were approximately 
1.6 and 2.2 respectively (Table 5.4). This indicated some extent of contribution of an 
efflux transport mechanism, though it is unclear which transporter, BCRP and/or p-
gp, was involved.  
However, the efflux mechanism found at the Caco-2 cell monolayers was not 
stereoselective for either K or N atropisomers (Table 5.4). This suggested, neither 
BCRP nor p-gp was involved in stereoselectively transporting K or N atropisomers 
through the Caco-2 cell monolayers. As a result, the stereoselective efflux 
transporter hypothesis is not supported. 
As a conclusion, there were influx (RBE4 cell monolayer and rat BF/PF ratios) and 
efflux (Caco-2 cell monolayer) mechanisms involved in transporting K and N 
atropisomers. However, none of these mechanisms was stereoselective for K and N 
atropisomers. Therefore, both of the stereoselective influx and efflux hypotheses are 
not supported; so this research does not support stereoselective transport across the 
BBB as the explanation for the different sedative effects caused by SN, RN, SK and 
RK. As a result, the next hypothesis, stereoselective specific binding to the CNS H1 
receptor, was tested. Before discussing these H1 receptor results, some limitations 
with the above results are discussed. 
8.1.3 Discrepancy in transporter results 
As discussed in the above sections, results from Caco-2 experiments showed that for 
both K and N, the Papp of B to A direction was higher than that of A to B direction 
(Table 5.4). The Papp ratios of B to A over the A to B directions were approximately 
1.6 and 2.2 for K and N respectively. This indicated an efflux mechanism involved in 
transporting K and N at the Caco-2 cell monolayers.  
In contrast, the in vivo results suggested a different story. The BF/PF ratios of K and N 
were approximately 40 and 10 respectively (Figures 7.5 and 7.6), which showed a 40 
(for K) and 10 (for N) times higher BF than PF. The difference between BF and PF 
indicated an influx mechanism participated in transporting K and N across the rat 
BBB. This is because assuming there was only a passive mechanism, the free brain 
concentrations of K and N would always be less or equal to the free plasma 
concentrations (Hu and Li, 2011). If there was an efflux mechanism, the free brain 
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concentration would be less than the free plasma concentration of K and N as efflux 
transporter pumps K and N back from brain to plasma. Therefore, the in vivo BF/PF 
ratios (Figures 7.5 and 7.6) indicated an influx mechanism involved in transporting 
K and N at the rat BBB. 
According to above results, there was a discrepancy between efflux or influx 
mechanism between the in vitro Caco-2 cell monolayer results and the in vivo rat free 
B/P ratios. 
This discrepancy could be a result of the following possibilities, which were mainly 
caused by using the Caco-2 cell monolayers as the model to study the BBB 
permeability. 
One possibility is that there are over expressed efflux transporters on the Caco-2 cell 
line. To investigate the BBB permeability, Lohmann’s and coworkers compared the 
Caco-2 cell monolayer with a BBB cell model, the primary cultured porcine brain 
capillary endothelial cells (PBCEC). Their results suggested that for the screened 
compounds, Caco-2 cell monolayers have a good correlation with the PBCEC for 
predicting the BBB permeability. However, Caco-2 cell monolayers did show a more 
restricted permeability for the P-gp substrate (cyclosporin A), which may have 
indicated an overexpression of P-gp at the Caco-2 cell monolayer (Lohmann et al, 
2002).  
Another possibility is that according to real-time PCR results, MRP2 is expressed 
(approximately 10 fold) more than P-gp on Caco-2 cells (Rodrigues et al, 2009). In 
addition, MRP3 was also expressed on Caco-2 cells (Sun and Pang, 2008). Both MRP2 
and MRP3 are not found on the luminal membrane of the human BBB (Dallas et al, 
2006). Although MRP 1, 3 and 5 have been found in RBE4 cells, they are at much 
lower levels compared to that of Caco-2 cells. Therefore, these transporters may 
cause the efflux mechanism indicated by Caco-2 cells.  
Besides these two possibilities, Caco-2 cells may not express the influx transporter, 
which is involved in transporting K and N at the BBB. These hypotheses could be 
tested by inhibitor studies, which were not carried out in this thesis. Moreover, Caco-
2 cell work was carried out over a 2 h period whereas the B/P ratio in vivo was 
performed at only one time point of 5 min. As a result, this short time, the 
equilibrium of the efflux mechanism may not be reached. Therefore, at a later time 
point, the efflux mechanism may be showing a greater influence. 
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8.2 Stereoselective specific binding hypothesis 
Beside the stereoselective transporter hypothesis, which was found not to 
contribute to the less sedative effect caused by SN (Section 8.1), stereoselective 
binding to the CNS H1 receptor is the next hypothesis to explain the observed 
different degrees of sedative effects caused by SN, RN, SK and RK.  
Stereoselective specific binding of compounds to CNS receptors, such as the 
muscarinic receptor, α2-noradrenergic receptor, D1 and D2-dopamine receptors, has 
been reported by different research groups (Table 1.11) (Farde et al, 1988; Messer, 
et al, 1992; Waelbroeck et al, 1990).  
Moreover, some second-generation antihistamines have been found having 
stereoselective affinity to H1 receptors. R-cetirizine has higher affinity to H1 
receptors than the racemic cetirizine and the S-cetirizine (Gillard et al, 2002). 
Whereas for fexofenadine, the S-enantiomer is a more potent H1 receptor antagonist 
compared to the R-enantiomer (Kusuhara et al, 2013). 
Similar results were found from our H1 receptor occupancy experiment (Table 6.1), 
which support the stereoselective binding of K and N atropisomers to the CNS H1 
receptor hypothesis.  
Results indicated significantly different affinities (KI) between SN (5.10 ± 2.00 nM) 
and SK (1.03 ± 0.42 nM), SN and RN (2.08 ± 0.75 nM) and SN and RK (1.65 ± 0.58 
nM), though the difference between SK and RK were not significant (Table 6.1 and 
Figure 6.9). The KI of SN was approximately 2.5 times of RN, 5 times that of SK and 3 
times that of RK. As a higher KI indicates a lower affinity of compounds for the 
receptor, this suggested SN has the least affinity to H1 receptors in rat brain 
homogenate for K and N atropisomers.  
However, this difference between SN and SK was significant but not substantial 
comparing to the reported KI for R-cetirizine, S-cetirizine, which were 3 and 100 nM 
respectively (Gillard et al, 2002). According to Gillard’s group, the KI of S-cetirizine 
was 33 times of the R-cetirizine, while base on our result, KI of SN was only 2.5 times 
of RN, 5 times of SK and 3 times of RK. On the other hand, Kusuhara’s group has 
reported the KI for R-fexofenadine and S-fexofenadine was 30 and 13 nM 
respectively, which difference (2.3 times difference) was similar to our result 
(Kusuhara et al, 2013). 
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Therefore, this stereoselective binding could be a factor, which contributes to the 
different sedative effects caused by SN (0 out of 10), RN (3 out of 10) and K (10 out 
of 10) (Table 1.6).  
Although this hypothesis was supported by the H1 receptor occupancy results, there 
was another hypothesis, the stereoselective non-specific binding hypothesis, may 
also participate in the different sedative effects caused by K and N atropisomers. 
8.3 Stereoselective non-specific binding hypothesis 
The stereoselective specific binding could be a factor that contributing to the lower 
sedative effect caused by SN compared to RN, SK and RK (as discussed in Section 
8.2). As non-specific binding also happens in chiral environments, it raised another 
hypothesis: stereoselective non-specific binding. Other research groups have 
reported stereoselective binding of compounds to plasma proteins (Martinez-Gomez 
et al, 2007; Shen et al, 2013).  
Moreover, it has been reported that stereoselective plasma protein binding takes 
place for the second-generation antihistamine cetirizine. R-cetirizine (85% bound) 
stereoselectively binds to plasma protein more than that of the S-enantiomer (50% 
bound) (Gupta et al, 2006). 
In this thesis, it was posited that stereoselective non-specific binding occurs such 
that: (a) more SN is bound to plasma proteins than RN, SK and RN thus less free SN is 
available in the plasma compared to RN, SK and RK and/or (b) more SN is bound to 
brain tissues than RN, SK and RK thus less free SN is available in the ISF for binding 
to the CNS H1 receptor. 
Results from the in vivo experiments (Figures 7.3 and 7.4) suggested, for both total 
and free plasma concentrations, there was no significant difference between 
concentrations of SK and RK or between SN and RN. As a result, there was no 
evidence for stereoselective non-specific binding of K or N atropisomers to plasma 
proteins. 
Similarly, there was no significant difference between concentrations of SK and RK 
or between SN and RN (Figures 7.1 and 7.2) in both total and free concentrations in 
brain homogenate. Therefore, there was no evidence for stereoselective non-specific 
binding of K or N atropisomers to brain tissue. 
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However, the original data suggesting SN caused less sedative effects than RN and K 
was obtained from mice (Table 1.6), while our in vivo experiment was performed in 
rats. There may be a factor of species, which contributed to the plasma protein 
binding result.  
It has been reported that sometimes the stereoselective binding to plasma protein 
can be species dependent. Differences were observed between human, bovine, dog 
(Fitos et al, 2002, Pistolozzi and Bertucci, 2008), and, between rat and rabbit (Zhu 
and Zhang, 2008). Nevertheless, no clear evidence indicated species difference 
between rat and mouse. Thus the plasma protein binding results obtained from rats 
could be a reasonable indicator for the plasma protein binding profiles in mice.  
In addition to the non-specific binding of K and N atropisomers to plasma protein, 
the non-specific binding of K and N atropisomers to brain tissues was also 
investigated. The total and free brain homogenate concentrations of K atropisomers 
indicated there was no stereoselective non-specific binding of SK or RK to rat brain 
tissues. Similar results were found for SN and RN that according to BT and BF of N 
atropisomers, there was no stereoselective non-specific binding of SN or RN to rat 
brain tissues. 
REB4 cell experiments agreed with this as there was no stereoselective non-specific 
binding of K or N atropisomers to REB4 cell monolayers (Figure 5.2), which 
suggested there was no stereoselective non-specific binding of K or N atropisomers 
to the rat BBB. 
As a conclusion, there was no evidence for non-specific binding of SN, RN, SK or RK 
to rat plasma proteins or brain tissues.  
Although there was no evidence of stereoselective non-specific binding of K or N 
atropisomers, on the other hand, there was different plasma protein binding 
between racemic K and N. N binds to plasma protein (approximately 90%) to a 
higher extent than that of K (approximately 75%) (Section 7.4.2). Besides the influx 
mechanism (Section 8.1.1), which leads to an approximately 4 times higher BF/PF of 
K compared to that of N (Figures 7.5 and 7.6), the higher plasma protein binding of N 
may contribute to the less free brain homogenate concentration of N than K (Figures 
7.1 and 7.2).  
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8.4 Other possible hypothesis  
 8.4.1 Stereoselective metabolism at the BBB 
The three main hypotheses were discussed in above sections (Section 8.1 − 8.3), but 
there is another possible hypothesis, the stereoselective metabolism at the BBB. The 
hypothesis is that at the BBB, enzymes stereoselectively break down more SN than 
RN, SK and RK when they cross the BBB. As a result, SN cannot reach the CNS or 
reaches the CNS in a very limited amount, thus much less sedative effect occurs. To 
posit the stereoselective metabolism hypothesis, it is important to understand the 
metabolism of N.  
It has been reported that N is metabolised into (a) reduced norketotifen (reduced N) 
through ketoreduction and (b) N-sulfate norketotifen (N-sulfate N) by sulfation 
(Figure 8.1) (Le Bigot et al, 1987). 
 
Figure 8.1 Structures of (a) reduced norketotifen and (b) N-sulfate norketotifen.  
For these two metabolites of N, N-sulfate N, however, was not found in either human 
or in rat from 4 h up to 4 days incubation with hepatocytes, while reduced N was not 
reported in the paper (Le Bigot et al, 1987). This may be caused by (a) the limitation 
of LOD of the analytical method in the 1980s, (b) oxidative N-demethylation is not a 
main route of K metabolism in human hepatocytes thus only a trace of N was found 
in human hepatocytes culture, and (c) in rats, although oxidative N-demethylation is 
a main metabolic route of K (62% of K turns to N in 4h), N-sulfate and ketoreduction 
are not main metabolic routes, thus the N-sulfate and ketoreduction metabolites of N 
could be very limited (Le Bigot et al, 1987). As a result of above reasons, there may 
be a further metabolic route of N that was not indicated in the results presented by 
Le Bigot’s group. Nonetheless, this possible metabolic route of N is not, at least not at 




First, although many enzymes were found in and near the BBB (De Lange, 2012, 
Shawahna et al, 2011), there is no clear evidence to suggest enzyme participation in 
metabolism of N either in or near the BBB.  
Ghosh’s group reviewed enzymes expressed in human brain tissue and/or the BBB. 
It has been confirmed that CYP1A1, CYP1B1, epoxide hydrolase and UGTs were 
found (Ghosh et al, 2011), in which UGT2B10, UGT1A3 and UGT1A4 are involved in 
K metabolism (Kato et al, 2013; Mey et al, 1999; Weiner et al, 2006). Although 
UGT1A3 and 1A4, especially UGT1A4, have been reported to participate in 
stereoselective metabolism of K by N-glucuronidation, which is restricted to 
primates, owing to species difference (Mey et al, 1999). Moreover, for N, N-
glucuronidation is not a reported metabolic route in human or rat. Therefore, in both 
peripheral and the CNS, N-glucuronidation is unlikely to be involved in 
stereoselective metabolism of N.  
In addition, Shawahna’s group suggested that only CYP1B1 and CYP2U1 were 
quantifiable CYPs at the BBB. It has been reported that only several main phase II 
enzymes were quantifiable at the BBB, which include glutathione S-transferase 
(GST) (GSTP1, GSTM3, GSTO1 and GSTM2) and catechol-O-methyltransferase 
(COMT) (Shawahna et al, 2011). However, none of them is involved in known 
metabolic pathways of N.  
In summary, according to the reported enzymes at or near the BBB and the 
metabolic routes of N, there is no evidence in literatures suggesting metabolism, let 
alone stereoselective metabolism, of N at the BBB.  
This is supported by the in vivo work in this thesis, which found no significant 
difference between SN and RN in either the BT or the BF in rat brain (Figure 7.2). 
However, these results may not be enough to fully support that there is no 
stereoselective metabolism of N at the rat BBB. This will be discussed in the 
following section (Section 8.5).  
As a conclusion, the stereoselective metabolism hypothesis was supported by 
neither literatures nor our in vivo results. Thus, the posited metabolic barrier may 
not be involved, at least not involved significantly, in the sedative difference between 
SN and RN. 
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8.4.2 Other GPCR receptors and ion channels 
As the sedative effects are caused by various reasons, in addition to hypotheses 
discussed above, it is also possible that the different sedative effects resulted from 
other GPCR receptors and/or ion channels instead of the H1 receptors.  
Although K and N are H1 receptor “inverse agonists”, they are not highly selective 
only for the H1 receptor. K has been reported to show affinity for several other 
receptors such as H2 receptors (858-fold lower affinity than for H1 receptors), H3 
receptors (1752-fold lower affinity than for H1 receptors) (Sharif et al, 1994) and 
muscarinic receptors (Mahdy and Webster, 2014, Simons and Simons, 2011). 
However, muscarinic receptors do not lead to sedation after interacting with K. 
Blockage of H3 receptors results in extended wakefulness rather than sedation (as 
discussed in Section 1.2). GPCR receptors (5-HT2 antagonism and α1 and α2-
adrenergic antagonism) may also be relevant to the sleep-wakefulness cycle (Krystal 
et al, 2013), but there is no evidence of affinity of K or N is more selective for these 
receptors than the H1 receptors (Gallois-Bernos and Thurmond, 2012; Takashima et 
al, 1992). 
There are two main ion channels involved in sedative effects, (a) calcium activated 
potassium channel (alcohol induced sedation) and (b) γ-aminobutyric acid type A 
(GABAA) gated chloride channel (intravenous anaesthetics induced sedation) 
(Sandstorm and Nash, 2004). Similarly, there is no evidence to indicate correlation 
between K and sedation due to affects on ion channels. 
As a result, it is unlikely that other GPCR receptors or ion channels are participated 
in the different sedative effects caused by K and N atropisomers.  
8.5 limitations of this thesis and further work  
As discussed at the end of last section (Section 8.4), the in vivo experiment showed 
no stereoselective metabolism of K or N atropisomers in rat brain. This was possibly 
due to the design of the in vivo work. It was designed to investigate the 
stereoselective transport of K and N atropisomers across the BBB. Therefore, it was 
terminated at 5 min to minimize the effects from possible metabolism of K and N. It 
was adequate to meet the designed purposes but it also has the following 
limitations: 
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First, the 5 min terminating point of the in vivo experiments could be not long 
enough to show a possible stereoselective metabolism of K and N, in neither 
peripheral nor CNS.  
Therefore, in future it would be interesting to investigate the metabolism of N. as the 
available paper was for research done in 1987 (Le Bigot et al, 1987), when the 
analytical assay had poor sensitivity compared with today’s quantification 
technologies. Also, to investigate if there is any stereoselective metabolism of N in 
peripheral and in the CNS would be useful, as these stereoselective metabolisms 
could be contributing to the less sedative effect caused by SN.  
Second, there was only one time point in the in vivo study, which was adequate to 
show there was no stereoselective influx mechanism (that is the predominant 
mechanism) of K or N atropisomers across the BBB. However, the single time point 
was not enough to review the kinetic of elimination of K or N. At 5 min, interactions 
of K and N with the efflux transporter or enzyme may not reach equilibrium. As a 
result, there could be potential a stereoselective mechanism of K or N which was not 
determined in this thesis. 
Therefore, the in vivo elimination kinetics of N may be another possible future work 
to look at. This is because the elimination kinetics maybe a better indicator on the 
possible stereoselective efflux and/or metabolism of N atropisomers.  
Third, as discussed in Section 8.2, the less sedative effect caused by SN may be 
attributed to the lowest affinity of SN for the CNS H1 receptors than that of RN, SK 
and RK; however, the antihistaminic effect also comes from binding of K and N to the 
H1 receptor in peripheral. As a result, in the CNS a lower affinity for the H1 receptor 
contributes to a less sedative effect, whereas in the peripheral a lower affinity for the 
H1 receptor leads to a lower antihistaminic therapeutic effect.  
Therefore, it is a rational question to ask if the stereoselective binding of SN only 
occurs to the CNS H1 receptor, by which it results in a less sedative side effect while 
maintaining the antihistaminic potency. On the other hand, if the stereoselective 
binding of SN also occurs to the peripheral H1 receptor, it will result in a less 
antihistaminic potency compared with racemic K and N.  
It has been reported in an in vitro study that for 18 tested antihistamines (including 
four sets of stereoisomers), there was no difference between the affinities to the 
cerebellum and lung H1 receptors in guinea pig. However, the density of the H1 
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receptor in the cerebellum tissue was six times higher than that of lung tissue (Ter 
Laak et al, 1993). Although Ter Laak’s group has not tested K or N and it was not 
clear if it was species dependent, it is a rational assumption that similar results could 
be observed for K and N atropisomers in mice and rats. As a result, it may be 
interesting to investigate in future if this stereoselective binding of SN to the H1 
receptor occurs only in the CNS or also in peripheral H1 receptors in different 
species. 
In addition to above limitations, receptor affinity (KI) values provide limited 
information on pharmacological actions, as compounds with similar KI values may 
have different second messengers, thus different pharmacological actions. 
Therefore, even K and N have been reported as “inverse agonist”for the H1 receptor, 
it is still interesting to investigate pharmacological actions of K and N atropisomers 
in future studies. 
8.6 Conclusion 
In conclusion, according to results from the B/P ratios and H1 receptor binding 
studies, the less sedative effect caused by SN compared to RN, SK and RK was due to 
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